Mississippi State University

Scholars Junction
Theses and Dissertations

Theses and Dissertations

5-7-2016

In Ovo Vaccination of Layer Chickens with Strain F Mycoplasma
Gallisepticum
Katie Collins

Follow this and additional works at: https://scholarsjunction.msstate.edu/td

Recommended Citation
Collins, Katie, "In Ovo Vaccination of Layer Chickens with Strain F Mycoplasma Gallisepticum" (2016).
Theses and Dissertations. 2664.
https://scholarsjunction.msstate.edu/td/2664

This Dissertation - Open Access is brought to you for free and open access by the Theses and Dissertations at
Scholars Junction. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of
Scholars Junction. For more information, please contact scholcomm@msstate.libanswers.com.

Template B v3.0 (beta): Created by J. Nail 06/2015

In ovo vaccination of layer chickens with strain F Mycoplasma gallisepticum

By
TITLE PAGE
Katie Elaine Collins

A Dissertation
Submitted to the Faculty of
Mississippi State University
in Partial Fulfillment of the Requirements
for the Degree of Doctor of Philosophy
in Agricultural Sciences
in the Department of Poultry Science
Mississippi State, Mississippi
May 2016

Copyright by
COPYRIGHT PAGE
Katie Elaine Collins
2016

In ovo vaccination of layer chickens with strain F Mycoplasma gallisepticum
By
APPROVAL PAGE
Katie Elaine Collins
Approved:
____________________________________
E. David Peebles
(Major Professor)
____________________________________
Scott L. Branton
(Committee Member)
____________________________________
Jeff D. Evans
(Committee Member)
____________________________________
G. Todd Pharr
(Committee Member)
____________________________________
Morgan B. Farnell
(Committee Member)
____________________________________
Christopher D. McDaniel
(Graduate Coordinator)
____________________________________
George M. Hopper
Dean
College of Agriculture and Life Sciences

Name: Katie Elaine Collins
Date of Degree: May 6, 2016

ABSTRACT

Institution: Mississippi State University
Major Field: Agricultural Sciences
Major Professor: E. David Peebles
Title of Study: In ovo vaccination of layer chickens with strain F Mycoplasma
gallisepticum
Pages in Study: 176
Candidate for Degree of Doctor of Philosophy
Mycoplasma gallisepticum (MG) is a bacterium that causes egg production losses
in layer chickens raised on multi-age layer hen complexes. To combat this loss, layer
chickens are vaccinated against MG before they are moved to the layer facility to begin
laying eggs. The objective of this dissertation research was to investigate the potential of
the in ovo vaccination of layer chickens against field strain MG infections to enhance
immunity, and reduce labor and material costs associated with the current post-hatch
vaccination method. Initial studies tested various dosages of a live attenuated strain F
(FMG) vaccine delivered in ovo by hand injection at 18 days of incubation. The greatest
dilution of vaccine (1-3 colony forming units (CFU) per dose) did not have an adverse
effect on hatch success and was able to induce initial antibody production against FMG in
approximately 50% of the birds raised through 6 weeks of age, with relatively low posthatch mortality. Higher dosages tested, starting at 102 CFU per dose, caused extremely
high (>50%) post-hatch mortality during the first 2 weeks and were considered
impractical. These in ovo-vaccinated birds, even at the lowest FMG dose, were able to
transmit the bacteria to other MG-clean birds with which they were in direct contact. The

lowest in ovo FMG dose was further tested for its ability to be applied using a current in
ovo vaccination machine. This machine externally disinfects each injection needle after
every injection. The FMG was detected in FMG-vaccinated birds at 6 weeks of age
whether or not they had received the disinfection step. Furthermore, birds hatched from
eggs that were injected with and without disinfection had comparable humoral immune
responses against FMG, with similar results to the hand injection study. Thus, the
disinfection step during in ovo vaccination caused no loss of FMG vaccine efficiency and
the in ovo vaccination of layer chickens against FMG could be readily practiced in the
poultry industry. Future work should evaluate how this in ovo vaccination regimen
compares with other post-hatch MG vaccination regimens for layer chickens through the
lay cycle and against a field strain MG challenge.
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INTRODUCTION
In ovo vaccination has proven to be a successful vaccination method against a
multitude of poultry pathogens, predominantly viral pathogens (Ricks et al., 1999). A
few studies have explored the potential to in ovo vaccinate chickens with bacteria such as
Salmonella, Campylobacter, and probiotic bacteria (Cox et al., 1992; Coloe et al., 1994;
Noor et al., 1995; Edens et al., 1997; Meijerhof and Hulet, 1997; Yamawaki et al., 2013;
De Oliveira et al., 2014).
Mycoplasma gallisepticum (MG) is a bacterium lacking a cell wall that is a
known pathogen of poultry causing respiratory illness (Yoder, Jr. and Hofstad, 1964;
Bradbury, 2005). Eradication is used for the control of MG in the broiler industry.
However, eradication is not economically feasible on multi-age layer hen complexes
(Olesiuk et al., 1967; Levisohn and Kleven, 1981; Levisohn and Kleven, 2000; Evans et
al., 2005; Ley, 2008). Mycoplasma gallisepticum causes egg production losses in laying
chickens. Therefore, these birds are commonly vaccinated as pullets with a live
attenuated vaccine to protect them against more virulent field strains of MG before they
are moved to the layer facility to begin laying eggs. Live attenuated MG vaccines,
derived from attenuated MG strains, are one of the major MG vaccine options, and are
administered by spraying the birds or by giving each bird an eyedrop form of the vaccine
(Whithear, 1996).
1

This dissertation explores an alternative MG vaccination method: the vaccination
of layer chickens against MG before they hatch. This work tests the in ovo
administration of a live attenuated strain FMG vaccine to determine if embryos can
survive the introduction of this live bacteria within the egg and successfully hatch,
survive beyond hatch, and achieve a sufficient humoral immune response. This work
could potentially reduce labor and material costs as well as reduce bird stress associated
with typical MG vaccination regimens employed during the pullet rearing period and may
induce an earlier immune response against MG at a point further away from the initiation
of the lay period.
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LITERATURE REVIEW
Evidence of Development of Immunocompetence in the Avian Embryo
The immune system of the chicken embryo has been investigated for over 100
years, and this review will highlight a brief account of this extensive subject. Of greatest
importance within the scope of this dissertation is that the embryonic chicken is capable
of defense against foreign pathogenic invaders, albeit to a limited extent as compared
with the fully developed and hatched bird.
The primary lymphoid organs of the avian immune system are visually
distinguishable early in development: the spleen (mesoderm origin) is stated to be
visualized on the latter half of the fourth day of incubation; the thymus (endoderm and
ectoderm origin) can be seen at five days of incubation; the rudimentary bursa (origin
from endoderm that also differentiates to form the cloaca) is found at five days of
incubation; and bone marrow (mesenchymal origin) starts forming around days eight or
nine of incubation depending on the bone type (Oláh et al., 1986; Romanoff, 1960; Seto,
1981). The yolk sac is also considered a primary lymphoid organ in the embryonic
chicken (Seto, 1981).
A multitude of studies have confirmed the early development of cell-mediated
immunity in chicken embryos. These studies were reviewed by Seto (1981), including
early studies using X-rays to eliminate T cell responses and “host versus graft”
3

experiments with chicken embryos. One study (Janković et al., 1975) confirmed cellmediated immunity in white Rock chicken embryos by evaluating the amount of
lymphocytes present in the thymus, bursa, spleen, and bone marrow from left and right
femurs at 12, 14, 16, 19, and 21 days of incubation and at 6 days post-hatch. They also
tested the introduction of foreign samples of thymus, bursa, spleen, bone marrow, and
blood from donor white Rock embryos to the chorioallantoic membrane of host white
Rock embryos at 12 days of incubation and evaluated the host embryos at 16 days of
incubation for any distinguishing “pock” formation. They additionally monitored the
host embryo for any spleen enlargement. The donor embryo cells were taken at days 14,
16, 19, and 21 of incubation and from 6 day post-hatch chicks. The thymus had a large
total amount of lymphocytes starting with the first measurement at 12 days of incubation,
with the bursa having the second highest total lymphocyte count. The bursa of the 6 day
post-hatch chick was equivalent in lymphocyte numbers to those of the thymus of the 14
day embryo. The thymus, therefore, had approximately three times as many lymphocytes
as the bursa, indicating that the thymus develops into a functional immune organ earlier
than the bursa. The spleen had the next highest amount of lymphocytes with the largest
increase at 19 days and 21 days of incubation, followed by a large increase in lymphocyte
counts in the 6 day post-hatch chick. Very few lymphocytes were found in the bone
marrow of hatchlings at hatch and in the 6 day post-hatch chick. Pocks were induced in
the chorioallantois membrane of host embryos from all cell types with the thymus cells
creating pocks with the greatest amount of lymphocytes present. Increasing number of
pocks formed with cells from older donors, with 6 day post-hatch chick cells causing the
most pock formation. Cells from the thymus and the bursa of 14 day old embryos, spleen
4

cells from 16 day old donor embryos, and the peripheral blood of 19 day old embryos
induced spleen enlargement in 12 day old host embryos. Bone marrow cells were not
found to cause spleen enlargement in the host embryos. The main conclusions from this
work were that the thymus and bursa contribute the majority of the lymphocytes
produced in the embryonic chicken and that bone marrow in chicken embryos is not a
major player in cell-mediated immunity.
Seto (1970) explored the idea of injecting chicken antibodies from an external
source into chicken embryos in order to provide “adoptive immunity.” He injected white
Leghorn embryos that had been incubated for 14 days with mouse red blood cells as the
antigen in conjunction with various amounts of blood from adult Leghorns that had been
previously immunized against mouse red blood cells. He measured antibody levels in the
embryos at day 20 of incubation. Using a microtiter hemagglutination method, his initial
findings indicated that injecting 14 day old chicken embryos with mouse red blood cells
alone as an antigen with no antibodies did not induce a detectable amount of antibody
production by the embryo. This data suggested that a 14 to 20 day white Leghorn
embryo was incapable of its own antibody production. Seto (1981) also concluded that
the majority of older published work indicated that embryos do not form their own
antibodies until after hatch, with only detection of maternal immunoglobulins present in
embryos. More recent work, however, has found antibody producing abilities in chicken
embryos (Negash et al., 2004).
Janković et al. (1977) explored the humoral immune response of chicken embryos
with specific interest being focused on the probability that chickens can produce some
antibodies, even without a bursa. They took white Rock embryos and bursectomized
5

them by removal of the bursal primordium at 52-64 hours of incubation. At 12 days of
incubation, they injected the embryo intravenously with guinea pig red blood cells. They
continued to incubate the embryos and took blood samples from embryos at 15, 17, and
19 days of incubation and from hatched chicks at 1, 6, and 10 days post-hatch. They
tested for antibody formation via agglutination. To be sure that embryonic surgery was
not a confounding factor, they also tested sham-bursectomized embryos and chicks as
well. They found that antibody production in embryos started at 15 days of incubation,
with less bursectomized embryos producing antibodies than sham-bursectomized
embryos. Antibodies found in embryos were retained through 6 days post-hatch. They
calculated the difference between sham and bursectomized embryos, so as to indicate that
the embryo itself makes antibodies and that these were not maternal antibodies at 15 days
of incubation (3 days after a challenge with guinea pig red blood cells). They also
hypothesized that since there was some antibody production in bursectomized embryos,
embryonic stem cells other than those from the bursa may additionally produce
antibodies for the bursectomized embryo. It was evidenced in this research that a chicken
embryo can produce its own antibodies in response to an injected antigen during late
incubation.
Vainio et al. (1978) investigated another venue of humoral immunity in embryos
by examining the formation of germinal centers, which are locations in which B cells
undergo somatic hypermutation and class switching (Murphy, 2012). They injected
white Leghorn chickens with sheep red blood cells, the bacteria Brucella abortus, and
bovine serum albumin, which had all been previously found to stimulate germinal center
formation. In this work, embryos were injected at 15 and 18 days of incubation, at hatch,
6

and at 3 days of age. Germinal center formation in the spleen was evaluated four days
after injection. The earliest that germinal center formation was observed was with
embryos injected intravenously at 18 days of incubation and at hatch. Non-immunized
chickens had germinal centers first appear at 10 days post-hatch.
Several studies have been conducted to determine if injecting a foreign substance
into an embryonated egg would induce future embryo tolerance to the injected substance.
The idea of tolerance was speculated upon after occurring when injecting embryos with
an antigenic agent. This speculation was explored by Buxton (1954), who injected brown
Leghorn embryos and chicks with Salmonella pullorum and subsequently evaluated posthatch antibody production. Preliminary work indicated that injecting live Salmonella
pullorum into developing embryos always killed the embryos. Therefore, the researchers
chose to only inject killed bacteria. The author injected killed bacteria into embryos
intravenously at 15 days of incubation, at 20 days of incubation, and at both 15 and 20
days of incubation with a reported 104 CFU (colony forming units) of bacteria. The birds
that hatched were raised to 45 days of age and were orally challenged with Salmonella
pullorum. They were subsequently tested for antibody production at various ages from
61 to 109 days of age. The chicks that had been previously injected with bacteria as
embryos at day 15 and both 15 and 20 days of incubation did not exhibit as large of an
antibody production response against S. pullorum as did embryos that were injected at
only 20 days of incubation. They further tested the intravenous injection of embryos at
12 days of incubation with different dosages of S. pullorum (104, 105, 106, and 107 CFU
administered). At 35 days of age, the birds were challenged with S. pullorum and were
tested for antibody production up to 115 days of age. All birds that had been injected as
7

12 day embryos, regardless of dosage, had much lower antibody titers than control birds
that had not been injected as embryos. The mechanism of tolerance of early chicken
embryos is still being investigated 58+ years later. Wu et al. (2010) researched how
embryonic blood cells may be involved with inducing tolerance to bovine serum albumin
by delivering injections at three days of incubation in order to cause tolerance to the
protein.
Dobrotӑ et al. (2013) evaluated the production of immune cells circulating in the
blood stream of embryonic Cobb 500 chickens from 7 to 20 days of incubation. They
observed the appearance of mature monocytes at eight days of incubation, heterophils at
nine days of incubation, basophils and macrophages at 10 days of incubation, and
eosinophils at 13 days of incubation. Lymphocytes were distinguished by size with
“large lymphoblasts” prevalent until 15 days of incubation, followed by small and
medium mature lymphocytes at 16 days of incubation. Their conclusion, which was
based on the prevalence of cell types, was that innate immunity in Cobb 500 broiler
embryos was functional at eight or nine days of incubation and that primary lymphoid
organs are producing mature cells at 15 days of incubation. Prevalence, however, may or
may not indicate functionality.
In summary, the embryonic chicken has the capabilities of mounting both a cell
mediated and a humoral immune response, with a clearer indication of humoral immune
response abilities becoming apparent during the latter portion of incubation.
Investigation of the in ovo vaccination technique
The conception of in ovo vaccination of chickens budded in the early 1980s from
the previously described evidences of immunity in the chicken embryo. This principle
8

began with the vaccination of broilers with the Marek’s disease vaccine (herpesvirus of
turkeys, HVT) prior to hatching in order for the chick to potentially develop an immune
response before it was immediately challenged with the Marek’s disease virus in the
poultry house environment (Sharma and Burmester, 1982). The vaccination procedures
at hatch left only hours from the time of vaccination to bird placement in the house
(Sharma and Burmester, 1982). This work compared in ovo vaccinated white Leghorn
embryos (vaccinated at either 8, 11, 16, 17, 18, 19, or 20 days of incubation) with white
Leghorn chicks vaccinated at hatch with 0.1mL of 1000 plaque forming units of HVT
vaccine with the usage of a 22 gauge, 1 inch needle. In this work, the birds were
subsequently challenged with Marek’s disease at 3, 7, 8, or 14 days post-hatch and the
rate of mortality was observed until 9 weeks of age. This first work comprised a series of
small trials in which only up to 120 egg were in ovo vaccinated in each trial. Only birds
vaccinated as 8 and 11 day embryos exhibited a significant depression in hatch success.
The authors found a decrease in mortality and lesions after a Marek’s disease challenge in
birds that had been in ovo-vaccinated at 16, 17, 18, 19, and 20 days of incubation in
comparison to those that had been vaccinated at hatch. Higher amounts of virus were also
isolated from in ovo-vaccinated birds. They found that the most protection was afforded
specifically when birds were in ovo-vaccinated at either 17 or 18 days of incubation.
They deemed 18 days of incubation as being beneficial for potential application due to
the fact that this was also the time of egg transfer from the setter to the hatcher.
Preliminary work, found in these trials, laid the groundwork for future in ovo
vaccination procedures (Sharma and Burmester, 1982). It was noted that these vaccines
were mainly deposited in the amniotic fluid of the 18 day embryo and that this placement
9

allowed for sufficient recovery of the virus, such that the musculature of the embryo did
not have to be injected for complete vaccination success. The authors also discovered
that the hole made in the eggshell during injection did not have to be resealed in order to
prevent any adverse effects on hatching success (Sharma and Burmester, 1982).
Molenaar et al. (2010) examined the effects on hatchability of creating a hole in
the eggshell and air cell (membranes) during late incubation. They created a hole in the
blunt end of Dekalb white embryonated chicken eggs using an 18 gauge needle on day 14
of incubation and found no deleterious effects on hatching success even when a larger
needle was used when compared with the 22 gauge needle used by Sharma and
Burmester (1982). Molenaar et al. (2010) found a 0.6% greater moisture loss by 18 days
of incubation in the eggs punctured with a hole at 14 days of incubation when compared
with nonpunctured eggs. The hole-punched eggs externally pipped an average of 3 hours
later but did not exhibit a significantly faster hatch time. This indicates that chicks spent
a shorter amount of time from external pip to final emergence from the egg. Final yolkfree chick weights were not different between the two treatments, yet the hole-punched
chicks had a 0.3 g lighter yolk sac weight 12 hours after hatch, and interestingly, lung
weight as a percentage of yolk-free body weight was larger in chicks from eggs that had
been hole-punched at 14 days of incubation. The hole made at 18 days of incubation by
the Inovoject injection machine (see next section) is stated to increase moisture loss by
0.15% (Ricks et al., 1999). However, this opening in the egg has only been found to be
an issue as it concerns mortalities due to bacterial or fungal infections in cases where
sanitation was inadequate (Ricks et al., 1999; Williams and Brake, 2000).
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Past research has indicated that in ovo vaccination efficiency is dependent on
where the embryo is injected (Wakenell et al., 2002; Williams and Hopkins, 2011).
Where the embryo is injected is dependent on the day of incubation when injections are
administered, as well as the stage of development of the embryo, which can vary based
on chicken breed or strain and the type of incubator used regardless of the day of
incubation on which injections are given (Williams, 2005; Avakian, 2006; Williams and
Hopkins, 2011). For example, the duration for layer chicken egg incubation has been
found to be 6 to 12 hours longer than that of broilers. Therefore, at 18 days of
incubation, layer embryos have been found to be at a reduced stage of development
compared with that of broilers even when both types of eggs are incubated in the same
incubator (Avakian, 2006). Workers experimenting with the in ovo administration of the
HVT vaccine determined that the most ideal vaccination location within the embryonated
egg for optimum protection against a post-hatch challenge scenario was in the amnion or
the musculature of the embryo (Wakenell et al., 2002). Reduced protection was found
when embryos were vaccinated in the allantois or the air cell.
Jochemsen and Jeurissen (2002) injected 0.1mL of different substances including
indian ink, bromodeoxyuridin (incorporated into the DNA of cells that are dividing),
fluorescent microspheres, and infectious bursal disease virus (IBDV) vaccine diluted with
NaCl2, into SPF white Leghorn embryos at either day 16 or day 18 of incubation using a
1 inch, 23 gauge needle. They allowed the embryos to incubate another 24 or 48 hours
and then evaluated where the substances were located. Tissue samples from various
organs including the bursa, intestine, spleen, and the lungs of 3 or 4 embryos at each time
and for each substance injected were evaluated for the presence of the injected material.
11

It was observed that embryos injected at day 16 of incubation had substances injected
into either the allantois or the amnion, and that day 18 injections targeted the amnion with
some having localized in the neck or right breast of the embryo. Overall, all substances
that were administered at later post-injection periods were found in all the organs the
researchers investigated, with higher percentages of embryos having greater amounts of
substances when the embryo was injected at the later day 18 of incubation. Specifically
in the lungs, the researchers found indian ink only after 48 hours after a day 16 injection,
but were able to find indian ink in the lungs of embryos 24 hours after a day 18 injection.
They confirmed through the use of small fluorescent microspheres that substances
reached the lungs and the intestines through the respiratory and gastrointestinal tract. The
microspheres also showed that the particles landed specifically in the parabronchi of the
lungs. The researchers speculated that the collection of substances in the lungs may be
due to movements within the embryonic respiratory tract starting between 17 and 18 days
of incubation. The live IBDV virus was found in all sites, with greater numbers of
embryos containing the IBDV virus at later time periods whether or not they were
injected on day 16 or day 18 of incubation. In embryos that were injected in the neck or
breast muscles, substances reached all of the organs and the authors hypothesized this
occurred due to leakage into the amnion. Larger particles such as indian ink remained in
the lumen of the intestine, while smaller substances such as microspheres were absorbed
in low amount by the intestine. This work confirmed, based on their ability to reach
target tissue sites in the embryo, that it is more efficient to inject the previously described
substances on day 18 rather than day 16. This work also specifically identified the tissue
sites where the in ovo-delivered substances resided, although their findings also indicated
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that the size and nature of the injected substances may have a bearing on organ
distribution.
Commercialization of in ovo vaccination
Following the discovery of in ovo vaccination against Marek’s disease for
chickens, a machine was engineered that could in ovo vaccinate large quantities of broiler
hatching eggs for commercial production (Gildersleeve et al., 1993). The major focus of
the manufacturer was to reduce labor at hatch time. The initial prototypes could
vaccinate either 144 or 168 or either 36 or 42 eggs at a time and employed a sanitation
step for all needles between every injection using a chlorine sanitizer. The prototype
machines were tested in a large-scale four year experiment consisting of 8 trials reported
by Gildersleeve et al. (1993). The authors compared the in ovo vaccination of broilers
(50 μL injection volume) to the vaccination of broilers by the “conventional” method,
which was to vaccinate for Marek’s disease at subcutaneously hatch with a 200 μL
injection volume. They mixed the vaccine so that each batch consisted of equal virus
titers regardless of vaccination route or injection volume. They used two different broiler
companies and approximately 25,000 eggs for each vaccination route in each trial. Eggs
were injected at either 17.5 or 18.5 days of incubation, depending on the company and
day of transfer. They used company records and examined percentage hatch of eggs set,
livability, body weight, feed conversion, leucosis condemnations at the plant, and a
calculated settlement cost, which was the number of chicks placed multiplied by chick
cost plus the pounds of feed multiplied by feed cost, and this was then divided by the
pounds of live weight produced. They did not see a huge improvement in broiler
performance with in ovo injection, yet this vaccination method did not hinder production
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success and was a less labor intensive method that had a lower calculated settlement cost.
In all but one trial, the in ovo injection route led to a better feed conversion. This helped
in making the settlement costs lower for in ovo injection than for the conventional
method.
Attempts for full scale commercial application of broiler hatching egg in ovo
injection were made successful by the manufacture of these machines by two major
companies (Embrex Inovoject System by Pfizer Animal Health and Intelliject System by
Avitech). In the following years, Pfizer compared the performances of the two brands of
machines in commercial hatcheries using broiler hatching eggs (Williams and Zedek,
2010; Williams and Hopkins, 2011).
Using the two brands of machines in a 9 week comparative study, Williams and
Zedek (2010) injected eggs at 18 and 19 days of incubation at a commercial broiler
hatchery that used Chickmaster 99 incubators for the incubation of their eggs. The
Inovoject system injected 50 µL volumes and the Intelliject system injected 100 µL
injection volumes. The concentrations in the two different volumes were adjusted to
achieve equivalent dosages of Marek’s disease vaccine. Two different studies were
conducted. The first was a “paired trial” in which a smaller number of eggs were used
and the birds were raised on a single farm (two different houses) with everything being
randomized at the hatchery (breeder age, storage time of eggs, etc.) for each injection
machine. In a second trial, they evaluated “whole hatchery production” in which the
different machines were used on alternate days at the hatchery and the breeder sources
were divided and used equally at set. In the paired trial, when injections were
administered on day 18 of incubation, a higher percentage hatch of live embryonated
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eggs was reported for the Inovoject system when compared with that of the Intelliject
system (with more late dead embryos, live pips, and cull chicks reported with the
Intelliject). However, no difference in hatch success was noted between machines when
injections were adminstered on day 19 of incubation. The whole hatchery trial also
reported a higher percentage hatchability of eggs set using the Inovoject system, like the
results of the paired trial. The observed increase by the Inovoject system was 2.3% and
1% higher for the Inovoject system for the 18 and 19 day injection periods, respectively.
Williams and Hopkins (2011) also compared the Inovoject to Intelliject systems
in commercial broiler hatcheries in order to evaluate the site of injection. One hatchery
used ChickMaster incubators and the other incubated with Jamesway incubators. The
eggs were transferred at 18 days and 7 hours in the Jamesway hatchery and at 19 days
and 1 hour of incubation in the ChickMaster hatchery. Technicians from each company
operated the machines as commercially accepted. The Inovoject machine injected a 50
µL volume and the Intelliject machine injected a 100 µL volume as in the previous
research. They injected the Marek’s disease vaccine diluent containing a protein staining
dye. They euthanized embryos and opened eggs to determine the site of injection
immediately following the injection administration. They analyzed the numbers of eggs
injected into the “correct” sites which are injections in the amnion and embryo body.
Alternatively “incorrect” injection sites are considered the air cell, allantois, and
injections that are traumatic to the embryo such as injections into the head, eye, or
abdomen. In comparison to the Intelliject system, the Inovoject system was found to
have 33.5% higher correct injections in the Chickmaster hatchery and 19.1% greater
correct injections in the Jamesway hatchery. The authors could not account for the large
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difference between the injection machines. The authors, however, did speculate that the
ChickMaster trays may have held the eggs tighter and better prevented the eggs from
being injected at an angle away from an upright axis. The eggs incubated in the
ChickMaster machines where injected at a later age, which may have yielded a higher
percentage of correct injection sites when the Intelliject injector was used.
These comparative trials demonstrate the successful application of in ovo
vaccination technology in commercial broiler hatcheries. Stemming from the success of
in ovo vaccination technology, an estimated 90% of broilers raised in the United States
are in ovo-vaccinated at the hatchery (Williams and Zedek, 2010). It is of interest to
remember that the initial experiment testing the in ovo vaccination of chickens against
Marek’s disease utilized white Leghorn embryonated eggs (Sharma and Burmester,
1982).
Other in ovo vaccines tested
Following the commercial success of administering Marek’s vaccine by in ovo
injection, a host of other vaccines and injectable substances have been and are still widely
tested. Research concerning the in ovo injection of various vaccines and other substances
comprised 5% of all abstracts presented at the 2015 International Poultry Scientific
Forum. Major areas of research have focused on vaccines against viral pathogens such as
infectious bronchitis, infectious bursal disease, Newcastle disease, avian influenza,
laryngotracheitis, metapneumovirus, and fowl pox (Sharma, 1985; Wakenell and Sharma,
1986; Stone et al., 1997; Ricks et al., 1999; Rautenschlein and Haase, 2005; Mast et al.,
2006; Tarpey et al., 2006; Tarpey and Huggins, 2007; Toro et al., 2007; Johnson et al.,
2010; Cai et al., 2011). In ovo vaccines against coccidiosis have also been tested (Ricks
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et al., 1999; Ding et al.,2004; 2005; Lee et al., 2012). In ovo vaccination research has
also investigated the success of combining multiple vaccines, producing recombinant
vaccines, utilizing DNA vaccines, and determining the effects of in ovo administration of
sex hormones, electrolytes, sucrose solutions, L-carnitine, and 25hydroxycholecaliciferol (Reddy et al., 1996; Burke, 1996; Johnston et al., 1997; Karaca
et al., 1998; Gagic et al., 1999; Rautenschlein et al., 2000; Oshop et al., 2002;
Kapczynski et al., 2003; Uni et al., 2005; Tarpey et al., 2007; Steel et al., 2008; Zhai et
al., 2008; Keralapurath et al., 2010; Rauw et al., 2010; McGruder et al., 2011a,b; Zhai et
al., 2011; Bello et al., 2014). The general trend with these in ovo vaccination options is
that vaccinations at the hatchery, on a worldwide scale, have increased in comparison to
“field” vaccinations (Zavala, 2013).
In ovo vaccinations of bacteria
A less researched area in general, and a focus of this dissertation, is in ovo
vaccinations against bacterial pathogens (Ricks et al., 1999).
One early in ovo vaccination experiment of a bacterial pathogen involved
commercial broiler chickens injected with live mutant gene aroA Salmonella
typhimurium (Coloe et al., 1994). They injected 104 and 106 CFU into embryonated eggs
from 14 days of incubation to hatch time at 21 days of incubation and found no
significant decline in hatch success compared with control embryos. The authors also
reported the vaccine prevented mortality when the hatched birds were challenged with
106 CFU of virulent Salmonella typhimurium, but the age of the bird when challenged
was not specified. Coloe (2001) also published a patent that details causing a mutation in
Salmonella for use as an in ovo vaccine.
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Another early bacterial in ovo vaccination experiment injected heat-killed
Campylobacter jejuni. This vaccination was hypothesized to induce an immune response
in the intestinal tract of chicks which would reduce C. jejuni (Noor et al., 1995). The
embryos were vaccinated on day 16 of incubation with a 0.5 mL injection volume
containing 108 CFU of bacteria following the in ovo vaccination procedure of Sharma
and Burmester (1982). Within the intestine and the peripheral blood in two week old
chickens, the authors found heightened IgA antibody production against C. jejuni in birds
vaccinated as embryos in comparison to non-vaccinated birds.
The majority of published in ovo experiments injecting live bacteria have focused
on the administration of probiotic organisms as a potential alternative to antibiotics. A
few papers have not found promising results for the use of probiotics in ovo. Meijerhof
and Hulet (1997) administered a competitive exclusion bacteria product to the air cell of
embryonated eggs at 18 days of incubation. They found a 10 to 13% reduction in hatch
from control birds when the competitive exclusion bacteria were injected. They stated
that diluting the competitive exclusion culture did not improve hatch, although the data
was not presented. Additionally, birds that hatched after the in ovo vaccination with the
competitive exclusion experienced high (12.5%) mortality during the first week. To test
the efficiency of the competitive exclusion action of the vaccine, the birds were
challenged with 104 CFU of Salmonella panama at one day of age post-hatch. The in
ovo-vaccinated birds were unable to exclude Salmonella panama in the ceca to as great a
level as chicks administered the competitive exclusion bacteria at hatch by the spray
vaccination route. Yamawaki et al. (2013) administered Lactobacillus acidophilus,
Lactobacillus fermentum, or Lactobacillus salivarius into the air cell of embryonated
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eggs at 18 days of incubation or by placing the embryonated egg in a culture of the
bacteria for 3 minutes at 18 days of incubation. The hatched birds were then challenged
with 108 CFU of Salmonella enteritidis two days post-hatch. The findings of this study
showed no difference in hatch success or ability to exclude Salmonella enteritidis in the
ceca between the Lactobacillus species tested or comparing the in ovo injection versus
the bacterial immersion technique.
Other papers, however, have reported positive results of in ovo application of
competitive exclusion bacteria. Cox et al. (1992) administered a diluted competitive
exclusion culture in the air cell or beneath the air cell membranes of embryonated eggs at
17 days of incubation. Higher hatch results were found when the competitive exclusion
culture was administered into the air cell of the egg and the hatched birds exhibited an
improved ability to exclude Salmonella typhimurium than control chicks. Edens et al.
(1997) found that 104, 106, and 108 CFU of Lactobacillus reuteri could be injected into
embryonated eggs at 18 days of incubation into the air cell or the amnion without a
reduction in hatch. These in ovo-vaccinated birds were able to partially exclude a 103
Salmonella typhimurium challenge delivered at external pipping, but the exclusion ability
decreased when the birds were reared beyond 3 and 6 days of age-post hatch.
Gentamicin administration post-hatch was required in addition to the in ovo vaccination
in order to maintain competitive exclusion success. De Oliveira et al. (2014) determined
109 CFU of Enterococcus faecium and Bacillus subtilis could be administered in ovo into
the amnion without detriment to hatch, yet also found, like Edens et al. (1997), that posthatch administration of antibiotics or further probiotic bacteria given in the diet would be
needed to maintain competitive exclusion.
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The work of this dissertation explores the application of in ovo vaccination
against one of the most financially costly bacterial pathogens in poultry: Mycoplasma
gallisepticum (Levisohn and Kleven, 2000; Zavala, 2013).
Mycoplasma gallisepticum: the Organism
Several species of Mycoplasma are capable of infecting birds. The major poultry
production birds (chickens and turkeys) are affected by Mycoplasma gallisepticum and
Mycoplasma synoviae while Mycoplasma meleagridis and Mycoplasma iowae mainly
causes disease only in turkeys (Kleven, 1998; Ley, 2008). For the purpose of this review,
we will focus on one of these organisms: Mycoplasma gallisepticum and predominantly
its importance for the layer chicken industry.
Mycoplasma gallisepticum (MG) was formerly designated as pleuropneumonialike organism “serotype A” that was known to contribute to respiratory symptoms in
birds termed chronic respiratory disease (Yoder, Jr. and Hofstad, 1964; Dierks, et al.,
1967). Mycoplasma gallisepticum colonies are small approximately 0.2 mm in diameter
that have a smaller darker center when viewed under a microscope described as a “fried
egg appearance” (Yoder, Jr. and Hofstad, 1964; Ley, 2008). Mycoplasma species are
very small and are the smallest known prokaryotes capable of self-replication (Bradbury,
2005). A MG bacterium consists of only double stranded DNA in plasmid form and
ribosomes (Bradbury, 2005; Ley, 2008). Mycoplasma gallisepticum strain R’s genome
was sequenced at 996 kb (Papazisi et al., 2003). One interesting finding about MG’s
genome is that the codon UGA codes for the amino acid tryptophan instead of a stop
codon (Inamine et al., 1990).
20

Frey’s Mycoplasma broth was developed to supply all needed nutrients to
adequately grow MG and other mycoplasma species (Frey et al., 1968). The media
utilizes swine serum, glucose, yeast autolysate, as well as other needed constituents in the
media to support MG growth such as thiamine, riboflavin, folic acid, calcium
pantothenate, sodium chloride, potassium chloride, and magnesium sulfate. Penicillin is
used as a selector against other bacteria as MG is not affected by penicillin (since MG has
no cell wall) and thallium acetate is added to the media to prevent fungi growth.
Mycoplasma gallisepticum grows at 37°C and grows slowly in comparison to other
bacteria commonly grown in lab settings, with colonies visible on plates in 3-5 days or
longer depending on the strain (Frey et al., 1968; Ley, 2008). Mycoplasma gallisepticum
is capable of fermenting glucose, dextrose, and maltose and but not lactose (Yoder, Jr.
and Hofstad, 1964; Ley, 2008).
Mycoplasma gallisepticum Infection
Mycoplasma gallisepticum is well known as a respiratory disease causing
pathogen in chickens (Ley, 2008). The severity of MG infections is dependent on the
strain and the virulence of the strain (Rodriguez and Kleven, 1980; Lin and Kleven, 1984;
Levisohn et al., 1986). These researchers noted that MG becomes more attenuated when
more highly passaged. The major strains of MG rank with S6 and R strains as the more
virulent MG strains, followed by strain F, and strains ts-11 and 6/85 are considered of
lesser virulence, although there is variation in symptom severity due to bacteria passage
rate and age of the bird when infected (Lin and Kleven, 1984; Abd-El-Motelib and
Kleven, 1993; Peebles et al., 2006; Ley, 2008; Peebles and Branton, 2012).
21

Mycoplasma infections in poultry can be distinguished using tests to detect
antibody production against the organism, such as serum plate agglutination (SPA)
testing, enzyme-linked immunosorbent assay (ELISA), and hemagglutination-inhibition
testing (Avakian et al., 1988). These serologic tests, though, can have “cross-reactions”
or “nonspecific” reactions which can prevent species identification (Ley, 2008).
Mycoplasma species can be distinguished by collecting samples of the bacteria from an
infected bird, growing the sample in Mycoplasma broth and agar, and using
immunofluorescence to distinguish species even when a mixture of different Mycoplasma
species are present in a sample (Bradbury, 1982). Mycoplasma species and specific
strains of Mycoplasma gallisepticum can also be distinguished using PCR (Raviv et al.,
2008; Raviv and Kleven, 2009).
Many studies have reported on MG’s ability to colonize the trachea of chickens
(Levisohn, 1984; Levisohn et al., 1986), and this is considered the main “portal of entry
in natural infection[s]” (Levisohn and Kleven, 2000). Levisohn et al. (1983) challenged
broiler chicks at two weeks of age with strain R and strain F (106 organisms in a 50 µL
dose) in the trachea and took scanning electron microscopy photographs of the trachea
four hours post-challenge and then each day post-challenge from days 1-5, then day 8,
12, and 14 days. They found the amount of MG increased in the trachea 1000-fold by
four days post-challenge and remained high for the remainder of the sampling. Body
weights were lowered for the MG challenged birds in comparison to the control birds for
both strain F and R, with R causing a more drastic reduction in body weight by 108 g at
12 days post-challenge. The scanning electron microscopy photographs showed bulging
of tracheal cells and deciliation caused by MG by 12 days post-challenge in strain F and 3
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days post-challenge in strain R. Interestingly, the MG cells of both strains bunched
together into MG “aggregates” on the surface of the trachea. The authors concluded that
the MG adhered to the surface of the trachea and cilia tightly enough to resist removal
from washing in the scanning electron microscopy procedure as well as the normal
physiological clearance processes in the respiratory tract. Levisohn (1984) found in
Leghorn chickens that higher pathogenic strains like R at a low passage rate caused
greater air sac lesion scores yet the ability for MG strains to adhere to trachea cells was
not a direct indication of the virulence of the MG strain. Lower virulence strains,
including strain F, adhered to trachea cells just as well as R-low.
The molecular mechanism of how MG directly infects its avian host is largely
uncertain (Razin et al., 1998; Bradbury, 2005). It is thought that the majority of the
damage to the bird/host is due to the immune system responses to the MG infection
(Razin et al., 1998). There is evidence that Mycoplasma gallisepticum both stimulates
and depresses immune function of the bird by causing arginine depletion, activating B
cells in a nonspecific/mitogenic way, and causing increased cytokine production (Razin,
et al., 1998). Researchers have identified specific genes in the MG genome that code for
adherence and penetration of host cells and have evaluated how MG can evade the
immune system of the host using “antigenic variation” (Kleven, 1998; Noormohammadi,
2007). Antigenic variation is a hypothesis that MG is able to modify its surface proteins
(antigens) genetically by turning genes on or off, by adding or removing the particular
proteins expressed on the cell surface, and by changing the size of proteins expressed on
the cell membrane surface in order to elude the immune system of the host (Bradbury,
2005; Noormohammadi, 2007; Ley, 2008). Several studies have investigated genes and
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proteins responsible for the initial step of pathogenesis, considered the contact/adherence
of MG cells to poultry cells, and have investigated specific protein antigens of MG
(Bradbury, 2005; Chen et al., 2011; Masukagami et al., 2013; Tseng et al., 2013; Rocha
et al., 2015). Other work has examined genes that have a role in allowing MG to enter
host cells (Winner et al., 2000; Bradbury, 2005; Tseng et al., 2013), and some of these
same genes have been found to have a role in allowing MG to form biofilms (Chen et al.,
2012).
As shown also by Levisohn (1984), MG infections alone can cause airsacculitis in
chickens depending on the virulence of the strain. Not all MG infections cause clinical
symptoms, yet still negatively affect the production abilities of the birds, equating to
reduced financial gain for the producer (Levisohn and Kleven, 2000). MG is known to
cause reduced weight gain and a decline in egg production in layer chickens of
approximately 10-15% that lasts 4-6 weeks and can prevent production levels from
returning to normal/expected rates (Carpenter et al., 1981; Lin and Kleven, 1982;
Burnham et al., 2002ab; Peebles et al., 2006; Ley, 2008; Hy-Line, 2013). Cost of egg
production loss due to MG infection in the area of southern California in 1984 was
estimated at $7 million (Mohammed et al., 1987). Mortality resulting from MG infection
is reported as low in layers but broilers can experience up to 30% mortality (Ley, 2008).
Once a bird is infected with MG, it is thought to remain infected for the life of the bird
with isolation of MG found one year post-infection (Levisohn and Kleven, 1981).
Chronic respiratory disease is a combination of MG interacting with one or more
other disease-causing organisms which can include Escherichia coli, Newcastle virus,
metapneumovirus, larynogotracheitis virus, infectious bronchitis virus, avian influenza,
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and other mycoplasma species (Kleven, 1998; Levisohn and Kleven, 2000; Bradbury,
2005; Zavala, 2013). Boyd and Edwards, Jr. (1962) found chicks inoculated with half
doses (0.05 ml or 50 µL each) of Escherichia coli and Mycoplasma gallisepticum
together at 3 weeks had a lower body weight at 6 weeks than chicks inoculated with a full
dose (0.1 ml) of either Escherichia coli (by an average 90.8 g) or Mycoplasma
gallisepticum (by an average 163.6 g).
Mycoplasma gallisepticum has been found in a number of bird species, besides
commercial chickens and turkeys, as reviewed by Ley (2008). Hobby backyard chickens
have also been identified as having encountered MG infections (McBride et al., 1991).
Infections in song birds were initially noted in 1994, particularly in house finches (Nolan
et al., 1998; Ley, 2008). The MG infection was reported to kill millions of house finches
within two years, the majority of which were males (Nolan et al., 1998). Interestingly,
Mycoplasma infections, such as Mycoplasma pulmonis, have also been found to be more
severe in male mice than in female mice, which is reduced in severity when the testes are
removed (Yancey et al., 2001).
Mycoplasma gallisepticum Control in Layer Chickens
Eradication and strict biosecurity are efficient means to control MG infections and
these measures are the means by which the broiler industry controls MG infections
(Olesiuk et al., 1967; Halvorson, 2011). However, commercial layer chickens in the
United States, are not raised in an “all-in-all-out” system and are often maintained on
large multi-age layer hen complexes. Mycoplasma gallisepticum infections are reported
as “endemic” in multi-age layer complexes since the young pullets become infected from
the older MG infected birds on the premises (Levisohn and Kleven, 1981; Ley, 2008).
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Eradication is utilized as a control method for great-grandparent and grandparent breeder
flocks to prevent vertical transmission to progeny, yet for control of MG in production
layers, vaccination has become the most feasible method of MG control (Levisohn and
Kleven, 2000; Evans et al., 2005).
There are several strains of MG which have been utilized for vaccines such as R,
F, 6/85, and ts-11 to combat the decline in egg production from an MG challenge
(Carpenter, 1981; Evans and Hafez, 1992; Abd-El-Motelib and Kleven, 1993; Evans et
al., 2005; Ley, 2008; Peebles and Branton, 2012; Hy-Line, 2013). Vaccines available
include live attenuated vaccines, bacterins, and more recently fowl pox vectored MG
vaccines (Whithear, 1996; Hy-Line, 2013). Levisohn and Kleven (1981) describe the
initial findings in the late 1970s to combat field strains of MG by vaccinating layers with
live strain F Mycoplasma gallisepticum (FMG). The practice described that live
attenuated strain F should be administered at between 5 x 105 – 5 x 107 CFU/mL by an
eye drop, nasal route or through drinking water before the pullets reached the lay period
at 10-18 weeks of age (Levisohn and Kleven, 1981).
Carpenter et al. (1981) took egg production data from the start of lay to 45 weeks
from 132 commercial laying flocks comparing MG negative flocks, MG vaccinated
flocks, and flocks that were naturally MG positive. Pullets that were vaccinated with
FMG were vaccinated by spray vaccination or through an alternative water source (not
the usual waterers, such as additional bell waterers) with 5 x 109 CFU/mL. They
compared production results accounting for bird age when vaccinated and effects of the
route of vaccination. There were significant layer strain (although the specific strains
were not specified), age of bird when vaccinated, and route of vaccination effects. The
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authors adjusted for layer strain effects when comparing MG treatments. Mycoplasma
gallisepticum negative flocks laid the most eggs over 45 weeks, MG-vaccinated birds laid
8.7 less eggs per hen housed than the negative flocks, and naturally infected MG flocks
laid 15.7 less eggs per hen housed than the negative flocks. Mycoplasma gallisepticumvaccinated flocks laid in a range of 5.5-14.5 greater eggs per hen housed than naturally
infected non-vaccinated MG positive flocks. The drinking water route vaccinated hens
laid 4.7 more eggs per hen housed than spray vaccinated birds. Pullets vaccinated
between the ages of 8-18 weeks laid 10.3 more eggs per hen housed than pullets
vaccinated later after 18 weeks. The conclusion from this paper is that birds perform best
when MG negative, but if a flock faces an MG challenge scenario then vaccination with
strain FMG can reduce production losses. Glisson and Kleven (1984) also reported
higher egg production (by an overall average of 12 eggs per hen) after 45 weeks in birds
vaccinated with strain F and/or bacterin at 16 and/or 20 weeks of age than control nonvaccinated birds when challenged with strain R at 28 weeks of age.
Branton et al. (1988) evaluated effects on egg production if layers were
vaccinated later in production at 45 weeks of age. Control birds and birds vaccinated
with FMG at 45 weeks of age were compared for egg production to 60 weeks of age. In
addition to egg production, the authors recorded shell strength, “pimpling,” thickness,
and if the egg contained meat or blood spots for each egg laid, and Haugh unit scores.
The reproductive tracts of the 60 week old hens were examined microscopically to
evaluate any lymphoid nodules and any heterophilic infiltration. Egg production was
found to be significantly higher for controls than the FMG vaccinated birds. There was
no difference between the control and FMG vaccinated groups for any of the evaluations
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of the reproductive tracts as well as no differences found between the groups for eggshell
strength, thickness, pimpling, or blood or meat spots. Haugh units were greater for FMG
vaccinated birds and was speculated to be because they laid less eggs and was not due to
any observable enhanced function of the magnum. Thus, FMG even administered late in
production was capable of reducing egg production in the absence of an MG challenge.
Cummings and Kleven (1986) evaluated if strain F vaccines realistically offer
protection for field encountered MG levels. They vaccinated Leghorn pullets at 6 weeks
of age with 2 x 108 CFU/mL of strain FMG vaccine that was Tylosin-sensitive via
eyedrop. Non-vaccinated birds were included as controls. At 12 weeks of age all birds
were challenged in the trachea with a dilution of strain 227B MG that was Tylosinresistant in serial dilutions from 10 to 10-9 in Mycoplasma broth, with one pen of 10 birds
each receiving a particular dosage. The MG, prior to dilution, was stated to have 7.5 x
108 CFU/mL. All birds’ tracheas were swabbed three days post-challenge to isolate MG
in the trachea utilizing media with and without Tylosin. Similar amounts of nonvaccinated birds were positive for MG with and without Tylosin. The samples from
vaccinated birds challenged with the 10-3 to 10-9 dilutions had no MG grow in media with
Tylosin included. All birds (controls and vaccinated) had viable MG in the media
without tylosin. These results indicated that the Tylosin-sensitive vaccine was able to
“displace” the Tylosin-resistant challenge strain and thus afford protection for the birds
that had been vaccinated. The displacement of field strains by a strain F vaccine was
further confirmed by Kleven et al. (1990) in a commercial setting where the farms had
been vaccinating with strain F for two or more years. They distinguished Mycoplasma
species from the farms using restriction fragment sizes cut by EcoRI and species specific
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probes to hybridize to the fragments and found that the recovered MG DNA was from
only the vaccine strain.
Kleven et al. (1998) further tested the idea of “displacement” of a virulent MG
strain through vaccination testing of all the live vaccine strains of strains F, ts-11, and
6/85. They started with five groups of 30 layer pullets, one group was left unchallenged
and the other four groups were challenged with R strain MG at 4 weeks of age via
eyedrop. They had three other groups of chickens that were vaccinated with either strain
F, ts-11, or 6/85 at 4 weeks of age and they continued to add younger chickens so that
birds were always vaccinated at 4 weeks of age. At 8 weeks of age (4 weeks after
challenge), 10 birds were removed from each of the five groups and replaced with 10
birds that had been vaccinated at 4 weeks of age or control birds, the initial vaccinated
chickens were tested to culture MG and identify the strain and to test for antibody
production against MG, this was also repeated. Each month 10 chickens (the oldest in
each group) were removed and a swab sample was taken from the trachea to culture MG
and distinguish the strain and bleed the birds for testing of antibodies against MG. Only
the first 3 months of sampled birds had been directly challenged with strain R, since they
kept adding young 8 week old chickens the birds removed at first were 8 week old, then
the next month were 12 week old, and then months 3-10 the birds removed were each 16
weeks old. Greater antibody production was found in F strain vaccinated birds than ts-11
or 6/85. F strain completely displaced R strain from the trachea by 8 months while ts-11
and 6/85 did not displace R strain at all. The authors had speculated that since field
strains are not as virulent as R strain, ts-11 and 6/85 may still displace field strainsalthough they could not displace strain R. The authors described an additional
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experiment where they vaccinated birds with ts-11 and found it displaced F strain and
then left the complex MG negative. They proposed an eradication program where
complexes vaccinate with strain F to displace the MG field strains for at least one year
and then switch to ts-11 or 6/85.
In another comparison of MG strains used for vaccination, Abd-El-Motelib and
Kleven (1993) vaccinated leghorns at 10 days of age with F, ts-11, or 6/85 in the eye or
with bacterin subcutaneously and administered an aerosol challenge with strain R at 30,
60, and 90 days after vaccination. Strain F vaccinated birds over all ages had a reduced
air sac lesion score, followed by ts-11 and 6/85 with bacterin exhibiting similar air sac
lesion scores to non-vaccinated challenged chickens. Strain F did cause slight respiratory
symptoms in the birds that was not seen in ts-11 and 6/85 which indicated strain F was a
more virulent strain. Strain F was reported to cause increased antibody production
against MG and was recovered from the trachea at higher levels at all ages than ts-11 or
6/85. Strain choice for vaccine use may be made based on the challenge scenario (AbdEl-Motelib and Kleven, 1993; Peebles and Branton, 2012). Strain F vaccines provide
protection from field MG strains for the life of the bird, while ts-11, 6/85, and bacterin
provide adequate protection until the middle of the laying cycle for a commercial flock
(Hy-Line, 2013).
Ferguson-Noel et al. (2012) compared a bacterin, strain F, and the fowl pox
vectored MG vaccines. The vaccines were administered to specific pathogen free pullets
at 10 weeks of age, and the birds were challenged with strain R by aerosol at 25 weeks of
age. There was adequate protection against air sac lesions from the bacterin and F strain
vaccines but not the fowl pox vectored MG vaccine. Another study evaluated the use of
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fowl pox vectored vaccination of pullets at 6 weeks with an additional strain F
vaccination at 45 weeks of age and found no difference in egg production compared with
fowl pox vectored vaccinated pullets and non-vaccinated birds reared to 52 weeks of age
(Leigh et al., 2013). It was concluded the fowl pox vectored vaccine may protect against
strain F’s slight depression in egg production on unchallenged birds.
Several studies have investigated these “overlay” vaccination programs
administering one of the MG vaccines early during pullet rearing and then another later
during the lay cycle (Peebles and Branton, 2012). Leigh et al. (2010), for example,
evaluated an overlay program of vaccinating pullets with 6/85 strain of MG at 10 weeks
of age and then vaccinating again with strain FMG at 22 or 45 wk in comparison to solely
vaccinating with 6/85 at 10 weeks of age with no booster/overlay vaccination during egg
production. The authors saw a higher SPA score in birds vaccinated a second time using
strain F than birds vaccinated once at 10 weeks with 6/85. No differences were observed
in any of the groups for egg production, egg size, eggshell strength, or interior egg quality
with Haugh unit measurements or blood and meat spot incidence. Birds that were
vaccinated with strain F at 22 weeks did have greater pimpling of the eggshell from
weeks 45-52 of egg production with no difference among the other treatments. The
conclusion of this study was that overlaying strain F after a 6/85 vaccination does add
additional protection and prevents drops in egg production previously seen with strain F
vaccinations administered early during pullet rearing. Other modifications to current MG
vaccines have also been investigated such as altering dosages and method of vaccine
administration (Evans et al., 2007, 2012, 2013, 2015).
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Mycoplasma gallisepticum Transmission
Transmission research has found that MG can be transmitted to poultry both
horizontally (between birds) and vertically (through an infected egg to the chick) (Ley,
2008). Olesiuk et al. (1967) conducted a series of transmission studies concerning MG.
Their findings indicated that birds infected with MG, whether showing respiratory
symptoms or not, could horizontally transmit the bacteria to pen mates with whom the
infected birds were in direct contact. Their findings also indicated that although
transmission is possible, it does not always occur. Some experiments showed a lack of
bacterial transmission even after 16-36 weeks of direct contact between infected birds
and non-infected pen mates. Their work did not show transmission of MG from infected
materials when non-infected birds were placed in a pen previously inhabited by infected
birds 2-12 days earlier.
Christensen, et al. (1994) demonstrated general length of time that MG bacteria
could remain alive on various materials. Indirect transmission is hypothesized to occur
through natural shedding of MG to the environment from an infected host potentially due
to mucus secretion. Using MG field strains, they tested various materials that could be
encountered in a poultry house environment. Mycoplasma gallisepticum was able to
survive on cotton for 2-4 days, rubber for 2 days, shavings and timber for a maximum of
one day, for 4 days in pelleted chicken feed, 2 days in tap water, 3-4 days on feathers, up
to 2-3 days on human hair and up to one day in a human nose, with duration of survival
depending on the MG strain. In general, they found that MG survived longer on
absorbent surfaces than smooth surfaces and speculated that the chemicals in shampoo
may have hindered MG growth on human hair.
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Kleven (1981) found that live attenuated F strain MG vaccine is transmissible
from vaccinated birds to non-vaccinated birds as long as they are in direct contact and in
direct contact closer to the time of vaccination. Ten layer chickens at 18 weeks of age
were vaccinated with strain F MG via 0.05 mL eyedrop at 8 x 108 cfu/mL and then put
them in direct contact with 10 other non-vaccinated pen mates but at different timings
post-vaccination. He also raised five pens of broilers and several pens of non-vaccinated
layer chickens next to the vaccinated layers to determine any transmission between
adjacent pens from the vaccinated layers. He found that no birds transmitted MG well
unless they were in direct contact. No MG was transmitted when there was an empty pen
or aisle separating birds. In only one pen of broilers, 5 out of 17 broilers tested positive
for MG at 8 weeks of age after being next to vaccinated layers at the onset of vaccination.
Layers in adjacent pens to vaccinated layers were noted to have a small serological
response but the author was not able to isolate MG. This study showed a low
transmission of MG to birds between adjacent pens. Birds that had been vaccinated
remained positive for MG 49 weeks post-vaccination yet percentages of positive birds
and amount of MG organisms isolated decreased with time. Control birds placed with
vaccinated birds developed antibodies against MG very quickly when placed earlier (6-12
weeks post-vaccination) in comparison to later (27 weeks post-vaccination).
Ley et al. (1997) vaccinated 10 layer pullets with the other live attenuated vaccine
strains of either 6/85 or ts-11 in different trials and placed 10 non-vaccinated/noninfected layer pullets into the pen with the vaccinated birds. They surrounded this central
pen with adjacent pens of MG clean layer pullets, broiler breeders, turkey breeders, and
turkeys for meat production so that the birds could contact the vaccinated birds through
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chain link fencing. Antibody production against MG by ELISA testing was only detected
in the ts-11 (eye drop application) vaccinated pullets, not the 6/85 (spray application)
vaccinated pullets, yet MG was able to be cultured from high percentages of the
vaccinated birds. Mycoplasma gallisepticum was not transmitted to any of the birds in
the adjacent pens from either of the vaccines tested. Mycoplasma gallisepticum was
transmissible to the pullets reared in the same pen as the ts-11 vaccinated birds but in low
percentages (10, 20, and 40% of the comingled pullets on days 21, 42, and 63 postvaccination). The bacteria was not transmitted from the 6/85 vaccinated pullets to their
pen mates.
Feberwee et al. (2005) infected layer chickens with various dosages of MG (102,
104, 105, or 108 CFU) and brought the birds in direct contact with a pen mate in 10 pens
or at a distance of 65 cm from single housed, non-infected birds in 5 pens one day after
infection. The trachea of all birds were swabbed for detection of MG using PCR and
bled for serology testing on several days ranging from 2-35 days post-infection of the
MG birds. Their findings showed transmission, through MG detection, to the birds in
direct contact with the infected bird and that transmission was possible across 65 cm,
although lower amounts of MG were detected in the lone birds separated by the 65 cm
distance than the directly contacted birds at all dosages. Only one of the lone birds,
receiving MG transmission from a 108 infected bird, was serologically positive for MG.
This study indicated a potential for MG transmission through the air. Levisohn and
Kleven (1981) state that transmission to birds across an empty pen may depend on the
environment of the house, such as variations in air speeds and air direction as well as
distances between birds. They state that vaccine strain FMG in commercial layer houses
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is able to spread slowly down an aisle of birds housed in cages, but with less transmission
between aisles of caged birds within a hen house.
Vertical transmission through the egg is summarized to have the greatest
percentage of transmission closest to time of infection (or challenge) with the highest
reported at 50% and decreases afterward to be less than 3% as a chronic infection (Lin
and Kleven, 1982; Ley, 2008). Lin and Kleven (1982) exposed MG clean breeding layer
chickens (10 or 11 pullets and two males per group) at 7 months of age to either strain F
or strain R by eye drop or aerosol (using a nebulizer). One group was given a saline eye
drop as a control. Each bird was given (by either route) 30 µL of R strain at 6 x 108
CFU/mL or a vaccine F strain administered at 2 x 108 CFU/mL. They monitored the
birds’ antibody production against MG and incubated their eggs each week of production
after challenge. The eggs were candled on days 5, 8, 11, and 15 days of incubation to
remove eggs for testing if non-viable. All remaining live embryos were sampled at 18
days of incubation. All eggs were sampled for the presence of MG. All chickens
exposed to MG, regardless of strain or administration route, were reported to have a
drastic decrease in percentage fertility determined at 5 days of incubation (by as much as
56.3% in both the R aerosol and the F eye drop treatments). The authors indicated they
removed the original males and replaced them with new males (assumed to be MG clean)
12 weeks after challenge but saw no change in fertility. The authors state they compared
semen concentration and quality between MG challenged and control males and saw no
difference. They state that no MG was isolated from semen. Strain R exposed chickens
by aerosol route had MG isolated in the eggs at 3.19% and F strain MG delivered by
aerosol was isolated in eggs at 1.59%. Eye drop route exposed chickens passed MG to
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their eggs less than the aerosols with strain R isolated in only 0.19% of the eggs and no
isolations of MG were found from eggs of hens challenged with eye drop of strain F. The
authors indicated most isolations were from 18 day live embryonated eggs and were
found during 3-7 weeks post-challenge. They did isolate MG from some dead embryos
and speculated that MG may have contributed to embryo death. Mycoplasma
gallisepticum caused a slight decline in egg production in all challenged groups with a
drastic drop that lasted 4 weeks in the birds challenged with strain R by aerosol (rate of
egg production declined from approximately 90% to 30%). Mycoplasma gallisepticum
was found in the trachea of all challenged groups and serum plate agglutination testing
was universally positive for all the hens exposed to MG. Hemagglutination inhibition
testing found strain R exposed hens had a larger antibody production than strain F birds
and aerosol route of exposure caused higher antibody production than eye drop exposure
1 month after challenge. The antibody titer levels were similar between the groups at 7
months after challenge. Glisson and Kleven (1984) also found that strain FMG
administered by eyedrop was not vertically transmitted to the egg.
Beyond natural transmission of MG to progeny though the egg, many researchers
have investigated the effects of injecting MG into embryonated eggs.
Mycoplasma gallisepticum Effects on the Chicken Embryo
Most early work concerning injecting MG into chicken embryos was concerned
with developing methods to evaluate the relative pathogenicity of different species of
Mycoplasma and different strains of MG in chickens (Yoder, Jr. and Hofstad, 1964;
Power and Jordan, 1973, 1976). This work inoculated fertilized eggs in the yolk sac
during early incubation at 7 days of incubation (Yoder, Jr. and Hofstad, 1964) and
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evaluated various incubation temperatures (34°C, 37°C, and 40°C) to best provide clear
demonstration of differences in virulence among strains of MG evidenced by embryonic
mortality and relative lesions including shunted growth, splenomegaly, hepatitis, edema,
and hemorrhaging under the skin (Yoder, Jr. and Hofstad, 1964; Power and Jordan,
1973). This work evaluated embryo mortality up until 19 days of incubation and did not
investigate if embryos could survive to hatch (Yoder, Jr. and Hofstad, 1964; Power and
Jordan, 1973).
Roberts and Olesiuk (1966) utilized fertile eggs from a MG clean breeder flock.
They administered a known virulent strain FMG into the yolk sac of live embryos at 7
days of incubation, and they investigated survival to hatch. They started with MG
organisms of different passage amounts starting at 108 CFU per mL and injected tenfold
dilutions of the starting bacteria solution from 10-3 to 10-8 dilutions into 50 embryos per
each dilution at 7 days of incubation into the yolk sac (100 µL injection), and evaluated
the number of chicks that hatched. The largest percentage hatch recorded was at the
highest passage (63) and the largest dilution (10-8) at 54 percent hatch of embryos
inoculated. They noted that highest embryonic mortality was noted at and under 34
passages of the bacteria and that lower dilutions (10-3, 10-4, and 10-5) tended to kill
embryos earlier (between 4 and 8 days after injection) while chicks that received higher
(10-6, 10-7, and 10-8) dilutions predominantly nearly made it to hatch with most mortality
as dead pips. Dead pips also made up greater percentages of the mortality in MG that had
undergone higher passage rates.
Roberts and Olesiuk (1966) also compared different embryonic ages, changed
injection sites, and investigated post-hatch antibody production with the intent to
37

investigate if tolerance would be induced by exposing a chicken to MG as an embryo.
They injected a 100 µL injection of the 10-5 dilution of the 108 CFU per mL FMG that
had been passaged 54 times in broth into either the yolk sac of embryos incubated for 7
days (n=250) or intravenously into embryos at 14 days of incubation (n=104) with 223228 CFU injected into each embryo. They reported 20% hatch in both age groups with
9.6% dead pips and 10.4% day 20 and 21 embryonic mortality in the 7 day injection
group and 33.7% dead pips and 41.3% day 20 and 21 embryonic mortality in the 14 day
injection group. They raised the hatched chicks until 4 weeks of age and measured
antibody production against MG with rapid slide agglutination and hemagglutination
inhibition testing. The 7 day injection group (n=50) experienced 12% post-hatch
mortality to 4 weeks of age and the 14 day injection group (n=21) experienced 52.4%
post-hatch mortality. The percentage of the surviving chickens that showed positive
results (antibody production) at 4 weeks of age was 40% by hemagglutination inhibition
and 48% by rapid slide agglutination in the 7th day of incubation injected group and was
90% for both hemagglutination inhibition and rapid slide agglutination in the 14 day
embryo injected group. The authors hypothesized that perhaps the yolk sac injection
prevented or limited the immune cells of the chick embryo from interacting with the MG.
Power and Jordan (1976) injected specific pathogen free (SPF) chicken embryos
in the yolk sac at a later embryonic age, at 18 days of incubation, with 0.1 mL of 108
CFU of different strains or passages of MG as well as Mycoplasma gallinarum and
evaluated post-hatch mortality to 4 weeks of age. They reported hatching the different
injection treatments/strains and rearing the birds in positive pressure isolation pens that
had wire flooring. Hatchability was not reported on the 18 day injected embryos. An S6
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strain of MG with low passage rate of 9 passages in SPF chick lungs, once on agar, and
once in MG broth produced 80.5% mortality (n=36 birds raised in total) in the first week
while an S6 strain passed 150 times in MG broth caused 8.9% mortality during the first
week (n=45 birds raised in total). Mycoplasma gallinarum caused no mortality during
the first week. Most mortality occurred during the first week of growout although 13.9%
additional mortality occurred in the highest mortality low passage S6 strain by 4 weeks of
age. The high mortality group were noted as “severely depressed” in the first week and
that “shortly before death, many of these chicks gasped intermittently and exhibited
opisthotonous, backwards somersaulting and circling movements” (Power and Jordan,
1976). These chicks also had reduced weight gain and “oedematous and congested”
lungs with yellow colored exudate present in the thoracic and/or abdominal air sacs and
sometimes the syrinx.
Power and Jordan (1976) additionally made tracheal organ cultures from chicken
embryos at 20 days of incubation to evaluate loss of cilia activity due to the different MG
strains at 108 bacteria counts. These embryonic trachea cultures lost all ciliary activity in
4 days with the low passage S6 strain that caused the high post-hatch mortality and other
MG strains took 5-7 days to lose all activity. Mycoplasma gallinarum caused loss in 68.5 days, the mycoplasma broth utilized caused loss in 9-11 days, and control tracheas
with no broth or MG addition lost activity in 10-13 days. They also injected embryos in
the yolk sac at 4, 7, 10, or 12 days of incubation and evaluated embryonic mortality until
19 days of incubation for the various strains of MG being tested as well as different
incubation temperatures as previously investigated (Power and Jordan 1973) of 34°C,
37°C, and 40°C. The lower passage MG caused greater embryonic mortality than the
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other MG strains, yet in general for each MG strain tested, greater percentage embryonic
mortality occurred when injected at the earlier ages during incubation.
Levisohn et al. (1985, 1986) did not find a reliable association between embryonic
mortality due to injection of an MG strain in an embryonated eggs and the pathogenicity
of MG strains in birds determined by air sac lesion scores and trachea cultures. Their
hypotheses for this finding were that perhaps MG can become more virulent in an
embryonated egg or that the “massive MG multiplication in the yolk and the resultant
inhibitory effects on the embryo” is the reason for embryonic mortality (Levisohn et al.,
1985). This study injected embryos with various dosages (ranging from 101 to 106 cfu in
each egg) of different MG strains as a 0.2 mL injection into the yolk of embryos at 6 days
of incubation (Levisohn et al., 1985). Similar lesions were found in the dead embryos as
in previous studies with edema, stunted embryos, and hemorrhaging apparent, and they
also found that in general lower dosages caused mortality in embryos at later ages.
Mycoplasma gallisepticum strains that were more pathogenic to chickens did cause
earlier embryonic mortality (4-7 days after the injection) while less virulent strains
generally caused later embryonic mortality (8-11 days after the injection). They reported
that certain strains of MG, including one of the F strains utilized in the study, did not
cause any embryonic mortality up to 19 days of incubation even when 108 cfu was
injected into the yolk of the 6 day embryo. They stated no difference in findings whether
using SPF free fertile eggs or eggs from an MG and MS clean breeder flock. This study
additionally tested the ability of maternal antibodies to inhibit embryonic death from the
MG injections and found nearly complete protection of the embryo until 11 days after the
MG injection.
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The work of Akhtar et al. (1991) injected embryos from a Mycoplasma clean
breeder flock at 8 days of incubation with a 0.2 mL injection of either S6, strain F, or MG
strains collected from birds with Mycoplasma symptoms from the Pakistan area at
dosages ranging from 105 to 109 cfu per mL into the yolk sac (n=24 embryos per dose
and MG strain). They drew similar general conclusions as Levisohn et al. (1985) that
MG strains that are less virulent cause embryonic mortality at later ages, including a
tested F strain. They calculated an LD50 value for strain F 7 days after injection as 9.29 x
108 cfu. The LD50 for S6 was calculated 5 days after injection as 7.0 x 106 cfu. These
researchers suggested that more emphasis should be placed on embryonic mortality that
occurs 3-5 days after MG administration into the yolk in order to best rate relative
virulence of an MG strain than later embryonic mortality. Mortality values were high in
all doses and strains with the lowest mortality recorded as 62.5% of the 24 initial
embryos (by 18 days of incubation) for strain F when 8.1 x 106 cfu/mL was administered
at 8 days of incubation.
The study that most closely resembles the experiments of this dissertation is the
work published by El-Safty et al. (2005). They in ovo vaccinated birds at 18 days of
incubation for either MG or infectious bursal disease or administered the vaccine at 7
days post-hatch through the water lines. They additionally challenged 10 birds with a
virulent strain at 3 and 5 weeks of age post-hatch. Antibody production measured via
ELISA testing was compared between the groups at 4 days of age and then each week up
until 4 weeks of age post-hatch. For the purpose of this review, we will focus on their
results vaccinating with MG. The MG strain used for vaccination was a “locally
prepared” F strain and the S6 strain was used as the challenge strain given in the nares.
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The main questionable parts of the information is the exactness of the numbers utilized in
the study and the deficiency of detailed specifics describing the methodology (such as no
dosage values). The study utilized both SPF fertilized eggs and fertile eggs from what
was described as a “commercial source” presumably with maternal antibodies deposited
within the egg. Their findings indicated that in ovo vaccinated SPF birds had larger
antibody titers against MG at hatch than all other treatments including the commercial
source birds that had been in ovo vaccinated, and these titer levels continued to increase
through 4 weeks post-hatch ending at a larger level of antibodies in the SPF in ovo
vaccinated birds than the commercial in ovo vaccinated birds or the SPF or commercial
post-hatch vaccinated birds. The commercial source in ovo vaccinated chicks had similar
titer values to both SPF and commercial chicks that had been vaccinated at 7 days posthatch. The commercial birds had maternal antibodies detected at hatch with a lower
value at 4 days post-hatch and none at 7 days post-hatch. The data collected after the
challenge with S6 was an air sac lesion score (not described) recorded 1 week after the
3rd week and 5th week challenge. The SPF in ovo vaccinated birds had the lowest lesion
scores, followed by the in ovo vaccinated commercial source birds with the post-hatch
vaccinated birds having the highest lesion scores. None of these data were analyzed for
significant differences among treatments and findings were based upon 10 birds in each
treatment.
Thus, the present work of this dissertation seeks to confirm if an MG in ovo
vaccination (at 18 days of incubation in a location other than the yolk-sac) is possible:
determine if layer embryos can hatch after MG administration and, if so, since previous
research reviewed here indicates embryonic survival to hatch is possible, if hatch is
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possible at a sufficient amount to be a practical vaccination technique for the layer
industry. This dissertation also investigates if embryos that survive to hatch will
succumb to the bacteria post-hatch or if they can mature to exhibit an immune response
against MG, as shown in past research, with future implications to potentially confer
protection against a true field challenge scenario. The utilization of modern in ovo
vaccination machinery and techniques that are currently employed in the commercial
broiler industry will also be addressed since the disinfection step noticeably may pose a
foreseeable obstacle to administration of bacteria in ovo.
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LAYER CHICKEN EMBRYO SURVIVAL TO HATCH WHEN ADMINISTERED AN
IN OVO VACCINATION OF STRAIN F MYCOPLASMA GALLISEPTICUM
AND LOCATIONS OF BACTERIAL PREDOMINANCE IN
THE NEWLY HATCHED CHICK
Abstract
Mycoplasma gallisepticum (MG) is a bacterial pathogen of poultry that in layer
chickens causes egg production losses. To combat MG, multiage layer facilities
vaccinate pullets by either spray or eye drop vaccination. The purpose of this paper is to
evaluate if in ovo vaccination of MG is a potential alternative vaccination route for MG
in layer chickens. This included determinations as to if layer embryos could survive to
hatch once administered a live attenuated strain F (FMG) vaccine in ovo. Layer embryos
at 18 days of incubation were either not-injected, or hand-injected with a diluent
injection, or a high, medium, low, or low-low dosage of an FMG vaccine. Hatch success
and residual egg embryonic mortality was noted after 23 days of incubation, and all
hatched chicks were weighed and their yolk sacs were removed and weighed. Six
hatched chicks per treatment were swabbed for the detection of FMG at four different
sites (trachea, mouth and esophagus, yolk sac membrane, and the lumen of the duodenal
loop) via real-time PCR. Embryos were found to be administered 106 colony forming
units (CFU) per dose in the high treatment, 104 CFU/dose in the medium treatment, 102
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CFU/dose in low, and between 5.06 and 5.93 CFU/dose in the low-low treatment. Hatch
of embryonated eggs was decreased by the medium and high doses (P=0.02), with
embryonic mortalities occurring as dead pips (P=0.004). No differences in yolk-free
chick weights were found at hatch (P=0.27). No FMG was detected in any of the sites in
the control and diluent injected chicks. However, FMG was detected at all dosages and
sites with greater amounts of positive chicks in the higher FMG dosage treatments.
These findings indicate the potential practicality of in ovo vaccinating layer embryos with
FMG based on hatch success at lower dosages, and that the bacteria, once injected into
the amnion, is present in the upper respiratory and gastrointestinal tracts as well the yolk
sac membrane and the small intestine of hatchlings. Future research will need to
ascertain any post-hatch mortality effects of in ovo administered FMG and its
implications on post-hatch immunity.
Introduction
Mycoplasma gallisepticum (MG) infections are considered an “endemic”
production issue on multiage layer complexes causing a reduction in egg production by
approximately 10-15% (Carpenter et al., 1981; Lin and Kleven, 1982; Evans et al., 2005;
Ley, 2008; Hy-Line, 2013). To combat egg losses, pullets are typically vaccinated
against MG between 8-18 weeks of age (before the start of egg production) utilizing an
oil emulsion bacterin or a live attenuated vaccine (Levisohn and Kleven, 1981; Whithear,
1996; Evans, et al., 2005). Live attenuated vaccines are delivered by either a spray or eye
drop method and bacterins are administered subcutaneously (Whithear, 1996). Thus,
these methods can be labor intensive.
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In ovo vaccination has been a successful technique eliminating the need to
manually vaccinate broilers post-hatch for Marek’s disease (Sharma and Burmester,
1982; Johnston et al., 1997; Ricks et al., 1999), and the technique has additionally
proven effective for other viral poultry diseases (Sharma, 1985; Wakenell and Sharma,
1986; Stone et al., 1997; Ricks et al., 1999; Rautenschlein and Haase, 2005; Mast et al.,
2006; Tarpey et al., 2006; Tarpey and Huggins, 2007; Toro et al., 2007; Johnson et al.,
2010; Cai et al., 2011). In ovo vaccination of a bacterial organism, however, has been
less fully investigated. A couple of papers have evaluated the potential of in ovo
vaccination against Camyplobacter and Salmonella (Coloe et al., 1994; Noor et al., 1995)
with the majority of published bacterial in ovo research investigating the in ovo
administration of probiotic bacteria (Cox et al., 1992; Edens et al., 1997; Meijerhof and
Hulet; 1997; Yamawaki et al., 2013; De Oliveira et al., 2014).
The purpose of the present study was to evaluate if the in ovo vaccination of live
attenuated strain F (FMG) has the potential to reduce labor costs and bird handling stress
during the pullet period. The initial discovery of the potential to vaccinate birds posthatch against MG was accomplished utilizing FMG (Levisohn and Kleven, 1981).
Vaccinating layer chickens with FMG post-hatch has been shown to provide adequate
protection against field strains of MG for the life of the laying hen, with an ability to
“displace” field strains in the trachea (Cummings and Kleven, 1986; Kleven et al., 1998;
Hy-Line, 2013). The FMG vaccine has been found to be more protective, yet more
virulent, in comparison to the other available live MG vaccine strains (6/85 and ts-11;
Abd-El-Motelib and Kleven, 1993; Kleven et al., 1998). Thus, the purpose of this study
was to investigate the in ovo vaccination of layer embryos with FMG.
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Whether or not chicken embryos can survive to hatch after an injection with live
MG is uncertain. Past researcher injected MG into embryonated chicken eggs with the
purpose to rate pathogenicity of various strains and passage levels of MG (Yoder, Jr. and
Hofstad, 1964; Roberts and Olesiuk, 1966; Power and Jordan, 1973, 1976; Levisohn et
al., 1985; Akhtar et al., 1991); however, only two of these studies reported allowing MG
injected embryos to hatch (Roberts and Olesiuk, 1966; Power and Jordan, 1976). Power
and Jordan (1976) injected MG into the yolk sac of specific pathogen free embryos at 18
days of incubation, and although they did not report the exact hatch results, it is clear
some embryos survived to hatch as they were able to rear birds for further post-hatch
evaluations.
The hatch results of Roberts and Olesiuk (1966) were more specific. In their
research, 0.1 mL (108 colony forming units (CFU) per mL) of FMG at various passage
levels and dilutions ranging from 10-3 to 10-8 of the starting bacterial culture were
injected into the yolk sac of embryonated chicken eggs at 7 days of incubation. The
largest percentage hatch recorded (54% of inoculated embryos) was at the highest
passage level (63) and the largest dilution (10-8). They noted the highest mortality in
embryos that were injected with FMG that had been passaged at and under 34 passages.
Furthermore, lower dilutions were found to cause embryonic death earlier (4-8 days after
injection), while embryos that received higher dilutions died later as dead pips. Dead
pips also made up a greater percentage of the mortalities of embryos receiving FMG that
had undergone higher passage rates.
Roberts and Olesiuk (1966) also compared embryonic survival rates when FMG
was injected at different embryonic ages and in different injection sites. They injected a
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0.1 mL volume of a 10-5 dilution of live FMG that had been passaged 54 times in broth
into either the yolk sac of embryos incubated for 7 days or intravenously into embryos at
14 days of incubation. The number of bacteria injected into each embryo was 223. They
reported a very low (20%) hatch in both age groups.
The objective of the current study seeks to determine if modern layer embryos can
survive to successfully hatch after in ovo-vaccinated with a current commercial live
attenuated FMG vaccine (Poulvac Myco F, Zoetis, New York, New York). To-date, this
vaccine has been administered post-hatch to pullets. This investigation serves as an
initial step to investigate if the in ovo vaccination of live FMG may serve as a viable and
potential labor saving vaccination option for the layer industry. Obviously, hatch success
would need to far exceed the highest noted hatch of embryonated eggs (54%) observed
by Roberts and Olesiuk (1966) to be a viable option. This study also investigated if MG
can be detected in different tissues of the chicks that survive to hatch.
Materials and Methods
Fertile Hy-Line W-36 layer eggs were obtained from a 34 week-old MG-clean
commercial breeder flock (National Poultry Improvement Plan, 2014). The eggs were
stored for four days before incubation. Three hundred and sixteen eggs were set in
eleven total plastic flats (30 egg capacity) within four 90-egg-capacity trays within a
calibrated NOM 45 NatureForm Incubator (NatureForm Incubator Company,
Jacksonville, Florida) set at 37.5°C and 53% relative humidity. All eggs were weighed as
a batch weight of 30 eggs (as a flat) prior to incubation and on days 12 and 18 of
incubation for moisture loss determination. The eggs were also candled on days 12 and
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18 of incubation and clear eggs and eggs containing dead embryos were opened to
determine fertility or the age of embryonic mortality.
On day 18 of incubation, all live embryonated eggs were randomly assigned to
hatching baskets. Three hatching baskets were allocated to each of six treatments. The
six treatments were designated as follows: non-injected control eggs, diluent injected
control eggs (Poulvac Marek’s diluent, Zoetis, Exton, Pennsylvania), and eggs injected
with high, medium, low, and low-low doses of Poulvac Myco F vaccine (Zoetis, New
York, New York) resuspended and diluted in Poulvac Marek’s disease vaccine diluent.
The high dose was taken directly from the vaccine vial of the manufacturer resuspended
in 50 mL of Marek’s disease vaccine diluent. The medium dose was a dilution of 10-2,
the low dose was a dilution of 10-4, and the low-low dose was a dilution of 10-6 of the
original resuspended vaccine vial. A “dry punch” treatment (creating an injection hole in
the embryonated egg but injecting only air) was not included in this trial due to similar
hatch results found in preliminary work between non-injected eggs, diluent-injected eggs,
and dry punch eggs (see Appendix). Additionally, other in ovo injection research has not
reported a depression in hatch success as a result of the creation of a hole in the large end
of the eggshell during the latter portion of incubation (Sharma and Burmester, 1982;
Molenaar et al., 2010). Thus, a dry punch treatment was not included in this trial to allow
for greater breadth of injection treatment dosages and a maximum amount of available
embryos to be allotted to each treatment.
Each hatch basket contained 16 live embryonated eggs, which were
systematically picked from each of the eleven flats. All injection treatments were handinjected with a total 50 µL injection volume following the procedures of the “Manual in
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ovo Vaccination Guide” by Embrex Inc. (2002). The eggs were cleaned immediately
prior to injection by wiping the large end of the egg with 70% isopropyl alcohol using a
cotton swab. Once the eggs were dry, a hole was made using an 18 gauge, 3.8 cm needle
that had been pushed through a number 3 rubber stopper, leaving 0.6 cm of the needle
protruding from the end of the stopper to inhibit the hole-punch needle from penetrating
through the inner shell membrane of the air cell. The stopper and needle were soaked in
70% isopropyl alcohol for at least 2 minutes prior to use. Each injection was made
through the premade hole using a 1 cc syringe and a 22 gauge, 2.5 cm short beveled
needle. The needle was inserted into each egg so that the hub of the syringe met with the
eggshell, and then the vaccine was injected. The treatments were injected in order from
the lowest dose to the highest dose to limit any potential changes in bacteria counts while
the vaccines were awaiting injection as well as to limit any unwanted transmission of
bacteria from higher dosages to lower dosages. The 1X vaccine from the vaccine vial
(high dose) was plated prior to and after injection of all eggs (two plates per time). The
post-injection vaccine remained at room temperature during the injections to determine
possible changes in bacterial concentration during the injection process.
Nine live embryonated eggs were injected with Coomassie brilliant blue R-250
dye (Genlantis, San Diego, California) at a concentration of 0.7 g in 50 mL of Marek’s
disease vaccine diluent at the time of vaccine administration to determine the site of
vaccine deposition in the embryo. All embryos were euthanized using carbon dioxide
surrounding the eggs for at least 20 minutes and by subsequent cooling at 4°C overnight.
These eggs were placed in a -12.8°C freezer one hour before opening the eggs to
determine the location of the dye as well as staging the embryos according to an embryo
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staging system developed by Embrex (Avakian, 2006). The staging system is used to
evaluate if the chick has externally pipped, has internally pipped through the inner shell
membrane, and if the chick has oriented itself in a hatching position with its head under
its right wing. The staging system also grades the level of yolk sac retraction. Embryo
stage scores range from 1-7.
All eggs for each treatment remained in plastic flats during injection and were
then placed in 64 cm long, 13.5 cm wide, and 9 cm deep metal hatching baskets. The
eggs in each hatch basket were subjected to one specific treatment (n=3 replicate
hatching baskets per treatment). An attempt was made to place each treatment on each of
the three levels within the incubator, although this ideal was not possible. Only five
hatch baskets would fit on levels 2 and 3 in the incubator, so 8 hatch baskets were placed
on the uppermost level in the incubator. Due to this inadequate treatment interspersion
during the hatching period, location was evaluated as a potential effect as well as
treatment.
The hatch was monitored for completion and all hatch baskets were removed from
the incubator when chicks appeared dry and no additional chicks had externally pipped.
All hatched chicks were counted and all residue eggs were opened to confirm a late stage
of embryonic death. The chicks were euthanized using carbon dioxide. All hatched
chicks were weighed individually post-mortem immediately after euthanasia, their yolk
sacs were removed and weighed, and their yolk sacs were dried at 65°C for 3 days until
there was no further weight loss and were then reweighed to determine yolk moisture
content.
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Six chicks from each treatment (two per each hatch basket) were swabbed using
sterile swabs prewetted in PBS. Each chick was swabbed at four locations to detect the
presence of strain F Mycoplasma gallisepticum. The locations were inside the mouth and
down the esophagus, down the trachea through the larynx, on the surface of the yolk sac
membrane, and inside the duodenal loop of the small intestine leading toward the
jejunum. Each swab sample was suspended in 110 µL of PBS. Any bacterial DNA in
the swab sample was extracted using the Qiagen BioSprint 96 One-For-All Vet Kit
(Qiagen, Valencia, CA). The samples were run as two replicates per sample using a 7500
Fast Real Time PCR System (Applied Biosystems, Foster City, CA) using F strain
specific primers and probe designed by Raviv et al. (2008). Primers were diluted to a 0.5
µM concentration and the probe used was a 0.1 µM concentration. Each total 25µl PCR
reaction volume consisted of 2.5 µl of the forward primer (5’
GTTCAAGAACCAACTCAACCA 3’), 2.5 µl of the reverse primer (5’
GATTAAGACCGAATTGTGGATTG 3’), 2.5 µl of the Probe (5’
CAACCAGGATTTAATCAACCTCAG 3’), 12.5 µl of Taqman Universal Master Mix
(Applied Biosystems, Foster City, CA), 2.5 µl solution of extracted DNA, and sterile
water. The cycling parameters were 95°C for 15 minutes and 40 cycles at 94°C for 15
seconds and 61°C for 1 minute. Sterile water was used as a negative control, and a
previously known F strain DNA sample was used as a positive control for the
determination of the standard curve at a dilution of 10-1, 10-2, 10-3, and 10-4. Since there
was variation in surface area of the swabbed area of each bird, results were determined on
a qualitative basis (positive or negative for MG presence).
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Egg weights and moisture loss, hatch data, and chick and yolk weights and
percentages were analyzed as a general linear model using SAS Version 9.3 to evaluate
differences between treatments and potential location effects within the incubator. Egg
weights and moisture loss were analyzed on a tray basis utilizing the three flats per tray
and after averaging the values of the 30 eggs per flat. Percentage hatch of live
embryonated eggs was analyzed using the hatch basket as the experimental unit, and
chick and yolk weights and percentages were analyzed on an individual chick or yolk
basis. Significance was based on P ≤ 0.05 and differences were determined using
Fisher’s least significant difference.
Results and Discussion
The eggs set averaged 58.8 g and had an average 7.0% moisture loss at 12 days
and an average 10.3% moisture loss at 18 days of incubation. There was no difference in
average egg weight (P=0.78) or average moisture loss at 12 or 18 days of incubation
between the four trays (P=0.83 and P=0.80, respectively), indicating similar incubation
conditions for all eggs within the incubator prior to treatment administration at 18 days of
incubation. In the total set of eggs, there were 3.2% infertile eggs, 2.2% early dead
embryonic mortalities (days 0-6 of incubation), and 0.6% middle stage embryonic
mortalites (days 7-13 of incubation).
The nine embryonated eggs injected with dye (9.4% of the total live embryonated
eggs in the study) were all at stage 2 of embryonic development, with the dye found
surrounding the embryo in the amniotic sac. These embryos had not pipped (externally
or internally) and they were not yet oriented for hatch. Instead all embryos were oriented
so that their heads were positioned between their legs. The unanimous finding that the
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injected dye was located in the amnion indicates that the vaccine treatments were injected
in the ideal location or compartment of the embryo (Williams and Hopkins, 2011). As
the chicken embryo prepares for hatching, its internal compartments increase in size, thus
creating a negative pressure, which allows the embryo to “swallow” its amnion starting at
18 days of incubation (Romanoff, 1960). The location of the injected solutions in the
amnion would, therefore, be presumably beneficial for the in ovo injection of live FMG
since MG is well known for colonizing the chicken trachea (Cummings and Kleven,
1986; Kleven et al., 1998).
The time elapsed from resuspension of the vaccine to the conclusion of the
injection process was approximately 1.5 hours. Upon observation of the plate counts of
the vaccine solution drawn from the vial prior to and after the completion of all
injections, it was concluded that the loss of bacteria from the beginning to the conclusion
of injections were negligible. Plate counts of the vaccine prior to the vaccination of a 104

dilution averaged 237 CFU/20µL and at the same dilution, plate counts of the vaccine

after sitting at room temperature until all the injections were completed averaged 202.5
CFU/20µL. These counts indicated that the high treatment was administered bacteria in a
concentration range of 5.06-5.93 x 106 CFU per dose, the medium treatment had 5.065.93 x 104 CFU per dose, the low dose had 5.06-5.93 x 102 CFU per dose, and the lowlow treatment had 5.06-5.93 CFU per dose.
The chicks were removed from the incubator at approximately 23 days of
incubation to ensure that all possible chicks emerged from their shells. Chicks in the high
dose appeared to hatch slower than those belonging to the other treatments, and the
control chicks appeared to hatch faster than all other treatments, although no specific
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hatch pattern was recorded. Live external pips were noted in the high treatment baskets
on 22 days of incubation. The extra incubation time was allotted mainly for the benefit
of these eggs, since the main focus of this trial was to determine embryo survival to
hatch. As seen in Table 3.1, those live external pips merely became dead external pips.
The percent hatch of live embryonated eggs (Tables 3.1 and 3.2) decreased with
increasing bacterial dosage (P=0.02). There was no location (P=0.85) effect within the
incubator for percentage hatch of live embryonated eggs. Even at the highest FMG
vaccine dosage of 106 organisms, approximately only 40% of the layer embryos were
inhibited from hatching. Of the embryos that failed to hatch (as observed by hatchery
residue analysis; Table 3.1), only the percentage of dead pips (embryos that had survived
to externally pip through the eggshell but died before fully emerging from the eggshell)
were higher in the medium and high doses (P=0.004). Percentages of dead chicks
(P=0.13), late dead embryos (P=0.60), and embryos that had externally pipped and were
found alive (P=0.37), were not different between the injection treatments. There were no
location effects (all P>0.1) for any of the residue egg categories. These current hatch
results are much higher than those of Roberts and Olesiuk (1966) who reported their
highest hatch of injected embryonated eggs at 54%. Roberts and Olesiuk (1966),
however, injected embryos in the yolk sac at 7 days of incubation. Those injections were
made eleven days earlier and in a different location than the injections of the present
study. This largest percentage hatch recorded by Roberts and Olesiuk (1966) was an
injection of a 0.1 mL solution containing an initial 108 CFU per mL of FMG that had
been passaged 63 times (the highest passage level tested) and was at the largest dilution
(10-8). The FMG vaccine utilized in this current study (Poulvac Myco F Zoetis, New
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York, New York) is potentially a less-virulent/higher passaged FMG than that used by
Roberts and Olisiuk (1966). Our findings agree, though, that the lower dosages of the
live FMG resulted in a better hatch than the higher FMG dosages (Table 3.2).
Chick weights (P=0.26), yolk-free chick weights (P=0.27), wet and dry yolk
weights (P=0.49 and P=0.21, respectively), and the percentage wet and dry yolks of the
initial chick weight (P=0.56 and P=0.26, respectively) were not different between the six
treatments. Furthermore, there were no differences in chick or yolk weights based on
location within the incubator (all P > 0.31). The average chick weight was 38.746 ±
0.172 g and the average yolk-free chick weight was 35.641 ± 0.139 g. Fresh yolk sac
weights and their contents averaged 3.104 ± 0.061 g and dry yolk sac weights and their
contents averaged 1.482 ± 0.030 g. The percentage of water in the yolk sac and its
contents differed between treatments (P < 0.0001, see Figure 3.1) but did not differ by
location within the hatcher (P=0.65). Chicks belonging to the non-injected treatment
group had less percentage water in their yolk sacs and contents than all other treatments,
with increasing amounts of water in their yolk sacs and contents in the higher dosage
treatment groups. This may be due to the general observation that the non-injected
chicks appeared to hatch faster than the other treatments and had more time to lose water
in the hatcher than did the chicks from the injected treatments, although a hatch pattern of
the different treatment groups was not monitored. Molenaar et al. (2010) found that
Dekalb white embryonated chicken eggs pierced with an 18 gauge needle on day 14 of
incubation in the blunt end of the egg spent a shorter amount of time from external pip to
final emergence. Specifically, in comparison to nonpunctured eggs, the time from
external pip to final emergence was 3 hours shorter in the pierced eggs. Therefore, the
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hole-punch alone, while not found to affect hatch success, may affect hatch time.
Injected chicks may be spending less time outside of the eggshell and thus less time
drying out in the hatcher. The bacterial challenge to the embryo may potentially also
have delayed the embryo’s ability to hatch from the egg, lending to less drying time in
the hatcher.
A total of five chicks were observed to exhibit “extended neck breathing” (Figure
3.2). There were two chicks in the medium dose basket #15, and one chick in each of the
high dose baskets that exhibited this behavior. The large amount of FMG in the medium
and high dosages could have colonized and affected the function of the trachea and lungs,
causing the respiratory distress. Tracheal colonization has been observed in work
conducted on adult chickens by Levisohn, et al. (1983). Further work would be needed to
determine if these chicks would recover from these effects when reared post-hatch or if
they would succumb to the bacterial load. This respiratory distress or decline in oxygen
intake may have contributed to the potential delay in hatch time which was evidenced by
the increased percentage of water in the yolk sac and its contents in the medium and high
treatment groups.
The PCR results from the swab samples taken at the four body sites within the
hatched chick are shown in Figure 3.3. No chicks in the control or diluent injected
treatments were positive for FMG at any of the swabbed sites. It is interesting to note
that although these treatments were interspersed within the hatcher, no FMG was
detectable in the interior of the control birds. Chicks in the low-low dose group
possessed FMG in the mouth and esophagus, trachea, and yolk sac membrane, but did not
possess FMG in the duodenal loop. Strain FMG was detected in all four sites of chicks in
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the other treatments with more positive samples being generally detected as the dosages
were increased. The site having the majority of positive samples was the trachea. This
was followed by the mouth and esophagus, then the yolk sac membrane. The FMG was
least detected in the in the duodenal loop. Jochemsen and Jeurissen (2002) injected a 0.1
mL volume of different substances including indian ink, bromodeoxyuridin (incorporated
into DNA of cells that are dividing), fluorescent microspheres, and infectious bursal
disease virus (IBDV) vaccine diluted with NaCl2, into SPF white Leghorn embryos at 18
of incubation using a 1 inch 23 gauge needle. This was performed in order to chart where
in ovo injected substances are predominantly found in the embryonated egg. Their
findings indicated that in ovo vaccinated substances do arrive in the intestines of
embryos. This was likewise observed in the present study. The finding that more chicks
tested positive for FMG in the trachea and mouth and esophagus supports the idea that
the embryo “swallows” the contents of the amnion. This is supported in the current study
particularly since the dye injected chicks were unanimously found to be injected in the
amnion. Injections into the amnion also bathe the feathers of the embryo, as seen by
dyed feathers in the dye-injected embryos. This injection location also has the potential
to allow for bacterial transmission between hatch mates once the chick emerges from the
shell. However, even if any horizontal transmission occurred at hatch in the present
study, FMG was still not detectable in any of the sites of the control and diluent chicks.
It is possible, due to the sensitivity of our PCR reaction, that the transmission of smaller
amounts of bacteria occurred within the hatcher via down and feathers without detection.
Future research should be conducted raising these birds to allow for bacterial growth to
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reach detectable levels to determine if horizontal transmission could indeed occur within
the hatcher merely through the circulation of infected down and feathers.
This initial trial showed that layer embryos from MG clean breeders are able to
survive to successfully hatch after being administered a live attenuated FMG vaccine at
18 days of incubation. The results show higher layer embryo mortality in response to
higher amounts of injected bacteria, although the high dose level only caused 40%
embryonic mortality, with a potential delay in hatch due to higher FMG levels. Future
work will consider post-hatch survival and immune responses of these FMG in ovovaccinated birds.
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Table 3.1

Basket
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
1Eggs

Hatch results and residue breakout by hatch basket of Hy-Line W-36
hatching eggs after in ovo injections at 18 days of incubation

Treatment1
No Injection
No Injection
No Injection
Diluent
Injection2
Diluent
Injection
Diluent
Injection
Low-low Dose3
Low-low Dose
Low-low Dose
Low Dose4
Low Dose
Low Dose
Medium Dose5
Medium Dose
Medium Dose
High Dose6
High Dose
High Dose

Residue Eggs
%
Late Live Dead
Hatch Dead Pip Pip
100.0
0
0
0
93.8
0
1
0
100.0
0
0
0

Initial
Embryo7 #
16
16
16

# Live
Chicks
16
15
16

Residue
Eggs
0
1
0

Dead
Chicks
0
0
0

16

16

0

0

100.0

0

0

0

16

13

3

0

81.3

2

1

0

16
16
16
16
16
16
16
16
16
16
16
16
16

16
14
16
16
14
14
14
12
12
12
7
14
8

0
2
0
0
2
1
1
4
3
3
9
1
8

0
0
0
0
0
1
1
0
1
1
0
1
0

100.0
87.5
100.0
100.0
87.5
87.5
87.5
75.0
75.0
75.0
43.8
87.5
50.0

0
2
0
0
1
1
0
0
1
0
0
0
0

0
0
0
0
0
0
0
1
0
0
2
0
1

0
0
0
0
1
0
1
3
2
3
7
1
7

were either not injected or injected at 18 days of incubation by hand injection with a 50 μL volume treatment.
injected embryos were injected with Marek’s Diluent, which was also used to dilute a strain F Mycoplasma
gallisepticum (FMG) vaccine, Poulvac Myco F.
3Low-low dose FMG injection was a 10-6 dilution of the original resuspended vaccine vial and was found to be
administered at 5.06-5.93 CFU, colony forming unit, per 50 μL dose.
4Low dose FMG injection was a 10-4 dilution of the original resuspended vaccine vial and was found to be administered
at 5.06-5.93 x 102 CFU per 50 μL dose.
5Medium dose FMG injection was a 10-2 dilution of the original resuspended vaccine vial and was found to be
administered at 5.06-5.93 x 104 CFU per 50 μL dose.
6High dose FMG injection was taken from the resuspended vaccine vial and was found to be administered at 5.06-5.93
x 106 CFU per 50 μL dose.
7Hy-Line W-36 embryos that were determined alive by candling at 18 days of incubation.
2Diluent
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Table 3.2

Average percent hatch of live embryonated Hy-Line W-36 eggs after in ovo
injections at 18 days of incubation
Treatment

Average percent hatch of
live embryonated eggs1
No Injection
97.9a
2
Diluent Injection
93.8ab
Low-low Dose3
95.8ab
Low Dose4
87.5ab
Medium Dose5
75.0bc
6
High Dose
60.4c
1
Based on three hatch baskets containing 16 live 18 day incubated Hy-Line W-36
embryonated eggs each. Treatment effect P=0.02. Means with differing superscript
letters indicate a difference between the treatments.
2
Diluent injected embryos were injected with 50 μL of Marek’s Diluent, which was also
used to dilute a strain F Mycoplasma gallisepticum (FMG) vaccine, Poulvac Myco F.
3
Low-low dose FMG injection was a 10-6 dilution of the original resuspended vaccine
vial and was found to be administered at 5.06-5.93 CFU, colony forming unit, per 50 μL
dose.
4
Low dose FMG injection was a 10-4 dilution of the original resuspended vaccine vial and
was found to be administered at 5.06-5.93 x 102 CFU per 50 μL dose.
5
Medium dose FMG injection was a 10-2 dilution of the original resuspended vaccine vial
and was found to be administered at 5.06-5.93 x 104 CFU per 50 μL dose.
6
High dose FMG injection was taken from the resuspended vaccine vial and was found to
be administered at 5.06-5.93 x 106 CFU per 50 μL dose.
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a

55

ab

Average % Water in the Yolk

54
53
52

d

c

bc

bc

51
50
49
48

No Injection

Diluent
Injection

Low Low

Low

Medium

High

Treatment

Figure 3.1

Average percent water in the yolk sac of hatched chicks after in ovo
vaccination with a live strain F Mycoplasma gallisepticum vaccine

Treatment were administered at 18 days of incubation as either: no injection, diluent
injection with Marek’s diluent, which was also used to dilute a live attenuated strain F
Mycoplasma gallisepticum vaccine administered as a low-low (10-6 dilution), low (10-4
dilution), medium (10-2 dilution), or high dosage taken from the original resuspended
vaccine vial. P < 0.0001.
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Figure 3.2

Chicks exhibiting “extended neck breathing”

This behavior was the only abnormality that was visibly apparent in hatched Hy-Line W36 layer chicks that had received an in ovo vaccination of a live attenuated strain F
Mycoplasma gallisepticum (FMG) vaccine at 18 days of incubation at a medium (10-2
dilution) and high (1X) dose. Chicks that hatched from lower FMG dosages (10-4 and 106
dilutions) were not observed to exhibit this behavior.
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Number of Positive Samples

7
6
5

Control

4

Diluent
Injected
Low Low

3
2

Low

1
0

Mouth and
Esophagus

Stacked Number of Postive
Samples

(a)

(b)
Figure 3.3

Trachea

Yolk Sac
Membrane
Swabbed Location

Duodenal
Loop

25
20
High

15

Medium

10

Low
Low Low

5
0

Diluent Injected
Mouth and Trachea Yolk Sac Duodenal
Esophagus
Membrane Loop
Swabbed Location

Control

Detection of strain F Mycoplasma gallisepticum in Hatched Chicks.

Real-time PCR results depicting the presence of F strain Mycoplasma gallisepticum (FMG) in
swabbed locations in six hatched chicks per treatment. The top graph (a) depicts the number of
positive samples at each site per each treatment, and the lower graph (b) depicts each treatment’s
number of positive samples stacked for each site. The Hy-Line W-36 layer embryos were either
not injected (controls), or injected at 18 days of incubation with Marek’s diluent, or a dilution of
FMG vaccine: low-low dose was a 10-6 dilution, low dose was a 10-4 dilution, medium dose was a
10-2 dilution, a high dose was vaccine taken directly from the original resuspended vaccine vial.
The FMG vaccine was resuspended and diluted in Marek’s diluent.
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CHICKEN EMBRYO SURVIVABILITY, EARLY POST-HATCH SURVIVAL AND
HUMORAL IMMUNE RESPONSE OF LAYER CHICKENS WHEN IN OVO
VACCINATED WITH STRAIN F MYCOPLASMA GALLISEPTICUM
Abstract
Layer hens reared on multi-age hen complexes are vaccinated during pullet
rearing to combat production losses due to the bacteria, Mycoplasma gallisepticum (MG).
In this study, the potential to in ovo vaccinate layer chickens against MG, potentially
reducing labor, bird stress, and promoting an earlier immune response was investigated.
Layer embryos were administered a dosage of a live attenuated strain F MG (FMG)
vaccine, that is ordinarily given post-hatch, at 18 days of incubation, in two replicate
trials. Treatments included control, non-injected eggs, eggs injected with diluent, a 1X
high dosage, a 10-2 medium dilution, a 10-4 low dilution, and a 10-6 low-low dilution.
Hatch success was noted and a subset of chicks were weighed and swabbed for detection
of FMG in the trachea. Hatched birds were reared for 6 weeks in which mortality was
recorded daily. At 6 weeks of age, the birds were swabbed for the detection of MG and a
blood sample was tested for antibody production against MG. Hatch was depressed only
in the high dose group, with greater percentages of dead chicks and dead pips found at
hatch (P<0.0001). Strain F Mycoplasma gallisepticum was detected in the trachea of
chicks in each FMG injection treatment, with decreasing numbers of positive chicks in
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the lower dosage groups. A high rate of mortality (>50%) was noted during the first 2
weeks post-hatch in the high, medium, and low treatments. Birds in the low-low dose
treatment experienced 3.5% and 11.7% post-hatch mortality in the two trials during the
first 2 weeks. The presence of FMG and antibody production was detected in in ovovaccinated FMG birds at 6 weeks, with no significant differences in percentage positive
birds between FMG treatments (P>0.2 for all tests). Fifty percent of the low-low dose
treated birds tested positive for IgM antibody production at 6 weeks of age. Body
weights at 6 weeks of age were diminished with increasing FMG dose. The lowest dose
tested was found to be the most practical, causing the least mortality, weight loss, and a
large humoral immune response. Further work is needed to evaluate how this in ovo
vaccine, promoting immunity earlier in life, would compare to post-hatch vaccination
against an MG challenge scenario.
Introduction
Layer chickens, particularly on multi-age farms, are vaccinated during pullet
rearing against Mycoplasma gallisepticum (MG) before the start of lay to combat egg
production losses resulting from field strain MG infections common in laying hen
complexes (Levisohn and Kleven, 1981). Interest has been shown towards the potential
in ovo vaccination of layer chickens against MG, with the prospect of saving labor,
reducing stress on birds, and reducing vaccine usage. Our initial results, found in
Chapter 3 of this dissertation, indicate that layer embryos are able to survive to hatch
even when given a high dosage (106 CFU (colony forming units) per dose) of a live
attenuated strain F MG (FMG) vaccine ordinarily administered post-hatch. This
preliminary study warrants a larger sample size for definitive conclusions on the correct
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dosage that has the least negative impact on the chicken embryo for hatching and posthatch growth and immunity. Only the hatch rate of inoculated embryos was determined
in our previous study, and information on the effects of the administered in ovo vaccine
on the initial immune response and mortality level in the birds post-hatch are needed.
Few studies have injected MG into embryonated chicken eggs and allowed the embryos
to hatch for an evaluation of how the birds fair post-hatch.
Roberts and Olesiuk (1966) injected a strain FMG into embryos. After hatching
the chicks, they investigated post-hatch antibody production in birds at 4 weeks of age
with an original intent to investigate if tolerance would be induced by exposing a chicken
to MG as an embryo. They injected a 0.1 mL injection of a 10-5 dilution of FMG that had
been passaged 54 times in broth into either the yolk sac of embryos incubated for 7 days
or intravenously into embryos at 14 days of incubation, with 223 bacteria injected into
each embryo. They reported a 20% hatch in both age groups. The 7 day injection group,
originally consisting of 50 birds, experienced a 12% post-hatch mortality to 4 weeks of
age and the 14 day injection group, originally consisting of 21 birds, experienced 52.4%
post-hatch mortality. The percentage of the surviving chickens that showed antibody
production at 4 weeks of age was 40% by hemagglutination inhibition and 48% by rapid
slide agglutination in the 7 day of incubation injection group and was 90% for both
hemagglutination inhibition and rapid slide agglutination in the 14 day embryo injection
group.
Power and Jordan (1976) injected the yolk sacs of specific pathogen free (SPF)
chicken embryos at 18 days of incubation with a 0.1 mL volume of 108 CFU dose of MG
of either strain S6 (9 passages or 150 passages) or strain A514 (reported cultured
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repeatedly in the lab). They also tested the effects of injecting Mycoplasma gallinarum
on post-hatch mortality to 4 weeks of age. Hatchability was not reported on the 18 dayinjected embryos, yet performance was evaluated after rearing the birds in positive
pressure isolation pens that had wire flooring. The S6 strain of MG with a low passage
rate (9 passages) caused an 80.5% post-hatch mortality rate in the first week in the 36
birds raised. However, the S6 strain passed 150 times caused only an 8.9% mortality
among 45 birds tested during the first week. These results demonstrated how increasing
passage levels can attenuate MG. The A514 MG strain caused no mortality at all and M.
gallinarum caused only one mortality in the total 4 weeks of rearing. The majority of the
post-hatch mortalities from the S6 MG injections occurred during the first week posthatch, with an additional 13.9% mortality occurring in in 2 to 4 week old birds in
response to the low passage S6 strain. Power and Jordan (1976) observed that the highest
mortality rate occurred in the group that had been injected as an embryo with the low
passage S6 MG, and described the affected birds as being “severely depressed” in the
first week. They further observed that “shortly before death, many of these chicks gasped
intermittently and exhibited opisthotonous, backwards somersaulting and circling
movements.” These chicks also exhibited a reduced weight gain and upon necropsy
displayed “oedematous and congested” lungs with yellow-colored exudate present in the
thoracic and abdominal air sacs and the syrinx.
El-Safty et al. (2005) experimented with in ovo-vaccinating SPF fertilized eggs
and fertile eggs from a “commercial source” at 18 days of incubation against MG using a
“locally prepared” F strain. It was presumed that the eggs from the commercial source
possessed maternal antibodies. These in ovo-vaccinated birds were compared with
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chickens vaccinated through the water lines with the same vaccine at 7 days post-hatch.
Ten vaccinated birds from each group were challenged with the S6 strain of MG in the
nares at 3 and 5 weeks of age post-hatch, and antibody production was measured at 4
days of age via ELISA testing. Testing for antibodies continued each week up until 4
weeks of age post-hatch. Their findings indicated that in ovo-vaccinated SPF birds had
larger antibody titers against MG at hatch than all other treatments including the
commercial source birds that had been in ovo vaccinated. Their results also indicated that
these titer levels continued to increase through 4 weeks post-hatch and ended at a larger
level of antibodies in the SPF in ovo-vaccinated birds in comparison to the commercial in
ovo-vaccinated birds or the SPF and commercial post-hatch vaccinated birds. Chicks
from the commercial source that had been in ovo-vaccinated had similar titer values to
both SPF and commercial chicks that had been vaccinated at 7 days post-hatch. Maternal
antibodies were detected in the commercial birds at hatch, with a lower value at 4 days
post-hatch and none at 7 days post-hatch. After the challenge with the S6 strain of MG
an air sac lesion score was recorded 1 week after the 3 week and 5 week challenges. The
SPF in ovo-vaccinated birds had the lowest lesion scores, followed by the in ovovaccinated commercial source birds, with the post-hatch-vaccinated birds having the
highest lesion scores. This work lacked detailed specifics describing the methodology
(such as no dosage values) and the findings were based upon only 10 birds in each
treatment.
Although bird survival is dependent on the strain of MG and the attenuation of the
bacteria, these past studies have shown that it is possible for embryonated chicken eggs to
be administered live MG and survive to hatch, as well as survive beyond hatching and
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produce antibodies against MG. This current study continues an investigation into the
potential practical application of the in ovo vaccination of layer chickens using a live
attenuated FMG vaccine, that is ordinarily administered post-hatch commercially. The
current study seeks to confirm our former hatch success with a larger sample size,
determine how the hatched birds survive, and to detect if any post-hatch antibody
production against MG occurs.
Materials and Methods
Two replicate trials were conducted. Fertile Hy-Line W-36 commercial layer
hatching eggs were obtained from 45 week-old (trial 1) and 56 week-old (trial 2)
Mycoplasma gallisepticum (MG) clean breeder flocks (National Poultry Improvement
Plan, 2014). A total of 2,340 eggs were set after 7 days of storage in trial 1 and a total of
2,160 eggs were set after 9 days of storage in trial 2. Eggs were set in 26 trays (90 egg
capacity) in trial 1 and 24 trays in trial 2 in a calibrated single-stage NMC2000
NatureForm Incubator (NatureForm Incubator Company, Jacksonville, Florida) set at
37.5°C and 53% relative humidity (29.01ºC wet bulb). The same incubator was used in
both trials. Eggs were assigned one of six treatments at the time of set, with a total of
four replicate trays assigned to each treatment. Treatments included control non-injected
eggs, control diluent only-injected (Poulvac Marek’s diluent, Zoetis, Exton,
Pennsylvania), and “low-low”, low, medium, and high dosage FMG injected treatments
(Poulvac Myco F vaccine, Zoetis, New York, New York). The FMG vaccine was
resuspended and diluted in Marek’s disease diluent. The high dose was taken directly
from the 1X resuspended vaccine, the medium dose was a 10-2 dilution, the low dose was
a 10-4 dilution, and the low-low dose was a 10-6 dilution. Two extra trays were set for
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additional control (non-injected) treatment chicks that were needed in the first trial for an
additional grow-out experiment (see Chapter 5).
All treatments were systematically placed in all levels of the incubator to
eliminate any potential location effects within the incubator. Batch tray weights of the
eggs were recorded at set, and again at 18 days of incubation for percentage moisture loss
calculations. Additionally, all eggs were candled at 12 and 18 days of incubation and any
clear eggs were broken open to distinguish infertile eggs from early (0-6 days of
incubation), middle (7-13 days of incubation), and late (14-21 days of incubation) stage
embryonic mortalities.
After being candled and weighed on day 18 of incubation, all live embryonated
eggs were hand-injected with a total 50 µL injection volume of their respective injection
treatment following the procedures of the “Manual in ovo Vaccination Guide” by Embrex
Inc. (2002). The blunt end of the egg was swabbed with 70% alcohol, a 0.6 cm deep hole
was punched in the large end of the egg shell with an 18 gauge needle, and the 50 μL
injection solution was injected using a 1 cc syringe and a 22 gauge 2.5 cm needle inserted
into the previously made hole until the hub of the needle met with the eggshell. The
FMG vaccine was plated prior to and after injections on Frey’s Mycoplasma Broth agar
(Frey et al., 1968) and incubated at 37°C for at least 5 days to confirm vaccine viability
and colony forming units (CFU) administered per dose.
Two eggs from each tray were injected with Coomassie brilliant blue R-250 dye
(Genlantis, San Diego, California) at the time of injection and transfer and were
immediately euthanized using carbon dioxide that surrounded the eggs for at least 20
minutes. The eggs were then cooled at 4°C overnight (n=52 in trial 1 and n=48 in trial
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2). These eggs were then placed in a -12.8°C freezer for two hours before they were
opened to determine the location of the injected dye as well as to distinguish the general
developmental stage of the embryo using an embryo staging system developed by
Embrex, Inc. (Avakian, 2006).
After injection of each treatment, the eggs were placed in plastic hatching baskets
(76.2 cm width, 71.1 cm length, and 11.4 cm deep) each of which consisted of two trays
of the same treatment with a divider between the trays. The control eggs (non-injected
and diluent-injected) were placed in a separate NMC2000 NatureForm incubator located
in the same room as the incubator where they spent their first 18 days of incubation to
prevent potential horizontal transmission of the bacteria to the control chicks within a
hatcher. The injection treatment eggs hatched in the same incubator where they had been
for the preceding 18 days of incubation. The hatch baskets that contained FMG-injected
eggs were stacked in the hatcher with the lower doses stacked above higher dosages in
order to limit any potential horizontal spread of bacteria due to the movement of fecal
droppings to the lower levels. The hatchers were reversed in the second trial to eliminate
any potential hatcher effect. The incubators were set at 36.7°C and 53% relative
humidity (28.33ºC wet bulb) during the hatch period and exhausted air from both
hatchers were filtered and shunted outdoors.
The hatched chicks were removed from their respective incubator at 22 days of
incubation. Control chicks were removed before the injection treatment chicks. All
hatched chicks were counted and residue eggs were opened to confirm when each
embryo died. A subset of 50 chicks were selected from all replicate trays in each
treatment group and were subsequently euthanized using carbon dioxide. Each chick was
88

weighed individually and their yolk sac and its contents was removed and weighed. The
yolk sac and its contents were dried at 65°C for 5 days until weight loss ceased and were
then reweighed. Thirty-two chicks per treatment (selected equally from all replicate
trays) were swabbed down the trachea through the larynx post-mortem for detection of
the presence of FMG using sterile swabs pre-wetted in PBS. Each swab sample was
suspended in 110 µL of PBS. The bacterial DNA from each tracheal swab sample was
extracted using the Qiagen BioSprint 96 One-For-All Vet Kit (Qiagen, Valencia, CA) and
samples were tested in duplicate using a 7500 Fast Real Time PCR System (Applied
Biosystems, Foster City, CA) using F-strain specific primers and a probe designed by
Raviv et al. (2008). The PCR reaction was a 25 µl PCR reaction volume consisting of
2.5 µl of the forward primer (5’ GTTCAAGAACCAACTCAACCA 3’), 2.5 µl of the
reverse primer (5’ GATTAAGACCGAATTGTGGATTG 3’), 2.5 µl of the Probe (5’
CAACCAGGATTTAATCAACCTCAG 3’), 12.5 µl of Taqman Universal Master Mix
(Applied Biosystems, Foster City, CA), 2.5 µl solution of extracted DNA, and sterile
water. Primers were a 0.5 µM concentration and the probe was a 0.1 µM concentration.
The cycling parameters were 95°C for 15 minutes and 40 cycles each of 94°C for 15
seconds and 61°C for 1 minute. Sterile water was used as a negative control, and an Fstrain DNA sample was used as a positive control. Results were determined on a
qualitative basis (positive or negative for MG presence).
A subset of birds were reared to 6 weeks of age in both trials. Eighty five total
chicks were equally selected from each treatment. Treatment selections were equalized
among each replicate incubation tray belonging to each treatment. The chicks were
raised in six 2.4 m x 2.4 m isolation chambers, with one treatment assigned to a chamber.
89

Bird density in each chamber was 0.07 m2 per bird, which meets the recommended
growing space for 0-8 week old Hy-Line W-36 breeders reared on the floor (Hy-Line Red
Book, Hy-Line International 2014). In trial 2, due to the unavailability of the facility
used in trial 1, the birds were reared in a different facility containing isolation units that
measured 64.8 cm wide and 142.2 cm long, providing a total 9,214.6 cm2 floor space per
unit (Branton and Simmons, 1992). A total of 60 birds per treatment were reared in trial
2. Thirty chicks were placed in each of two replicate isolation units per treatment. In
each unit there was equal bird representation from each incubation tray. A stocking
density of 307.1 cm2 was provided for each bird in each unit, which met the
recommended colony cage space requirement for W-36 breeder pullets and cockerels that
are reared comingled during the growing period of a recommended 303.2-348.4 cm2 per
bird (Hy-line Red Book, Hy-Line International, 2014). In both trials, feed and water
were provided ad libitum during the 6 week grow out period. The feed provided was a
mashed layer pullet starter diet that was formulated to meet or exceed NRC requirements
(NRC, 1994). Lighting was provided according to the Hy-Line lighting program for 0 to
6 week old Hy-Line W-36 pullets housed in a black-out facility (Hy-Line Red Book, HyLine International 2014). The lighting program started with 21 hours of light with 3
hours of dark for the first week, and light duration was decreased by 1 hour each week.
Brooding temperatures followed the recommendations set by Hy-Line. Floor
temperature started between 33 and 35°C and was decreased by 2 to 3°C per week.
Mortality was recorded daily and all dead birds were necropsied for lesion detection and
to determine the apparent cause of death. The isolation units were opened minimally
only to remove any dead birds and to add feed and water when needed. The units
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containing control and diluent birds were checked first, followed by the FMG treatments
from lowest to highest dose.
At 6 weeks of age, all birds in each unit were swabbed in the choanal cleft for
detection of the presence of MG. They were also bled for serum plate agglutination
(SPA) to test for IgM antibody production against MG and to test for initiation of IgG
antibody production against MG using ELISA. When isolating MG, the choanal cleft has
been shown to be a site superior to tracheal swabbing in adult layer chickens (Branton et
al., 1984). Serum plate agglutination testing with MG antigen (Charles River
Laboratories International, Wilmington, MA) was performed by an experienced
technician and ELISA tests were carried out by an independent laboratory utilizing
IDEXX MG antibody testing (IDEXX Laboratories, Westbrook, ME).
All birds were weighed individually and were euthanized by carbon dioxide (trial
1) or cervical dislocation (trial 2). Birds were weighed immediately post mortem in trial
1. In layers, fatty liver hemorrhagic syndrome (FLHS) has been linked with MG
infections in laying hens (Burnham et al., 2002). Thus, an additional subset of 10 birds
per treatment in trial 1 had their livers removed and weighed for a preliminary
determination of any potential hepatomegaly which served as a potential indicator of
FLHS. All bird incubation, rearing, and handling practices were approved by a USDAARS Animal Care and Use Committee.
Early and hatch residue analyses, moisture loss, hatchability, absolute and relative
chick and yolk weights, post-hatch mortality, and body weights at 6 weeks of age were
analyzed using the general linear model procedure of SAS (Version 9.4) in order to
evaluate treatment and trial effects. The sex effect was also analyzed for the post-hatch
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body weights. Mycoplasma gallisepticum detection using PCR and MG-antibody
detection from the SPA and ELISA tests were analyzed as a general linear model to
evaluate treatment and trial effects on the percentage of birds in each tray that tested
positive at hatch and within each isolation unit (6 week old birds). Since control and
diluent treatments tested negative for MG detection and antibody production, they were
eliminated from the MG and antibody detection analyses in order to only compare the
percentage of positive birds among the MG treatments. Tray was designated as the
experimental unit for all hatch data and the rearing unit was the experimental unit for all
post-hatch data. Any P values less than or equal to 0.05 were regarded as significant and
significant differences were compared using Fisher’s Least Significant Difference.
Results and Discussion
Egg weights of the 45 week-old flock (trial 1) averaged 62.3 ± 0.16 g and the egg
weights of the 56 week-old breeder flock (trial 2) averaged 60.8 ± 0.08 g when they were
initially placed in the incubator. The mean weights of the eggs in trials 1 and 2 were
different (P<.0001). There were no differences among weights of the egg assigned to the
different injection treatment groups (P=0.10). There was no difference in the percentage
of infertile eggs (P=0.77), early embryonic mortality (P=0.48), middle stage embryonic
mortality (P=0.89), percentage late embryonic mortality up to 18 days of incubation
(P=0.72), percent cracked eggs (P=0.49), or percentage contaminated eggs (P=98) among
the treatments prior to the day of injection. There was higher percentage of early dead
embryos in trial 2 (4.3%) than in trial 1 (2.6%) (P=0.008). However, no other differences
in embryonic mortality through 18 days of incubation were found between trials (all
P>0.17). The following hatchery residue parameters and their percentages were
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observed: the percent infertile eggs = 3.1 ± 0.3%, early dead embryos = 3.4 ± 0.3%,
middle dead embryos = 0.6 ± 0.1%, late stage (14-18 days of incubation) embryos = 0.1 ±
0.05%, cracked eggs = 0.1 ± 0.05%, and contaminated eggs = 0.2 ± 0.1%. Moisture loss
by 18 days of incubation was not different between the trials (P=0.73) and treatments
(P=0.59) with an overall average of 11.5 ± 0.1%. These data indicate that all groups of
eggs assigned to the various treatments had similar embryonic mortality rates and
eggshell qualities prior to treatment administration at 18 days of incubation.
Plate counts of the vaccine plated immediately prior to the vaccination of a 10-4
dilution averaged 97.5 CFU/20µL in trial 1 and averaged 53.5 CFU/20μL in trial 2.
These counts indicated that the high treatment level contained bacterial concentrations in
the range of 106 CFU per 50 µL dose. Furthermore, the average CFU per 50 μL in ovo
dose in the medium, low, and low-low treatments were 104, 102, and 1.3 or 2.4,
respectively (Table 4.1). The vials used for the injections were plated after all injections
were finished and were grown on Frey’s Mycoplasma media to confirm viability.
The average embryo stage score in trial 1 was 1.75 ± 0.08, and in trial 2 was an
average score of 2.02 ± 0.06. The dye injection of 52 embryos in trial 1 indicated that the
majority of injections (71.2%) were administered in the amnion, whereas 19.2% were
injected into the allantois, and 9.6% of the injections were administered to the embryo
intramuscularly (IM) (Figure 4.1). The IM injections were located in the right breast of
the embryo with the exception of one embryo in trial 1 that was injected into the muscles
under the lower mandible. In trial 2, the dye was located in the amnion in 77.1% of the
embryos. Dye was likewise located in the allantois of 14.6% of the embryos,
intramuscularly in 4.2% of the embryos, and in the air cell of 4.2% of the embryos. All
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embryos in trial 2 that were injected IM were injected in the right breast muscle. The in
ovo injection location that is most preferred is the amnion surrounding the embryo
(Wakenell et al., 2002; Williams and Hopkins, 2011). Thus the majority of injections of
the current trials were both delivered to the ideal compartment of the embryo. This
finding also confirms the amnion injections observed in our smaller scale preliminary
experiment (Chapter 3).
The percentage hatchability of eggs containing live 18 day old embryos did not
differ by trial (P=0.96) but was significantly lower in the high dose treatment. However,
percentage hatchability of live embryonated eggs in all other treatments did not differ
from that in the control non-injected eggs (Table 4.2). Even when injected with a 106
CFU/dose at 18 days of incubation, over 60% of the embryos were able to survive to
hatch. Although a higher hatch of embryonated eggs was observed in the low and
medium dosage treatments in this current study, these hatch findings confirm the results
in the preliminary smaller scale trial reported in Chapter 3. The high dose treatment had
a greater percentage of chicks that hatched and then died before removal from the
incubator (dead chicks) as well as a greater percentage of embryos that externally pipped
and died before emerging from the shell (dead pips). There was a greater percentage of
dead chicks in the medium dose treatment group than in the control and lower MG
dosage groups. However, the percentage dead chicks in the medium dose were still much
lower than in the high dose group. Thus, embryos belonging to the high dose treatment
group that died prior to removal from the hatcher did so after externally pipping or
hatching. Perhaps the extra exertion by the emerging chick during the hatching process
coupled with the large bacterial challenge, and a potential limitation of oxygen
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availability due to the respiratory effects of MG caused this heightened mortality in the
embryos belonging to the high dose group. There was a trial and treatment interaction
(P=0.015) with a greater percentage of cull chicks (chicks that were noticeably unable to
survive such as exhibiting protruding intestines) in the high MG dose group in trial 1
(1.2%) in comparison to those in trial 2 (0%). There was a main effect due to trial
(P=0.03) in that the percentage of contaminated eggs found at hatch in trial 1 was 0.4%
whereas there were no contaminated eggs at hatch in trial 2. No other trial effects (all
P>0.2) were found in any of the other residue egg categories.
Of the 50 chicks sampled per treatment (n=600 chicks over both trials), injection
treatment had no effect on chick weight (P=0.45), yolk weight (P=0.18), dry yolk weight
(P=0.20), and yolk and dry yolk weight as percentages of chick weight (P=0.12 and
P=0.19, respectively). The percentage of water in the yolk sac and its contents was not
different between injection treatments (P=0.26), which differs from the greater moisture
content of the yolk sac and its contents that was observed in the higher MG in ovo dosage
groups in Chapter 3. Chick weights were heavier in trial 1 in association with the heavier
egg weight in trial 1 (P=0.002), with chicks in trial 1 averaging 40.0 ± 0.17 g and chicks
in trial 2 averaging 39.2 ± 0.16 g. Yolk-free chick weights were heaviest in the low and
medium dose treatment groups only in trial 1 (P=0.003; Figure 4.2). No other trial
effects (all P>0.07) were found for absolute and relative yolk weights.
Mycoplasma gallisepticum was detected in the trachea of chicks at hatch in each
of the MG in ovo-vaccinated treatments (Table 4.3). No MG was detected in chicks
belonging to the control or diluent-injected treatment groups. Of the 32 chicks sampled
from each of the MG treatments in each trial, the percentage of chicks that tested positive
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was dose dependent. The high and medium dose treatments had the highest percentage
of chicks with FMG that was detected in the trachea. Chicks in the low dose treatment
had the next highest percentage of FMG detected in the trachea, and the low-low dose
treatment had the least percentage of chicks (39.1%) that tested positive for FMG in the
trachea. There was greater percentage FMG-positive chicks at hatch in trial 1 than in trial
2 (85.9% versus 69.5%; P=0.008). The percentage positive chicks at hatch are also
presented by trial in Figure 4.3. This trial difference may be due to the slightly greater
numbers of bacteria injected into the embryos in trial 1 than in trial 2 (Table 4.1).
During post-hatch rearing, all FMG in ovo-vaccinated groups experienced a
higher mortality than did controls. The majority of the mortality occurred during the first
2 weeks of post-hatch age (Figure 4.4). The mortality was dose-dependent. Mortality on
the first day after placement was elevated in the high dose treatment. In turn, on the
second day, mortality in the medium dose treatment group was greatest. On the third day
after placement, the first low dose mortality occurred in trial 1. In trial 2, the first low
dose mortality occurred on the second day and mortality percentages increased until 4
days post-hatch. Mortality in the low-low dose group peaked at 5 days of age in trials 1
and at 5 and 6 days of age in trial 2, but at a much lower percentages than in the higher
FMG dose groups. Over the total six week post-hatch period, no control birds died in
either trial. Only one diluent-injected chick died in trial 1 (on day 5 post-hatch) which
brought total mortality to 1.2% in the diluent treatment in trial 1. No diluent-injected
birds died in trial 2. During the first two weeks, birds in the low-low dose group
experienced a 3.5% mortality in trial 1 and a heightened mortality at 11.7% in trial 2.
Mortality in the low treatment group was 52.4% during the first two weeks in trial 1 and
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was 55.0% during the first two weeks in trial 2. Mortality in the medium dose group was
72.9% in trial 1 and was 76.7% in trial 2. Nearly all birds in the high dose treatment died
during the first two weeks of age in both trials (88.2% mortality in trial 1 and 90.0%
mortality in trial 2). After 13 days post-hatch, only two more birds died in trial 1. One
bird in the low dose group died on day 14 and another one in the high dose group died on
day 20. No birds died from days 21 to 42 in trial 1. In trial 2, three further birds died
after 13 days of age. One bird in the high dose and one low dose bird died on day 14 and
one bird in the low dose group died on day 22. No other mortalities occurred after day 22
of age through the end of the study at 42 days of age.
All dead birds were necropsied. In general, dead birds, including those on the
first day post-hatch, had feed predominantly in both the crop and the gizzard and had
congested lungs. Out of all the medium and high dose treatment group mortalities on day
one post-hatch, 78.8% in trial 1 and 93.3% in trial 2 had congested lungs. Of the chick
mortalities in the high dose treatment beginning on the first day in trial 1, 7% also
exhibited hemorrhaging in the lungs, although this hemorrhaging was not seen in trial 2.
Birds in the high and medium dose treatments that died on the first day already had feed
present in their gizzards (78.8% in trial 1 and 43.3% in trial 2). Ultimately, flecks of
caseous exudate were visible in the air sacs of dead chicks from all FMG treatment
groups, which were initially found in chicks belonging to the medium and high dose
treatments (Figure 4.5). In trial 1, caseous exudate was first found at four days of age in
37.5% of the dead birds in the medium dose treatment and in 25.0% of the dead birds in
the high dose treatment. In trial 2, caseous exudate was found earlier in birds that died on
the first day of age. This occurred in 22.2% of the dead birds in the medium dose
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treatment and in 50.0% of the dead birds in the high dose treatment. These trends
continued in all the dead birds belonging to the FMG treatments with the majority of
birds exhibiting feed in the crop and the gizzard and with caseous exudate findings
predominantly in the air sacs. The one diluent-injected bird that died in trial 1 on day
five post-hatch did not have congested lungs or caseous exudate present in its air sacs.
That bird had no feed in its crop or gizzard and appeared emaciated. The fact that the
majority of birds had feed in their digestive tracts indicates that even near time of death
due to the FMG bacterial load, the bird felt well enough to consume feed. Our hypothesis
for the cause of death is respiratory distress or asphyxiation since many chicks in the
medium and high dosage groups were observed to exhibit extended neck breathing, or
gasping for air by extending their necks and opening their beaks. This behavior was
observed when the medium and high dose chicks were removed from the hatcher, much
like was observed in the chicks from medium and high dose treatments described in
Chapter 3. It is of interest to note that the high dose treatment birds of this study that
were observed during the first week before death, exhibited symptoms strikingly like
those reported by Powers and Jordan (1976), who injected embryos with an S6 strain of
MG in the yolk sac at 18 days of incubation. The chicks in that study “gasped
intermittently.” Powers and Jordan (1976) also noted that their chicks that eventually
died during the first week had lungs that were “oedematous and congested,” with yellowcolored exudate present in their air sacs.
The body weights of the 322 birds still living in trial 1 and 216 birds remaining at
6 weeks in trial 2 averaged 53.2 g heavier in trial 2 (P<0.0001), and males averaged 86.7
g heavier than females (P<0.0001). Body weight was reduced with increasing dosage of
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FMG (Table 4.4; P<0.0001). A reduction in the weight gain of birds that had been
injected with a more virulent S6 MG at 18 days of incubation was also observed by
Powers and Jordan (1976). Percentage liver weight of the subgroup (10) of birds
sampled per treatment in trial 1 was not different among the injection treatments
(P=0.14). Relative liver weight was 0.2% greater in females than that of the male birds
(P=0.03). Average liver weight as a percentage of body weight in males was 3.1% and in
females was 3.3%.
Detection of FMG in the choanal cleft, detection of IgM antibodies by the serum
plate agglutination (SPA) results, and the detection of IgG antibodies by ELISA at 6
weeks of age post-hatch are presented in Table 4.3 and within trial in Figure 4.6. One
diluent-injected bird tested SPA positive in trial 1, but did not test positive for MG
detection by real time PCR or by ELISA. Therefore, this SPA sample was most likely a
false positive. There were no differences in the percentages of positive birds between the
FMG treatments at 6 weeks of age for FMG according to tests from the choanal cleft
swabs using PCR (P=0.96), or by the testing of birds for antibody production against MG
detected by SPA (P=0.61), and by ELISA (P=0.25). No trial effect was found for FMG
detection through PCR (P=0.36), or MG antibody detection by SPA (P=0.68) and ELISA
(P=0.45) testing. These findings may be related to sample size with a smaller number of
birds left surviving by sampling time in the higher dosage treatments and with only a
combined total of three replicate isolation units in each treatment group across the two
trials. These results do indicate that a humoral immune response, or initial antibody
production, was induced due to the in ovo vaccination treatments. Approximately half of
the birds in the low-low dose treatment group (46.3% in trial 1 and 64.2% in trial 2 based
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on an individual bird basis) were positive for MG by the SPA test. The layer industry
considers that finding 50% or more birds that test positive using SPA at 6 weeks after
vaccination indicates that vaccination was adequate (Branton et al., 2005). By this
definition, the in ovo vaccination of layer chickens with even the lowest dosage tested
would be considered a successful vaccination. However, this definition is based upon the
vaccination of birds during the pullet rearing period. The in ovo-vaccinated birds of this
study achieve significant antibody production much earlier in life. How this level and
timing of antibody production would compare with those in response to conventional
post-hatch vaccination in association with a challenge scenario is unknown.
Mycoplasma gallisepticum has been found to have a more pronounced effect on
males than females in house finches (Nolan et al., 1998). Mycoplasma infections, such as
Mycoplasma pulmonis, have also been found to be more severe in male mice than in
female mice, which is reduced in severity when the testes are removed (Yancey et al.,
2001). Straight run layer chickens were utilized in the present study. To evaluate a
possible sex effect on immunity, we investigated sex effects on the ELISA titer values
obtained and found a treatment and sex interaction (P<0.0001). Within the control,
diluent, low-low, and high dose treatments, there was no significant difference between
the sexes for IgG antibody production. In the low FMG dose treatment, males had a
greater ELISA titer, but in the medium dose treatment, females had a greater ELISA titer.
These results suggest that, at least in surviving birds, sex does not seem to influence
antibody production in chickens subjected to an FMG challenge at a young age. Dead
birds were also not sexed when necropsied, so we cannot definitively confirm if one sex
succumbed to FMG more than the other. However, the sex ratios of the surviving birds
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administered FMG were similar in comparison to surviving birds belonging to the control
and diluent-injected treatments. Male and female birds in the control and diluent-injected
treatments in both trials (420 total birds) at 6 weeks of age were 37.1% and 62.9%,
respectively. Of all FMG in ovo-vaccinated birds remaining alive at 6 weeks of age
across both trials (367 total remaining birds), 36.2% were male and 63.8% were female.
Since the sex ratios of the FMG in ovo-vaccinated birds are similar to the control and
diluent-injected birds, these ratios indicate that males were not selected against by the
FMG challenge.
The hatch results of this study reflect those in the previous smaller scale
preliminary trial of Chapter 3 with the exception of higher hatch in the low and medium
dosage treatments. This current study only found reduction in hatch in the highest FMG
dose treatment. Increasing the FMG dosage was also found to increase post-hatch
mortality, particularly during the first 2 weeks of life. Based upon post hatch values, only
the “low-low” FMG dosage exhibited acceptable post-hatch mortality levels, with the
“low” dose causing mortality to exceed over 50% within the first 2 weeks post-hatch.
This study confirmed that an immune response is possible in a 6 week-old bird when an
FMG vaccine is administered in ovo at 18 days of incubation. How this immune
response would compare to the current practice of vaccination of pullets around 9 weeks
of age is uncertain. These FMG in ovo-vaccinated birds are mounting an immune
response earlier in life that is more distant from the start of the lay period in comparison
to current commercial pullet vaccination practices. This earlier immune response may
have potential benefits by limiting stress on the birds at an already physiologically
stressful period. Future research is needed to evaluate how in ovo FMG vaccination
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compares to FMG vaccination of pullets with regards to the immunocompetence and
protection of layers against field-strain MG challenges.
Table 4.1

Mean colony forming units (CFU) of strain F Mycoplasma gallisepticum
(FMG) in each 50 μL dose administered by in ovo injection to layer
chicken embryos at 18 days of incubation

Treatment1,2 Trial 1
Trial 2
High
2.4 x 106 1.3 x 106
Medium
2.4 x 104 1.3 x 104
Low
2.4 x 102 1.3 x 102
Low-Low
2.4
1.3
1
Colony forming unit (CFU) determination was accomplished by plating the original live
strain F Mycoplasma gallisepticum (FMG) vaccine on two plates per trial. Accurate
counts were determined on a 10-4 dilution of the vaccine. Counts per each treatment were
then calculated.
2
Treatments were a dilution (using Poulvac Marek’s Diluent) of a live attenuated FMG
vaccine (Poulvac Myco F). The 1,000 dose vaccine vial was resuspended in 50mL
diluent and administered as a 1X 50 μL dose for the high dose treatment, the medium
dose treatment was a 10-2 dilution of the original vaccine vial, the low dose treatment was
a 10-4 dilution, and the low-low dose treatment was a 10-6 dilution.
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Table 4.2

Hatch and embryonic mortality of embryonated Hy-Line W-36 layer eggs
in ovo vaccinated with a live attenuated strain F Mycoplasma gallisepticum
(FMG) vaccine
Control2, 3DiluentLow-low Low Medium High Pooled SEMTrt Effect

% Hatch1

95.5a

95.3a

95.2a 95.4a 92.5a 66.1b

1.6

<0.0001

% Dead Chicks

0.0c

0.2c

0.0c

0.0c

2.6b 16.3a

0.9

<0.0001

% Dead Pip

0.2b

0.3b

0.3b

0.2b

1.2b 11.5a

0.6

<0.0001

% Live Pip

0.5

0.8

0.3

0.2

0.0

0.8

0.1

0.0733

% Middle Dead

0.0

0.0

0.0

0.0

0.0

0.2

0.03

0.3963

% Late Dead

3.3

3.1

3.9

3.5

3.2

4.2

0.3

0.9004

% Cracked

0.0

0.2

0.0

0.2

0.2

0.0

0.04

0.6604

% Contaminated

0.3

0.0

0.0

0.5

0.2

0.3

0.1

0.6284

% Cull Chicks

0.1

0.0

0.3

0.2

0.2

0.6

0.1

0.1647

% Live in Shell

0.1

0.2

0.0

0.0

0.0

0.2

0.04

0.7620

1Embryonic

Mortality includes mortality/residue egg categories from days 18-22 of incubation. The categories defined
are: hatch (embryos that survived to successfully hatch and were alive when removed from the hatcher), dead chicks
are chicks that survived to fully hatch yet were found dead when removed from the hatcher, dead pips are embryos that
externally pipped through the eggshell yet died before fully emerging from the shell, live pips are embryos that
externally pipped yet did not fully exit the eggshell and were found alive when removed from the hatcher, middle dead
embryos are any embryos from days 7-13 of incubation that were missed during 12 and 18 day candling, late deads are
embryos age 14-22 days of incubation that did not externally pip and were found dead when removed from the
eggshell, cracked eggs are embryos that died due to drying down from a previously cracked egg, contaminated eggs are
embryos that died due to contamination, cull chicks are chicks that hatched and were alive when removed from the
hatcher yet were unable to survive such as protruding internal organs or major inability to walk, embryos live in the
shell are embryos age 18-22 days of incubation that had not externally pipped when removed from the hatcher yet were
found alive when removed from the eggshell.
2Embryonated Eggs were injected at 18 days of incubation with either Marek’s diluent or a dosage of Poulvac Myco F:
high dose was a 1000 dose vaccine vial resuspended in 50 mL Marek’s diluent (1X), medium dose was a 10-2 dilution
of the 1X dose, low dose was a 10-4 dilution of the 1X dose, and low-low dose was a 10-6 dilution of the 1X dose,
diluent eggs were injected with only Marek’s diluent, and control eggs were not injected.
3All percentages are based off the number of embryos determined live at 18 days of incubation by candling.
Percentages are based upon a total of 50 trays and 4060 embryos in ovo vaccinated from two trials. Values within a
row with differing superscripts are significantly different P<0.05 distinguished by least squared means.
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Table 4.3

Mean percentages of positive birds for Mycoplasma gallisepticum (MG)
and antibodies against Mycoplasma gallisepticum in Hy-Line W-36 layer
chickens that had been in ovo vaccinated with a live attenuated strain F MG
(FMG) at 18 days of incubation

Treatment1 Hatch FMG2 6wk FMG3 6wk SPA4 6wk ELISA5
Control
0.06
0.0
0.0
0.0
Diluent
0.0
0.0
0.47
0.0
c
Low-low
39.1
75.9
58.2
42.0
Low
78.1b
89.3
91.0
79.9
a
Medium
98.4
79.5
78.1
73.7
High
95.3a
66.7
74.1
57.4
Probability
<0.0001
0.3613
0.6808
0.4525
1
Embryonated Hy-Line W-36 eggs were injected at 18 days of incubation with either
Marek’s diluent or a dosage of Poulvac Myco F: high dose was a 1000 dose vaccine vial
resuspended in 50 mL Marek’s diluent (1X), medium dose was a 10-2 dilution of the 1X
dose, low dose was a 10-4 dilution of the 1X dose, and low-low dose was a 10-6 dilution
of the 1X dose, diluent eggs were injected with only Marek’s diluent, and control eggs
were not injected.
2
Chicks swabbed in the trachea at hatch for detection of strain F Mycoplasma
gallisepticum (FMG) tested with PCR: n=64 chicks per treatment (32 in each of 2 trials).
3
Birds swabbed in the choanal cleft at 6 weeks of age for the detection of FMG; n=one
unit per treatment in trial 1 and two units per treatment in trial 2 containing surviving
birds at 6wk of age. Each unit in trial 1 originally started with 85 birds, each unit in trial
2 originally started with 30 birds each.
4
Birds bled at 6 weeks of age for serum plate agglutination (SPA) testing for detection of
IgM antibodies against MG; n=one unit per treatment in trial 1 and two units per
treatment in trial 2 containing surviving birds at 6wk of age. Each unit in trial 1
originally started with 85 birds, each unit in trial 2 originally started with 30 birds each.
5
Birds bled at 6 weeks of age for ELISA testing for detection of IgG antibodies against
MG; n=one unit per treatment in trial 1 and two units per treatment in trial 2 containing
surviving birds at 6wk of age. Each unit in trial 1 originally started with 85 birds, each
unit in trial 2 originally started with 30 birds each.
6
Control and diluent treatments were not included in the analysis due to all negative
(zero) results, as expected, to allow for comparisons between MG treatments.
7
One diluent bird tested SPA positive in trial 1, yet this bird did not test positive for MG
detection by PCR and did not test positive for ELISA testing, so this result is most likely
a false positive.
Means with differing superscripts within a column are significantly different detected by
least squared means. N = 32 incubator tray of 8 birds per tray sampled for a total of 32
chicks per treatment.

104

Table 4.4

Mean body weight of Hy-Line W-36 layer chickens at 6 weeks of age that
had been in ovo vaccinated at 18 days of incubation with a strain F
Mycoplasma gallisepticum (FMG) vaccine

Treatment1
Body Weight (g)
Control
485.1a
Diluent
491.4a
Low-low
471.3b
Low
463.9bc
Medium
450.1c
High
407.3d
Pooled SEM
3.1
1
Embryonated eggs were injected at 18 days of incubation with either Marek’s diluent or
a dosage of Poulvac Myco F: high dose was a 1000 dose vaccine vial resuspended in 50
mL Marek’s diluent (1X), medium dose was a 10-2 dilution of the 1X dose, low dose was
a 10-4 dilution of the 1X dose, and low-low dose was a 10-6 dilution of the 1X dose,
diluent eggs were injected with only Marek’s diluent, and control eggs were not injected.
P<0.0001.
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Figure 4.1

Examples of dye-injected embryos

Examples of Hy-Line W-36 embryos at 18 days of incubation that were injected with Coomassie
blue dye to determine the location of the in ovo injection. Top left photo depicts the embryo
surrounded by a dyed amniotic sac. Top right photo shows the one embryo who received an
injection in the lower mandible muscles. Bottom left depicts a stained allantois membrane.
Bottom right shows a right breast intramuscular (IM) injection with the pectoralis major muscle
cross sectioned to distinguish an IM versus a subcutaneous injection. The majority of injections
were in the amnion, with the feathers of the chicks exhibiting extensive blue staining.
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Figure 4.2

High

Medium

Low

Low-low

Diluent

Control

High

Medium

Low

Low-low

33.5

Diluent

34.0
Control

Average Yolk-Free Chick Weight (g)

38.5

Trial 2

Mean yolk-free chick weights at hatch after strain F Mycoplasma
gallisepticum in ovo vaccination

Mean yolk-free chick weight in each of the six in ovo injection treatments within trials 1
and 2. Hy-Line W-36 embryonated eggs were injected at 18 days of incubation with
either Marek’s diluent or a dosage of Poulvac Myco F. The high dose was a 1000 dose
vaccine vial resuspended in 50 mL Marek’s diluent (1X), medium dose was a 10-2
dilution of the 1X dose, low dose was a 10-4 dilution of the 1X dose, and low-low dose
was a 10-6 dilution of the 1X dose, diluent-injected eggs were injected with only Marek’s
diluent, and control eggs were not injected. There was an interaction between trial and
treatment (P=0.003).
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Figure 4.3

Percentage strain F Mycoplasma gallisepticum (FMG) positive chicks at
hatch after in ovo vaccination with a live FMG vaccine at 18 days of
incubation

Mean percentage Hy-Line W-36 chicks testing positive for strain F Mycoplasma
gallisepticum (FMG) in the trachea at hatch. Embryonated eggs were injected at 18 days
of incubation with either Marek’s diluent or a dosage of Poulvac Myco F. The High dose
was a 1000 dose vaccine vial resuspended in 50 mL Marek’s diluent (1X), medium dose
was a 10-2 dilution of the 1X dose, low dose was a 10-4 dilution of the 1X dose, and lowlow dose was a 10-6 dilution of the 1X dose, diluent-injected eggs were injected with only
Marek’s diluent, and control eggs were not injected. There was an interaction between
trial and treatment (P=0.003). Thirty-two chicks per treatment in each of two trials were
sampled.
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Percentage post-hatch mortality by day in trials 1 and 2

Percentage mortality of Hy-Line W-36 layer chickens each day during the first 13 days after
hatch in six strain F Mycoplasma gallisepticum (FMG) in ovo injection treatments in trial 1 (a)
and trial 2 (b). Embryonated eggs were injected at 18 days of incubation with either Marek’s
diluent or a dosage of Poulvac Myco F. The high dose was a 1000 dose vaccine vial resuspended
in 50 mL Marek’s diluent (1X), the medium dose was a 10-2 dilution of the 1X dose, the low dose
was a 10-4 dilution of the 1X dose, the low-low dose was a 10-6 dilution of the 1X dose. Diluent
eggs were injected with only Marek’s diluent, and control eggs were not injected.
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Figure 4.5

Example of caseous exudate in a deceased chick

A deceased Hy-Line W-36 layer chick exhibiting some of the caseous exudate visually
present starting at four days of age in trial 1 and at the first day of age in trial 2.
Embryonated eggs were injected at 18 days of incubation with a dosage of a live
attenuated strain F Mycoplasma gallisepticum (FMG) vaccine (Poulvac Myco F). The
High dose was a 1000 dose vaccine vial resuspended in 50 mL Marek’s diluent (1X), the
medium dose was a 10-2 dilution of the 1X dose, the low dose was a 10-4 dilution of the
1X dose, the low-low dose was a 10-6 dilution of the 1X dose. Caseous exudate was
initially found in chicks belonging to the high and medium dose treatments, but was
eventually discovered in all FMG dosages. The chick pictured is 7 days old.
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Percentage of birds that had been in ovo vaccinated with a strain F
Mycoplasma gallisepticum (FMG) vaccine and tested positive at 6 weeks
of age for FMG and MG antibody production trials 1 and 2

Percentage of Hy-Line W-36 chickens testing positive for Mycoplasma gallisepticum (MG) at 6 weeks of
age detected by PCR, SPA, and ELISA testing in replicate trials: trial 1 (a) and trial 2 (b). PCR indicates
strain F MG (FMG) detection in the choanal cleft, SPA (serum plate agglutination) testing indicates IgM
antibody production against MG, and ELISA testing indicates IgG antibody production against MG.
Embryonated eggs were injected at 18 days of incubation with either Marek’s diluent or a dosage of a live
attenuated FMG vaccine (Poulvac Myco F). The High dose was a 1000 dose vaccine vial resuspended in
50 mL Marek’s diluent (1X), the medium dose was a 10-2 dilution of the 1X dose, the low dose was a 10-4
dilution of the 1X dose, the low-low dose was a 10-6 dilution of the 1X dose. Diluent eggs were injected
with only Marek’s diluent, and control eggs were not injected. In trial 1 the number of birds tested at 6
weeks of age per each treatment in (from a start of 85 birds) was control 85 birds, diluent 84 birds, low-low
82 birds, low 39 birds, medium 23 birds, high 9 birds. In trial 2 the number of birds tested at 6 weeks of
age per each treatment (from a start of 60 birds) was control 59 birds, diluent 60 birds, low-low 53 birds,
low 25 birds, medium 14 birds, high 5 birds.
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OCCURRENCE OF HORIZONTAL TRANSMISSION IN LAYER CHICKENS
AFTER ADMINISTRATION OF AN IN OVO STRAIN F MYCOPLASMA
GALLISEPTICUM VACCINE
Abstract
Mycoplasma gallisepticum (MG) is known to be transmitted from infected birds
to non-infected. This study was performed to determine the transmissibility of live
attenuated strain F MG (FMG) from chicks having been in ovo-vaccinated with FMG to
non-vaccinated pen mates. Eggs from an MG clean flock were incubated together for 18
days, at which point all live embryonated eggs were either not injected or administered a
50 µL injection volume of a dilution (using Poulvac Marek’s diluent) of an FMG vaccine
(Poulvac Myco F). High (1X resuspended vaccine), medium (10-2 dilution), low (10-4
dilution), or low-low dose (10-6 dilution) dosages of the FMG vaccine were administered.
Non-injected eggs were hatched in a separate incubator. Ten non-injected, sentinel birds,
and one in ovo-vaccinated chick at one of the 4 doses (low-low, low, medium, high) were
each placed in each of 32 isolation units located in 2 replicate rooms. At 6 weeks of age,
birds that had been injected in ovo were removed, swabbed for FMG detection by PCR,
and bled for serum plate agglutination (SPA) and ELISA testing for the presence of
antibodies against MG. At 12 weeks of age, the remaining sentinel birds were likewise
sampled. No sentinel birds died and out of the in ovo-vaccinated chicks, 1 high, 2
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medium, 6 low, and all 8 low-low dose treated chicks survived through week 6. The in
ovo-vaccinated birds that survived to week 6 were serologically positive except for 5
birds in the low-low dose treatment. The percentages of MG positive sentinel birds and
sentinel birds with antibody production against MG from each unit were not different
between all MG dosages. The P values for the treatment effects for the percentage FMG
positive, percentage SPA positive, and percentage ELISA positive tests were 0.48, 0.77,
and 0.85, respectively. Body weights of the in ovo vaccinated chicks at 6 weeks of age
(P=0.43) and the sentinel birds at 12 weeks of age (P=0.95) were each not affected due to
the FMG treatment. These findings indicate that layer chickens in ovo-vaccinated with a
live attenuated FMG vaccine were able to horizontally transmit FMG to other chicks with
which they were in direct contact.
Introduction
Mycoplasma gallisepticum (MG) infections, present on multiage layer hen
complexes, require the layer industry to vaccinate the birds to combat a decline in egg
production associated with MG infections (Carpenter et al., 1981; Levisohn and Kleven,
1981). The birds are ordinarily vaccinated before the beginning of lay, with the objective
of vaccinating them before they encounter a field MG challenge (Levisohn and Kleven,
1981). Vaccinations can include a killed MG bacterin or live attenuated strains of MG
(Whithear, 1996). Live attenuated strain F MG (FMG) vaccine is regarded as an
acceptable means of providing protection from most field strains for the entire life of the
laying hen (Kleven et al., 1990; Whithear, 1996; Hy-Line, 2013).
The present study has investigated the potential to in ovo vaccinate layer chickens
with a live attenuated FMG vaccine instead of during pullet rearing by eye drop or spray
115

vaccination method in order to reduce labor and associated stress on the birds (Whithear,
1996; Evans et al., 2005). Mycoplasma gallisepticum infections are known to be both
vertically and horizontally transmitted between chickens (Olesiuk et al., 1967; Lin and
Kleven, 1982). The use of FMG as a vaccine, administered to pullets by eyedrop, is also
transmissible from vaccinated to non-vaccinated birds as long as they are in direct contact
closer to the time of vaccination (Kleven, 1981). Levisohn and Kleven (1981) stated that
the transmission of MG from bird to bird through the air, such as across an empty pen,
may depend on the housing condition where the birds are raised, such as the ventilation
system, air speeds, and air directions. They stated that FMG in commercial houses is
able to spread slowly down an aisle of birds housed in cages, but that less transmission
occurs between aisles of caged birds within a hen house.
This current study seeks to determine if chickens that are in ovo-vaccinated with
FMG are also able to transmit the bacteria to other chickens with which they are in direct
contact. Current research concerning in ovo vaccination with FMG has indicated that
very low dosages of live FMG are more practical (Chapter 4). Research to determine
how the bacteria is spread amongst layers that were in ovo-vaccinated is warranted, since
greater dilutions of live FMG vaccine (lower amount of suspended bacteria) increases the
chance of inadvertently omitting bacteria administration (aka vaccination) to the embryo.
Thus if any eggs are “missed” and do not receive bacteria from the in ovo solution,
horizontal transmission could be beneficial in allowing bacterial colonization of these
“missed” chicks after hatch from successfully vaccinated pen mates. This type of
research could also contribute to a better understanding of how the in ovo dosage of the
FMG vaccine relates to the post-hatch transmission of FMG between neighboring hens.
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Materials and Methods
A total of 2,340 Hy-Line W-36 hatching eggs were obtained from a 45 week-old
NPIP MG clean breeder flock (National Poultry Improvement Plan, 2014) and were
incubated in 26 trays (90 egg capacity) in a single calibrated NMC2000 NatureForm
Incubator (NatureForm Incubator Company, Jacksonville, Florida) set at 37.5°C and 53%
relative humidity (29.01ºC wet bulb). Eggs were assigned to one of six treatments at the
time of set. Eggs belonging to the control (non-injected) treatment were set in six of the
trays to ensure that a sufficient number of chicks hatched from the control treatment.
Eggs belonging to each of the five injection treatments (a diluent only injection (Poulvac
Marek’s diluent, Zoetis, Exton, Pennsylvania), and “low-low”, low, medium, and high
dose injections of Poulvac Myco F vaccine (Zoetis, New York, New York) resuspended
and diluted in Poulvac Marek’s diluent) were set in each of four replicate trays. The high
dose was taken directly from the 1X resuspended vaccine vial, and the medium, low, and
low-low dosages were 10-2, 10-4, and 10-6 dilutions, respectively, of the high vaccine
dosage. The vaccines were plated prior to and after all injections on Frey Mycoplasma
Broth agar (Frey et al., 1968) and incubated at 37°C for at least 5 days to confirm vaccine
viability and the colony forming units (CFU) administered per dose.
All eggs containing live embryos at 18 days of incubation, determined by
candling, were administered a total 50µL injection volume of their respective treatment
following the procedures of the “Manual in ovo Vaccination Guide” by Embrex Inc.
(Embrex Inc., 2002). Due to horizontal transmission concerns within the NMC2000
hatcher, control and diluent treatment eggs were not hatched in the same hatcher that was
used for the FMG treatment eggs. Trays containing eggs from the lower FMG treatments
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were stacked above those containing eggs from the higher FMG treatments in order to
limit any potential horizontal spread via droppings passed to the lower levels from the
higher levels within the hatcher. Eggs within both hatchers were incubated at 36.7°C dry
bulb and 28.33ºC wet bulb (53% relative humidity). All exhausted air from both hatchers
were filtered and shunted outdoors.
The hatched chicks were removed from their respective incubator at 22 days of
incubation. Non-injected and diluent-injected control chicks were removed prior to the
removal of the chicks belonging to the FMG treatment groups. A total of 320 control
non-injected chicks (sentinel birds) were placed. Ten sentinel chicks were placed in each
of 32 individual isolation units. There were 16 units in each of two rooms (Branton and
Simmons, 1992). Control chicks were equally and systemically chosen from each of the
six incubation trays to limit any potential location effect among the control trays. In
addition to the 10 sentinel chicks, one chick from an FMG treatment group was placed in
each isolation unit. From among four replicate hatcher trays in each treatment group, two
chicks belonging to a common replicate tray were randomly selected, separated, and then
individually placed in an isolation unit in each room. Therefore four chicks were placed
in each of the two rooms with a total of eight FMG treatment chicks being placed. Room
was considered as a blocking factor with 4 replicate units per injection treatment in each
room. Due to plumbing concerns of a potential risk for bacterial spread within a row,
each FMG dose treatment was placed in a row of four connected units. A diagram of the
orientation of the treatments in both rooms is represented in Figure 5.1. Each isolation
unit measured 64.8 cm wide and 142.2 cm long, which provided a total area of 9214.6
cm2 per unit. This provided 837.7 cm2 for each of the 11 birds in the unit. This available
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area far exceeded the 309.7 cm2 per bird recommended for commercial layer pullets
reared in cages (Hy-Line International, Hy-Line Red Book, 2014).
The birds were reared on paper flooring for the first 3 weeks, after which the
paper was removed and the birds walked on plastic slatting. During the duration of the
study, birds were provided feed and water ad libitum. Birds within a unit shared water
from a bell waterer positioned under a continuously running water supply. Birds were
provided a layer pullet starter mash feed until 9 weeks of age and were then provided a
layer pullet grower feed until 12 weeks of age. Both diets were formulated to meet or
exceed NRC requirements (NRC, 1994). Lighting provided to the birds followed the HyLine lighting program for 0 to 6 week old Hy-Line W-36 birds grown in a black out
facility (Hy-Line Red Book, Hy-Line International 2014). This program started with 21
hours of light with 3 hours of dark for the first week, and light duration was decreased by
1 hour each week. Brooding temperatures followed the recommendations set by HyLine. Floor temperature started in the range of 33 to 35°C and decreased by 2 to 3°C per
week. Mortality was recorded daily and birds were checked daily, with the observer
moving from the lowest to the highest FMG treatment groups in both rooms to minimize
the risk of cross-contamination. All incubation and animal care practices were reviewed
and approved by a USDA-ARS Animal Care and Use Committee.
The FMG in ovo-injected birds were raised in the isolation units for 6 weeks. At
6 weeks of age post-hatch, the bird belonging to the FMG injection treatment group was
removed from each unit. Each of those birds were individually weighed and sexed, a
swab sample was taken from their choanal cleft to test for the presence of MG, and a
blood sample was taken for Serum Plate Agglutination (SPA) and ELISA testing for the
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detection of IgM and IgG antibodies against MG, respectively. The remaining sentinel
birds remained in the isolation units another 6 weeks. At 12 weeks of age, all sentinel
birds were removed from their units and they were likewise sexed, weighed, swabbed in
the choanal cleft for MG presence, and bled for SPA and ELISA testing. Sex
determination was based upon external secondary sexual characteristics.
Detection of FMG from swab samples taken from the chaonal cleft was
accomplished by real-time PCR. Sample DNA was extracted using the Qiagen BioSprint
96 One-For-All Vet Kit (Qiagen, Valencia, CA), and samples were run in duplicate using
a 7500 Fast Real Time PCR System (Applied Biosystems, Foster City, CA). For FMG
detection, specific primers (forward primer, 5’ GTTCAAGAACCAACTCAACCA 3’,
reverse primer, 5’ GATTAAGACCGAATTGTGGATTG 3’), and probe (5’
CAACCAGGATTTAATCAACCTCAG 3’) designed by Raviv et al. (2008) were
utilized in the PCR reaction. Primers were diluted to a 0.5 µM concentration and the
probe used was a 0.1 µM concentration. Each total 25µl PCR reaction volume consisted
of 2.5 µl of the Forward primer, 2.5 µl of the Reverse primer, 2.5 µl of probe, 12.5 µl of
Taqman Universal Master Mix (Applied Biosystems, Foster City, CA), 2.5 µl solution of
extracted DNA, and sterile water. The cycling parameters were 95°C for 15 minutes and
40 cycles of 94°C for 15 seconds and 61°C for 1 minutes. Sterile water was used as a
negative control, and a previously known FMG DNA sample was used as a positive
control. Results were determined on a qualitative basis. Any duplicate samples not in
agreement were re-run using 5μL of DNA in the reaction. Serum plate agglutination
testing with MG antigen (Charles River Laboratories International, Wilmington, MA)
was performed by an experienced technician and ELISA tests were carried out by an
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independent laboratory utilizing IDEXX MG antibody testing (IDEXX Laboratories,
Westbrook, ME).
The data were analyzed as a mixed model with room considered a random effect
and injection treatment as a fixed effect (SAS Version 9.4). Sex effects were also
considered for individual body weights. Treatment effects for the percentage of sentinel
birds that tested positive in each unit were analyzed (PCR, SPA, and ELISA positive
tests). A P value less than or equal to 0.05 was considered significant. Any significant
differences were evaluated using least squared means.
Results and Discussion
Detailed hatch results from this trial are presented in Chapter 4. Control noninjected birds from the same hatch reared in the first trial of Chapter 4 all tested negative
for the presence of FMG by real-time PCR and were serologically negative for MG at 6
weeks of age by SPA and ELISA testing. This indicates that the biosecurity measures
taken during hatch prevented horizontal transmission of MG within the hatchery.
Therefore, the sentinel birds of the current study were MG-clean prior to exposure to the
FMG in ovo-vaccinated chick that was placed in their respective isolation pens.
Plate counts of the FMG vaccine administered to the in ovo-vaccinated chicks
averaged 97.5 CFU/20 µL at a 10-4 dilution prior to vaccination. These counts indicated
that the embryos belonging to the high in ovo injection treatment received approximately
2.4 x 106 CFU of bacteria per 50 µL dose. The medium treatment received 2.4 x 104
CFU per dose, the low dose received 2.4 x 102 CFU per dose, and the low-low treatment
received 2.4 CFU per dose. The vaccine remaining in the vials used for the injections
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were plated after all injections were finished and were grown until too numerous to
count. This confirmed vaccine viability through the duration of injections.
All results (mortality, FMG detection by PCR, and MG antibody detection by
SPA and ELISA) are presented by treatment for each isolation unit in the two rooms in
Tables 5.1 through 5.4. No sentinel birds died during the 12 week duration of the
experiment. The in ovo-injected birds experienced similar trends in mortality as was
observed in Chapter 4. Birds belonging to the higher in ovo dosage treatment
experienced the highest rate of mortality and generally died at an earlier age than those in
the lower dosage treatments. Only one chick in the high dose treatment group survived to
6 weeks of age. All other chicks in the high dose treatment died within the first week.
Two chicks in the medium dose treatment survived to 6 weeks, and both were housed in
room 2. All other chicks died within the first 10 days post-hatch. The low dosevaccinated birds survived to 6 weeks of age, except for two chicks (one per room) that
died at 6 and 7 days post-hatch. All low-low dose vaccinated chicks survived to 6 weeks
of age.
The body weights of the 17 remaining in ovo-injected birds at 6 weeks of age
were not affected by treatment (P=0.43), but the seven remaining males were 97.6 g
heavier than the ten remaining females (P=0.0078). Body weights of the sentinel birds at
12 weeks of age (n=320) were likewise not affected by exposure to the single chick that
was placed in their isolation pen regardless of the dose of FMG that the in ovo injected
chick received (P=0.95). Furthermore, males were 306.1 g heavier than females at this
age (P<0.0001).
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The percentage of sentinel birds that tested positive for FMG by PCR was not
different between treatments (P=0.48). The same was also true for the percentages of
SPA (P=0.77) and ELISA (P=0.85) positive sentinel birds. The equivalency of the FMG
transmission percentages among the various treatment groups may be partly due to the
exposure time of the in ovo-vaccinated chick to its pen mates. The in ovo-vaccinated
chicks in the medium and high dose treatments died earlier and thus exposed their
sentinel birds to FMG for a shorter duration. The low and low-low dose treatments in
ovo-vaccinated chicks survived longer and exposed their sentinel birds to FMG for a
longer period of time.
In the majority of the isolation units, if the in ovo-vaccinated bird that was tested
at 6 weeks of age was PCR positive, but not positive for antibody production,
transmission to the sentinel birds was very low or nonexistent. Conversely, if the in ovovaccinated bird was serologically positive then transmission of FMG to the sentinel birds
usually readily occurred. This trend was exhibited in the low-low dose treatment (Table
5.1). The in ovo-injected birds in isolation units 4, 19, and 20 were PCR positive for
FMG and were positive for MG antibody production by SPA and ELISA. This resulted
in all (100%) of the sentinel birds in those units being colonized by FMG. In addition, by
SPA testing, and 90% or 100% of the sentinel birds exhibited IgM antibody production
against MG. Similarly, 50%, 70%, and 100% of those birds also exhibited IgG antibody
production. Transmission was very low among birds in all other units in the low-low
dose treatment group, where the in ovo-vaccinated bird did not test positive for MG
antibody production, even if MG was detected in its choanal cleft. This was observed in
units 1 and 18. The birds in the low-low in ovo-vaccinated treatment that were
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serologically negative for MG and specifically negative for FMG, yet transmitted FMG
to a low percentage of their pen mates (units 2 and 3) most likely were infected with
FMG but not at a detectable level.
In the low dose treatment group, in ovo-injected birds that tested serologically
positive for MG transmitted MG to a large percentage of their pen mates in isolation units
5 and 24 (Table 5.2). However, isolation units 6, 8, and 22 were exceptions to this
pattern. In those units, the in ovo-injected birds were serologically positive for MG
antibody production, yet none of their pen mates picked up MG or had a humoral
immune response against MG. Olesiuk et al. (1967) also noted irregular transmission
rates of MG among pen mates. Their findings, in a series of MG transmission studies,
indicated that birds infected with MG, whether showing respiratory symptoms or not,
could horizontally transmit the bacteria to pen mates with whom the infected birds were
in direct contact. Nevertheless, their findings also indicated that although transmission is
possible, it does not always occur. In this study, there were instances where the bacteria
was not spread even after there was direct contact between infected birds and noninfected pen mates after 16-36 weeks. Birds in the low dose treatment group that died on
days 6 and 7 (units 7 and 21) may not have lived long enough to transmit the bacteria.
The serum sample taken from the in ovo-injected bird in unit 23 gelled, making SPA and
ELISA testing impossible. Although FMG was detected in that bird, transmission did not
occur to any of its pen mates.
The two birds in the medium dose in ovo injection treatment group that survived
to 6 weeks of age were both serologically positive for MG and transmitted FMG, which
induced a humoral immune response in the majority of the sentinel birds in those units
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(units 27 and 28; Table 5.3). As detected by PCR, birds in the other six units that
belonged to the medium dose in ovo injected birds, which died at 2, 3, 4, 8, and 10 days
of age, did not transmit FMG (units 9, 10, 11, and 25) or only did to a small percentage
(10% or 20% in units 12 and 26) of their pen mates.
Most of the in ovo-injected birds that received the high dose of FMG and died
early (1, 2, or 7 days post-hatch in units 13, 14, 15, 29, and 30) did not transmit FMG to
any of their sentinel pen mates (Table 5.4). The in ovo-injected bird in unit 31, however,
died at 3 days of age and transmitted FMG to all of its sentinel birds. It also induced IgM
production in all of the sentinel birds, and IgG antibody production was detected in 80%
of the sentinels. A slightly lower but somewhat similar rate of transmission occurred in
unit 32, where the in ovo-injected bird died on day 4 post-hatch, yet transmitted FMG to
the majority of its sentinel birds. There was an irregular and unexplainable occurrence of
FMG transmission in isolation unit 16. The only high dose in ovo-vaccinated chick that
survived to 6 weeks of age was from unit 16. This chick tested positive for FMG and
antibody production, yet none of its pen mates picked up FMG or had a humoral immune
response against FMG.
The results of this study show that a layer chicken that is in ovo-vaccinated with a
live attenuated FMG vaccine at 18 days of incubation is able to horizontally transmit the
bacteria to pen mates by 6 weeks of age that are in direct contact with it. This
transmission further elicits a humoral immune response against FMG in sentinel pen
mates. This predominantly occurs only if the vaccinated chick also tested serologically
positive for antibody production against MG, although transmission is not guaranteed.
These results indicate that if layer chicken embryos are successfully vaccinated in ovo
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with a very low dosage of FMG, even if some are not administered an adequate amount
of FMG to induce immunity, these birds may still successfully transmit the FMG to pen
mates that they are in direct contract with and cause the pen mates to mount an immune
response. Further work on horizontal transmission of FMG from in ovo-vaccinated birds
to other surrounding birds should explore include an exploration of the potential for MG
transmission to occur within the hatcher.
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Post-hatch horizontal transmission of strain F Mycoplasma gallisepticum
(FMG) from birds vaccinated with a low-low dose of FMG at 18 days of
incubation

Room 2

Room 1

Table 5.1

In ovo-injected Bird1, 2

10 Sentinels

Unit 1

PCR +
SPA ELISA -

40% PCR +
0% SPA +
0% ELISA +

Unit 2

PCR SPA ELISA -

10% PCR +
0% SPA +
0% ELISA +

Unit 3

PCR SPA ELISA -

50% PCR +
0% SPA +
0% ELISA +

Unit 4

PCR +
SPA +
ELISA +

100% PCR +
100% SPA +
70% ELISA +

Unit 17

PCR SPA ELISA -

0% PCR +
0% SPA +
0% ELISA +

Unit 18

PCR +
SPA ELISA -

0% PCR +
0% SPA +
0% ELISA +

Unit 19

PCR +
SPA +
ELISA +

100% PCR +
100% SPA +
100% ELISA +

Unit 20

PCR +
SPA +
ELISA +

100% PCR +
90% SPA +
50% ELISA +

1

Low-low dose was a 10-6 dilution of an original 1X vaccine vial of Poulvac Myco F
resuspended in 50mL of Marek’s diluent of approximately 2.4 colony forming units per
50 µL dose.
2
A single in ovo-injected bird was placed in each unit in 2 rooms with 10 noninjected
sentinel birds. PCR indicates detection of FMG in the choanal cleft of the birds (+ is
detection – is negative). Serum plate agglutination (SPA) tests were used for the
detection of IgM antibody production against MG. ELISA tests were used for the
detection of IgG antibody production against MG.
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Post-hatch horizontal transmission of strain F Mycoplasma gallisepticum
(FMG) from birds vaccinated with a low dose of FMG at 18 days of
incubation

Room 2

Room 1

Table 5.2

In ovo-injected Bird1, 2

10 Sentinels

Unit 5

PCR +
SPA +
ELISA +

70% PCR +
50% SPA +
50% ELISA +

Unit 6

PCR +
SPA +
ELISA +

0% PCR +
0% SPA +
0% ELISA +

Unit 7

Dead Day 6

0% PCR +
0% SPA +
0% ELISA +

Unit 8

PCR +
SPA +
ELISA +

0% PCR +
0% SPA +
0% ELISA +

Unit 21

Dead Day 7

0% PCR +
0% SPA +
0% ELISA +

Unit 22

PCR +
SPA +
ELISA +

0% PCR +
0% SPA +
0% ELISA +

Unit 23

PCR +
Serum Sample Gelled

0% PCR +
0% SPA +
0% ELISA +

Unit 24

PCR +
SPA +
ELISA +

100% PCR +
100% SPA +
100% ELISA +

1

Low dose was a 10-4 dilution of an original 1X vaccine vial of Poulvac Myco F resuspended in
50mL of Marek’s diluent of approximately 2.4 x 102 colony forming units per 50μL dose. 2A
single in ovo-injected bird was placed in each unit in 2 rooms with 10 noninjected sentinel birds.
PCR indicates detection of FMG in the choanal cleft of the birds (+ is detection – is negative).
Serum plate agglutination (SPA) tests were used for the detection of IgM antibody production
against MG. ELISA tests were used for the detection of IgG antibody production against MG.
Dead Day indicates the age post-hatch when the in ovo vaccinated bird was found dead and
removed. Serum sample gelled was a gelled sample unable to be tested for SPA and ELISA.
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Post-Hatch horizontal transmission of strain F Mycoplasma gallisepticum
(FMG) from birds vaccinated with a medium dose of FMG at 18 days of
incubation

Room 2

Room 1

Table 5.3

In ovo-vaccinated Bird1, 2

10 Sentinels

Unit 9

Dead Day 10

0% PCR +
0% SPA +
0% ELISA +

Unit
10

Dead Day 2

0% PCR +
0% SPA +
0% ELISA +

Unit
11

Dead Day 8

0% PCR +
0% SPA +
0% ELISA +

Unit
12

Dead Day 3

10% PCR +
0% SPA +
0% ELISA +

Unit
25

Dead Day 2

0% PCR +
0% SPA +
0% ELISA +

Unit
26

Dead Day 4

20% PCR +
0% SPA +
0% ELISA +

Unit
27

PCR +
SPA +
ELISA +

70% PCR +
60% SPA +
50% ELISA +

Unit
28

PCR +
SPA +
ELISA +

80% PCR +
90% SPA +
80% ELISA +

1

Medium dose was a 10-2 dilution of an original 1X vaccine vial of Poulvac Myco F resuspended
in 50mL of Marek’s diluent of approximately 2.4 x 104 colony forming units per 50 μL dose
2
A single in ovo-injected bird was placed in each unit in 2 rooms with 10 noninjected sentinel
birds. PCR indicates detection of FMG in the choanal cleft of the birds (+ is detection – is
negative). Serum plate agglutination (SPA) tests were used for the detection of IgM antibody
production against MG. ELISA tests were used for the detection of IgG antibody production
against MG. Dead day indicates the age post-hatch when the in ovo vaccinated bird was found
dead and removed.
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Post-hatch horizontal transmission of Mycoplasma gallisepticum (FMG)
from birds vaccinated with a high dose of FMG at 18 days of incubation

Room 2

Room 1

Table 5.4

In ovo-vaccinated Bird1, 2

10 Sentinels

Unit 13

Dead Day 1

0% PCR +
0% SPA +
0% ELISA +

Unit 14

Dead Day 7

0% PCR +
0% SPA +
0% ELISA +

Unit 15

Dead Day 1

0% PCR +
0% SPA +
0% ELISA +

Unit 16

PCR +
SPA +
ELISA +

0% PCR +
0% SPA +
0% ELISA +

Unit 29

Dead Day 1

0% PCR +
0% SPA +
0% ELISA +

Unit 30

Dead Day 2

0% PCR +
0% SPA +
0% ELISA +

Unit 31

Dead Day 3

100% PCR +
100% SPA +
80% ELISA +

Unit 32

Dead Day 4

70% PCR +
60% SPA +
30% ELISA +

1

High dose was an in ovo vaccination using a 1X vaccine vial of Poulvac Myco F
resuspended in 50mL of Marek’s diluent of approximately 2.4 x 106 colony forming units
per 50 μL dose.
2
A single in ovo-injected bird was placed in each unit in 2 rooms with 10 noninjected
sentinel birds. PCR indicates detection of FMG in the choanal cleft of the birds (+ is
detection – is negative). Serum plate agglutination (SPA) tests were used for the
detection of IgM antibody production against MG. ELISA tests were used for the
detection of IgG antibody production against MG. Dead day indicates the age post-hatch
when the in ovo vaccinated bird was found dead and removed.
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13
High

9
Medium

5
Low

Building Orientation
Door
1
17
Low low
Low low

14
High

10
Medium

6
Low

2
Low low

18
Low low

22
Low

26
Medium

30
High

15
High

11
Medium

7
Low

3
Low low

19
Low low

23
Low

27
Medium

31
High

16
High

12
Medium

8
Low

4
Low low

20
Low low

24
Low

28
Medium

32
High

Figure 5.1

Room 1

Room 2
21
25
Low
Medium

29
High

Diagram of isolation units

Representation of the isolation units of this study located in two rooms. The top number
in each box indicates the unit number, followed by the treatment of the single in ovoinjected chick that was placed in that unit along with 10 control non-injected sentinel
chicks. A single treatment was placed in a connected row (located vertically in a column
in the diagram) instead of interspersing the treatments, due to plumbing concerns of
possible bacterial transmission within a row.
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EVALUATION OF THE POTENTIAL INFLUENCE OF THE DISINFECTION
CYCLE ON THE EFFICACY OF STRAIN F MYCOPLASMA
GALLISEPTICUM VACCINE ADMINISTERED BY IN
OVO INJECTION TO LAYER HATCHING EGGS
Abstract
Post-hatch vaccination is the current commercial method to combat egg
production losses in layer chickens caused by the bacterial pathogen, Mycoplasma
gallisepticum (MG). In ovo vaccination of F-strain MG vaccine has proven to be a
promising technique for layer chickens in previous trials. However, its practical
application within current in ovo vaccination procedures, employing disinfection after
each injection using a 2,500 ppm chlorinated solution, is uncertain. The objective of this
experiment was to determine the ability of FMG to survive the disinfection step to elicit a
post-hatch immune response in pullets. Two trials were conducted in which 5 trays of 72
eggs (Hy-Line W-36 hatching eggs from MG-clean breeder flocks) were represented in
each of 5 treatments. Treatments were: control non-injected eggs, diluent-injected
(Poulvac Marek’s) eggs with or without a disinfection step, and eggs vaccinated with an
FMG vaccine (Poulvac Myco F at 10-6 dilution) with or without a disinfection step. Eggs
were injected with a 50 µL injection volume at 18 d of incubation with a 42-egg capacity
Embrex Inovoject machine operated by a trained company technician. The FMG vaccine
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was plated before and after injections. A total of 90 hatched chicks per treatment in both
trials were raised to 6 weeks of age and were bled for Serum plate agglutination (SPA)
and ELISA testing for detection of antibody production against MG. Plate counts
indicated that the eggs were injected with an average of 2.7 colony forming units in each
50 µL dose. Data were analyzed as a mixed model. Hatchability of live embryonated
eggs was lower in the FMG with disinfectant treatment, which was not different from the
MG without disinfectant and diluent without disinfectant treatments (P=0.034).
Percentages of birds having MG detected in their choanal cleft at 6 weeks of age were
equal among all MG injection treatments. Birds vaccinated with FMG also developed
antibody responses regardless of employment of the disinfection step. Overall, SPA and
ELISA positive responses in the FMG with and without disinfectant treatments were 81.6
and 30.5%, and 62.2 and 30.3%, respectively. With the exception of one ELISA positive
bird in the non-injected group in the first trial, birds in the non-injected and diluentinjected controls were serologically negative in response to FMG. These results indicate
that FMG does survive the disinfection step employed by commercial machines and
could be readily applied to current commercial procedures of in ovo vaccination with no
detriment to vaccine efficacy.
Introduction
Following the successful experiments in which chickens were vaccinated for
Marek’s disease by an in ovo route, a machine was constructed to in ovo inject
commercial chicken eggs on a large scale (Sharma and Burmester, 1982; Gildersleeve et
al., 1993). This early machine employed a disinfection step between each egg injection,
because the need for sanitization when opening a sterile egg to an external environment
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was recognized (Gildersleeve et al., 1993). One reason for the depression in hatch after
in ovo injections in commercial hatcheries has been found to be due to the fungi
Aspergillus fumigatus (Ricks et al., 1999; Williams and Brake, 2000). Previous
experiments in a lab setting have found that when a hole is made in the eggshell late in
incubation, it may remain unsealed with no significant adverse effects on hatch success
(Sharma and Burmester, 1982; Molenaar et al., 2010). However, these reports also
disinfected the eggshell with 70% alcohol prior to puncturing the eggshell.
Previous trials (Chapters 3, 4, and 5) have shown that there is the potential to
successfully deliver a live attenuated strain F Mycoplasma gallisepticum (FMG) vaccine
to induce immunity in layer chickens against MG challenges encountered in the laying
house. In these previous trials, eggs were hand-injected, and the surface of the eggshell
was wiped with 70% alcohol prior to injection. In ovo vaccination of FMG has the
potential to save labor and reduce stress on birds in comparison to the handling of each
pullet when administering eyedrop vaccinations of FMG to pullets (Levisohn and Kleven,
1981).
Relative to other bacteria commonly grown in the laboratory, MG is a sensitive
bacteria which lacks a cell wall and requires a specific media and a long incubation time
(Yoder Jr. and Hofstad, 1964; Frey et al., 1968; Badbury, 2005). Christensen et al.
(1994) found that MG could survive in chlorinated tap water if the initial bacterial
numbers were high. In previous preliminary work (See Appendix) it was shown that MG
can be readily killed by a 10% bleach solution (approximately >5000 ppm). Whether the
industry practice of disinfecting with a 2,500 ppm chlorine solution between every in ovo
injection would affect the live FMG in ovo vaccine is uncertain. Additionally, the
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majority of in ovo vaccines have been developed and tested for viral pathogens, with few
studies investigating in ovo injection of a living bacteria into embryonated chicken eggs
(Ricks et al., 1999)
The purpose of the present experiment was to confirm if in ovo vaccination using
a live attenuated FMG vaccine for layer chickens could be readily used for commercial
application using an in ovo injection machine that employs the industry standard
disinfection step between injections, or if modifications to the in ovo procedure would be
required. In this study, the importance of the disinfectant step during in ovo vaccinations
for hatch success and post-hatch survival was also investigated.
Materials and Methods
Two preliminary trials were conducted in which 120 hollow plastic ovoid eggsimulation devices were in ovo-injected with a live attenuated FMG vaccine to test for the
potential of the industry standard disinfectant step between each egg injection to mix with
(and kill) the bacteria within the vaccine. The egg-simulated devices were engineered to
capture the in ovo vaccine and mimic an authentic egg. The simulation devices were cut
at the blunt end to create a circular opening measuring 2.86 cm in diameter. The devices
were soaked in 70% isopropyl alcohol (CleanPro, Eden Prairie, MN) for at least 2
minutes, air dried and then stored in a class 11 biosafety cabinet (Labconco Corporation,
Kansas City, MO) where they were then exposed to ultraviolet light for 3 hours.
Laboratory parafilm (Bemis, Neenah, WI) was secured over the opening of each device.
The simulation devices remained in the biosafety cabinet until injection time. Poulvac
Myco F vaccine (Zoetis, New York, New York) was resuspended in 50 mL Poulvac
Marek’s diluent (Zoetis, Exton, Pennsylvania) and diluted to a 10-2 dilution. This vaccine
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solution was in ovo-injected through the parafilm into the ovoid plastic devices using a 42
egg capacity Embrex Inovoject® machine operated by an experienced company
technician. The disinfectant was a 2,500 ppm chlorine solution which was made using
Inovotabs (Embrex, New York, New York) according to the manufacturer’s instructions.
The 120 simulation devices were either injected with Marek’s diluent without a
disinfectant step (n=40), injected with the FMG vaccine without a disinfectant step
(n=40), or injected with the FMG vaccine with a disinfectant step (n=40). Each set of
eggs was injected at one time in a single 42 egg capacity flat. Prior to the injection of
each treatment, the functionality of the desired vaccine and disinfectant step was tested
immediately prior to the experimental injection of the flat of simulation devices. After
the simulation eggs were injected, the solution that was injected into each simulation egg
was immediately plated (as a 1X, 10-1, 10-2, and 10-3 dilutions) and grown on Frey’s
Mycoplasma Broth agar (Frey et al., 1968) at 37°C for at least 5 days to determine the
amount of viable bacteria present in the sample. In each preliminary trial, two additional
simulation eggs were only injected with air followed by a functional disinfectant step.
These two simulation eggs were subsequently opened to examine the amount of
disinfectant delivered to them internally.
In the following experiment a total of 2,100 fertile Hy-Line W-36 hatching eggs
from a Mycoplasma gallisepticum (MG) clean breeder flock (National Poultry
Improvement Plan, 2014) were set in each of two replicate trials. In trial 1, a 41 week old
breeder flock was used and in trial 2 a 51 week old breeder flock was used. In each trial,
eggs were incubated in 25 trays (72 egg capacity) in a single calibrated NMC2000
NatureForm Incubator (NatureForm Incubator Company, Jacksonville, Florida) set at
138

37.5°C and 53% relative humidity (29.01ºC wet bulb). Each tray consisted of two 42 egg
capacity flats that were made for use in a Jamesway 500 incubator. The trays were
fastened to NatureForm trays, as the Jamesway flats provided the egg orientation required
for use with the Embrex Inovoject machine. Treatments were assigned at the time of set,
with five trays of eggs set for each of five treatments. The treatment groups were: control
non-injection, a diluent-only injection with no disinfectant step (Poulvac Marek’s diluent,
Zoetis, Exton, Pennsylvania), a diluent injection with a disinfection step between egg
injections, and an MG in ovo vaccination with no disinfection step or with a disinfection
step between each injection. The in ovo FMG vaccine was a 10-6 dilution of Poulvac
Myco F vaccine (Zoetis, New York, New York) resuspended and diluted in Poulvac
Marek’s diluent. This FMG vaccine dosage was previously found to be practical for in
ovo administration (Chapter 4). All treatments were systematically placed in all levels of
the incubator and were re-randomized in the second trial.
For additional observations as to the effect of the disinfection step during in ovo
vaccinations on hatch success, an additional 8 trays of the eggs (84 egg capacity) were set
in another NOM2000 NatureForm incubator in both trials. Four replicate trays were
assigned to each of the diluent without a disinfectant step and 4 trays of a diluent with a
disinfectant step treatments. It is thought that a disinfectant step is needed between all
egg injections to decrease bacterial contamination between eggs when injecting viral
vaccines in ovo. However, this step may be deleterious to the survival of bacterial
vaccines. These additional trays were included to evaluate any depression in the hatch of
W-36 layer hatching eggs provided from a commercial source associated with the
absence of a disinfection step between egg injections.
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All eggs were weighed on a batch tray basis at set, and at 12 and 18 days of
incubation for percentage moisture loss calculations. Additionally, all the eggs were
candled at 12 and 18 days of incubation and culled eggs were opened to categorize the
eggs as either infertile, or early or middle stage embryonic mortalities.
After candling and weighing on day 18 of incubation, all live embryonated eggs
(including control eggs) were transported approximately 2 miles via climate controlled
vans from the Mississippi USDA-ARS incubation facility to Mississippi State
University’s egg injection facility. Control and diluent-injected eggs were placed in a
separate van from the FMG-injected eggs in order to limit any potential horizontal
transmission of FMG. All diluent and FMG-vaccinated eggs were administered a 50 μL
injection volume by an Embrex Inovoject machine with a 42 egg capacity. The Inovoject
machine was operated by an experienced company technician to adequately dispense or
turn off the disinfectant step when required. The disinfectant was prepared by
commercial standards using Inovotabs which created a 2,500 ppm chlorine solution.
Nine trays of eggs were injected with diluent without a disinfectant step, and then nine
trays of eggs were injected with diluent with a disinfectant step. The five trays of eggs
that received an FMG injection without a disinfectant step were injected next (third set of
injection), and the last group of eggs that were injected consisted of 5 trays of eggs that
were injected with FMG with a disinfectant step. This order of injections was chosen to
limit potential FMG transmission between diluent and MG-injected eggs and to limit the
potential of transmission of residual disinfectant to the non-disinfectant treatment groups.
Two embryonated eggs from each of the 25 trays in each trial were injected with
Coomassie brilliant blue R-250 dye (Genlantis, San Diego, California) using the
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Inovoject machine. These embryos were immediately euthanized using carbon dioxide
surrounding the eggs for at least 20 minutes. The eggs were then cooled at 4°C
overnight. These eggs were placed in a -12.8°C freezer two hours before opening the
eggs to determine the location of the injected dye using an embryo staging system
developed by Embrex (Avakian, 2006).
After all injections were completed, the eggs were returned to the USDA
incubation facility and placed in plastic hatching baskets (76.2 cm width, 71.1 cm length,
and 11.4 cm deep). Each basket contained eggs from two incubation trays belonging to
the same treatment group with a divider placed between the eggs from the two different
trays. The control eggs (non-injected and diluent-injected) were placed in a separate
NMC2000 NatureForm incubator (used as a hatcher unit) located in the same room that
held the incubator that was used to incubate these eggs through the first 18 days of
incubation. This was done to prevent possible horizontal transmission of the bacteria to
the control chicks within the hatcher unit. The hatcher units containing the control and
treated eggs both had their exhausted air separately filtered and shunted out of the
hatchery. Treatment orientation in the incubator switched between trials (the FMG
treated chicks hatched in the other incubator in the second trial) to eliminate any hatcher
effect. The control, diluent with a disinfectant step, and diluent without a disinfectant
step treatment groups were interspersed within their hatcher. In the other hatcher, the
eggs that were injected with FMG with a disinfectant step were placed above those that
were injected with FMG without a disinfectant step to potentially reduce the transmission
of FMG via fecal droppings from those birds treated without a disinfectant step to those
treated with a disinfectant step. It was supposed that the fecal droppings from the birds
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with a disinfection step had a lower bacterial load. Temperature in the hatcher was
lowered to 36.7°C.
The hatched chicks were removed from their respective incubator at 22 days of
incubation. All measurements on non-injected and diluent-injected treatment groups
were taken before the chicks from the FMG injection treatments were removed from their
incubator. All hatched chicks were counted and all unhatched eggs were opened for
hatchery residue analysis. No further measurements were taken of chicks from the extra
8 trays that belonged to the diluent with or without a disinfectant step treatment groups.
Fifty chicks per treatment (10 from each of the five replicate trays per treatment
out of the original 25 trays) were euthanized using carbon dioxide and were weighed
individually and each of their yolk sacs was removed and weighed. Yolk sacs and their
contents were dried at 65°C for 5 days and reweighed. The yolk sacs were cooled and let
sit at room temperature for 5 hours before weighing. Thirty eight chicks per treatment
(approximately eight chicks per tray from the initial 25 trays) were swabbed postmortem. Swabs of the trachea were taken through the larynx to test for the presence of
MG using swabs pre-wetted in PBS. The swab samples were then suspended in 110 µL
of PBS. The DNA from each trachea swab sample was extracted using the Qiagen
BioSprint 96 One-For-All Vet Kit (Qiagen, Valencia, CA) and were tested in duplicate
using a 7500 Fast Real Time PCR System (Applied Biosystems, Foster City, CA) using F
strain specific primers and probe designed by Raviv et al. (2008). The PCR reaction was
a 25 µl PCR reaction volume consisting of 2.5 µl of the forward primer (5’
GTTCAAGAACCAACTCAACCA 3’), 2.5 µl of the reverse primer (5’
GATTAAGACCGAATTGTGGATTG 3’), 2.5 µl of the probe (5’
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CAACCAGGATTTAATCAACCTCAG 3’), 12.5 µl of Taqman Universal Master Mix
(Applied Biosystems, Foster City, CA), 2.5 µl solution of extracted DNA, and 2.5 µL of
sterile water. The concentrations of the primer and probe were 0.5 and 0.1 µM,
respectively. The cycling parameters were 95°C for 15 minutes and 40 cycles of 94°C
for 15 seconds and 61°C for 1 minute. Sterile water was used as a negative control, and
an F strain DNA sample was used as a positive control. Results were determined on a
qualitative basis (positive or negative for MG presence).
A subset of chicks from each treatment that were equally selected from each tray
from the initial 25 trays, and were raised in isolation units (Branton and Simmons, 1992).
Each isolation unit contained 30 chicks per unit. There were three units per treatment for
a total of 90 chicks per treatment. This stocking density provided 307.1 cm2 per bird
which met the recommended colony cage space requirements for Hy-Line W-36 breeder
pullets and cockerels that are reared comingled during the growing period (Hy-Line Red
Book, Hy-Line International 2014). The birds were reared for 6 weeks with feed and
water provided ad libitum. A layer pullet mash starter diet was formulated to meet NRC
requirements (NRC, 1994) and was provided for the entire 6 week duration of the study.
All dead chicks were immediately removed and were subsequently necropsied for
evaluation of any signs of MG infection and for the potential cause of death. Brooding
temperatures followed the recommendations set by Hy-Line. The starting floor
temperature ranged from 33 to 35°C and was decreased by 2 to 3°C per week. Birds
were provided 21 hours of light the first week and the light duration was decreased by
one hour each week as recommended for 0 to 6 week-old Hy-Line W-36 pullets (Hy-Line
Red Book, Hy-Line International 2014). The isolation units were only opened to remove
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dead birds and to add feed and water when needed. At 6 weeks of age, the choanal cleft
of all birds in each unit were swabbed to test for the detection of FMG by PCR, and each
bird was bled for serum plate agglutination (SPA) and ELISA testing for the detection of
antibodies against MG. The birds were individually weighed and were then euthanized
by cervical dislocation. All bird rearing and handling practices were approved by a
USDA-ARS Animal Care and Use Committee.
The data were analyzed as a mixed model utilizing SAS (Version 9.4) to
investigate the effects of injection treatment, with trial considered a random effect. For
the incubational period, the data collected from the main 25 trays in both trials were
analyzed separately from the 8 additional trays belonging to the diluent-injected
treatment in both trials. These data were analyzed separately because the extra trays were
incubated in a separate incubator in both trials. Sex was analyzed as a fixed effect for the
individual body weight data. The percentages of birds that tested positive (PCR, SPA,
and ELISA testing) at 6 weeks of age in each unit were analyzed to test for their possible
differences between treatments. A P value that was less than or equal to 0.05 was
considered significant. Any significant differences were evaluated using least squares
means.
Results and Discussion
Preliminary investigations of the injection of simulation eggs by the Embrex
Inovoject machine found that no disinfectant visually entered the artificial egg. This was
shown after examining two simulation eggs that were injected with air in the vaccine line
in the two trials. However, disinfectant was apparent resting on top of the parafilm that
was stretched over the circular opening of the simulated eggs. The lack of injection of
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the disinfectant into the simulation eggs suggests that the chlorine solution does not mix
with the vaccine within the embryonated egg. The plating results, however, did not
confirm these visual results. In both preliminary trials, no MG growth was observed in
the diluent only treatment group. In both preliminary trials, FMG was alive within the
simulation eggs in the FMG vaccine that was administered without a disinfectant step.
Average colony forming units (CFU) per egg was 3.51 x 106 and 3.38 x 105 in trials 1 and
2, respectively. However, in the FMG vaccine administered with a disinfectant step, only
13 of the 40 simulation eggs contained live MG in trial 1 and no simulated eggs
contained any live MG in trial 2. These conflicting results (visual versus MG growth
data) suggests that there may be some slight mixing of the vaccine with the disinfectant
within an egg after vaccination with the Inovoject machine. Additionally, the parafilm
stretched over the opening in the simulation egg resulted in a flat surface, which
obviously differs dramatically from the rounded blunt end of an authentic egg. Thus, the
full scale experiments with the two replicate trials were necessary to answer the question
as to whether or not disinfectant and vaccine mixing occurred and could affect the
efficacy of the FMG vaccine within “actual” embryonated eggs.
In the two replicate “actual” egg trials, egg weights on a tray basis for each of the
50 total trays (25 trays per trial) were recorded when the eggs were initially placed in the
incubator. Average tray egg weights were not different (P=0.83) and egg moisture loss
by 18 days of incubation was consistent between the treatments (P=0.65). The same was
true for the eggs incubated in the separate incubator that was used to evaluate the effect
of disinfection on hatch success. Average egg weights and 18 day moisture losses were
consistent between all 16 trays (8 per trial) (P=0.94 and P=0.79, respectively). For the
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main 25 trays and the extra trays used to further test disinfection effects, the percentage
of infertile eggs, and the percentages of early, middle, and late dead embryonic
mortalities were alike among all treatments during the first 18 days of incubation (All
P>0.1). These data indicate eggs and incubation conditions were similar for all
treatments prior to the in ovo injections at 18 days of incubation.
The FMG vaccine at a 10-4 dilution was plated in replicate prior to injection and it
was found that the 10-6 dilution that was injected delivered an average of 1.64 CFU per
50 μL volume to each embryonated egg. It was found after post-injection plating of the
10-6 dilution vaccine that was used for the injections that there were 1, 3, 4, 5, and 0 CFU
on the 5 replicate plates. In the second trial, bacteria viability was proven, yet CFU
determination was not possible. It is estimated that this dilution also provided between 1
and 5 CFU per dose, as has also been found at this dilution in previous trials (Chapters 3
and 4).
In trial 1, upon the injection of dye into two embryonated eggs per tray at 18 days
of incubation, it was found that in the first 25 trays that average embryo were scores 2.2 ±
0.1 and were 2.4 ± 0.2 in the extra diluent injection treatment trays in the separate
incubator, respectively. For the first 25 trays, the dye was located in the allantois in 10%
of the embryos, and in the yolk sac in 2% of the embryos. The majority of embryos
(88%) received in ovo injections in the amnion. Of the 16 embryos from the extra diluent
trays, dye was found in the allantois of one embryo and was found in the amnion of the
other 15 embryos. In trial 2, embryos in the main 25 trays had an average embryo stage
score of 1.8 ± 0.1, and the embryos in the separate diluent group had an average embryo
stage score of 1.9 ± 0.1. The 50 embryos from the initial 25 trays were all injected in the
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amnion with one embryo that was injected in the air cell. The 16 embryos from the extra
diluent trays in trial 2 were injected into the amnion with the exception of three embryos,
which were injected in the air cell.
Hatchability of chicks in the extra diluent trays was not affected by the
employment of a disinfectant step (P=0.73). The eggs utilized in this study were from
commercial flocks, and appeared very clean. Therefore, the disinfectant step may
potentially cause a greater difference in hatchability when floor eggs or eggs from older
breeder flocks are set. The hatch rate of embryonated eggs in the 25 trays per trial was
significantly affected by treatment (P=0.03) with the lowest hatch rate of live
embryonated eggs in the FMG with disinfectant treatment group. Nevertheless, the
hatchability of those eggs was not different from those belonging to the FMG without and
diluent without disinfectant treatment groups (Table 6.1). Upon performing the residue
breakout, it was found that only an increase in percentage cull chicks occurred in the
FMG with disinfectant treatment group (0.6%) (P=0.01). This percentage cull chicks
were significantly higher than all other treatments except in comparison to the control
non-injected treatment group which experienced 0.3% cull chicks. The FMG without
disinfectant and diluent with or without disinfectant treatment groups contained no culled
chicks in either trial. No other residue egg category differed from that of the control eggs
in the diluent or FMG injection treatment groups whether or not a disinfectant step was
used (middle dead embryos P=0.42; late dead embryos P=0.09; embryos that died due to
a cracked egg at transfer P=0.42; contaminated eggs P=0.49; live pips P=0.53; dead pips
P=0.74; embryos found live in the shell P=0.84).
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All measured variables in chicks taken at hatch were similar among all the
treatments (n=600) including chick weight (P=0.49), yolk-free chick weight (P=0.49),
yolk weight (P=0.70), dry yolk weight (P=0.81), and the percentage moisture content of
the yolk sac (P=0.41).
The percentages of birds positive for FMG at hatch and at 6 weeks of age and
subsequently produced antibodies against MG at 6 weeks of age are presented in Table
6.2. No difference was found in the percentages of chicks that tested positive for FMG at
hatch detected in the by PCR testing. This is perhaps due to the low amounts of FMG
that the chicks were inoculated with. At 6 weeks of age, however, the chicks that were
vaccinated in ovo with FMG showed larger MG positive percentages in the choanal cleft
with no difference in the percentage of positive birds between those that had or did not
have a disinfectant step after being vaccinated in ovo with FMG. This finding indicates
that the disinfection step during the in ovo injection process did not kill the bacteria, since
a live FMG population survived 6 weeks beyond the in ovo vaccination. The FMG with
disinfectant step treatment had 19.4% greater percentage of birds that had IgM antibody
production against MG as detected by SPA testing than did the FMG without disinfectant
treatment (Table 6.2). Both FMG injection treatments (with or without a disinfectant
step) had over 50% SPA positive birds 6 weeks after vaccination, which is considered an
adequate MG vaccination by industry standards (Branton et al., 2005). Why the FMG
with disinfectant treatment produced a larger percentage of SPA positive birds in
comparison to the FMG treatment without a disinfectant step is uncertain. ELISA
positive birds in the FMG treatments, though, were not different whether the disinfectant
step was used or not during vaccine administration. One control bird in trial 1 tested
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ELISA positive for MG, although this bird’s choanal cleft swab sample tested negative
for FMG by PCR and also tested negative for MG by SPA.
Body weights of the birds at six weeks of age were not affected by the in ovo
administration of FMG or by the employment of a disinfection step (P=0.85). Body
weights for males averaged 541.7 ± 2.7 g and those for females averaged 459.0 ± 2.2 g
(P<0.0001). This information conflicts with the decrease in body weights found when
this FMG dosage was used in the experiment reported in Chapter 4. However, this
dosage used in Chapter 4 produced body weights that were closer to the body weights of
the control birds in comparison to those in the higher FMG dosage treatments.
In trial 1, there was a total of 10 mortalities out of a total of 450 birds that were
raised to 6 weeks of age. One bird died at 1 day of age in the diluent without disinfectant
treatment. That chick had a pasted vent and upon necropsy was noted to have no feed
present in its crop or gizzard. Eight of the birds that died in trial 1 were from the FMG
without disinfectant treatment. One bird died at each of 3 and 6 days post-hatch and two
birds died on each of days 7, 9, and 11 days post-hatch. Mortality occurred in all three
units. Necropsy results of the dead birds showed that all eight had congested lungs, yet
all were still eating prior to death. Three had swollen kidneys and four had exudate
present in their air sacs. One bird in the FMG with disinfectant treatment died at 18 days
of age and was found to have no feed in its crop. Nevertheless, it had feed in its gizzard,
and had congested lungs and exudate present in its air sacs.
Mortality was slightly less in trial 2 with only 5 total mortalities occurring over
the 6 week period. There were two mortalities in the FMG with disinfectant treatment.
One mortality occurred on day 5 and the other occurred on day 7 post-hatch. Both birds
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had congested lungs and swollen kidneys, and one had yellow exudate present in its air
sacs. The other’s air sacs were cloudy in appearance. One bird in the FMG without
disinfectant treatment died at 12 days of age and only had congested lungs. Two birds in
the diluent without disinfectant treatment died. One died at 6 days of age, and was not
eating and appeared emaciated at necropsy. The other bird was euthanized at 24 days of
age due to its depressed behavior and inability to walk. The bird’s right hock was
inflamed and it was dehydrated and emaciated.
No birds in the control non-injected and no birds in the diluent with disinfectant
treatments died in either trial during the 6 week rearing period. This may indicate that
the disinfectant step applied during in ovo injection provided some benefit for post-hatch
survival. In trial 1, mortality in the FMG without disinfectant treatment was much higher
than in the FMG with disinfectant treatment. The result in trial 1 was similar to that in
trial 2. The one chick in trial 1 and two chicks in trial 2 that died in the diluent without
disinfectant treatment, died being weak chick or because they stopped eating.
Nevertheless, these birds exhibited no visual signs of a bacterial infection at necropsy.
Birds in the FMG in ovo-injection treatment that died post-hatch appeared to have died in
response to the bacteria. There was a unanimous finding of lung congestion in those
birds, with some having affected air sacs. However, normal eating was apparent in those
birds (feed present in the crop and gizzard and the birds did not appear to be emaciated).
The total mortality percentages in each treatment are presented in table 6.3.
The results of these trials indicate that there was no evidence that the disinfectant
mixed with the bacteria in the in ovo vaccine when it was administered by the Embrex
Inovoject machine. This suggests that the live FMG vaccine delivered in ovo may be
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readily applied under the current industry practices. The disinfectant step during in ovo
vaccinations did not influence hatch success in these trials, yet the results of these trials
indicate it may improve post-hatch survival. These findings may also have implications
for the ready application of other bacterial in ovo vaccines.

Table 6.1

Percent hatch of live embryonated layer chicken eggs administered an in
ovo vaccination of a strain F Mycoplasma gallisepticum vaccine (FMG) at
18 days of incubation with or without a disinfection step between egg
injections
Injection Treatment2
Control

Disinfectant
Step Between
Egg Injections
Not Injected

Diluent

No

Diluent

Yes

FMG vaccine

No

FMG vaccine

Yes

% Injected Eggs
that Hatched1
a

96.2

ab

93.9

a

95.5

ab

94.3

b

91.6
0.5

Pooled SEM
Probability
1
Percentage is based on embryos deemed live at 18 days of incubation by candling.
P=0.0342 and means with differing superscripts are significantly different. Means are the
average hatch of embryonated eggs from 10 trays of an initial 72 eggs per tray (5 trays
per two trials) per each treatment.
2
In ovo treatments administered at 18 days of incubation included control non-injected
eggs, eggs injected with Marek’s diluent either using a chlorine based disinfectant step
between injections or not, and eggs administered a live attenuated strain F Mycoplasma
gallisepticum (FMG) vaccine at a 10-6 dilution using a chlorine based disinfectant step
between egg injections or not.
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Table 6.2

Mean percentages of positive birds for strain F Mycoplasma gallisepticum
(FMG) and antibodies against FMG after vaccination at 18 days of
incubation with FMG with or without a disinfection step between each
injection

Treatment1
Hatch FMG2 6wk FMG3 6wk SPA4 6wk ELISA5
Control
0.0
0.0b
0.0c
0.6b
b
c
Diluent without Dis.
0.0
0.0
0.0
0.0b
Diluent with Dis.
0.0
0.0b
0.0c
0.0b
a
b
FMG without Dis.
27.7
89.4
62.2
30.3a
FMG with Dis.
18.6
91.6a
81.6a
30.5a
Probability
0.1060
<0.0001
<0.0001
0.0323
1
In ovo treatments administered at 18 days of incubation included control non-injected
eggs, eggs injected with Marek’s diluent either using a chlorine based disinfectant step
between injections or not, and eggs administered a live attenuated strain F MG vaccine at
a 10-6 dilution using a chlorine based disinfectant step between egg injections or not.
2
Chicks swabbed in the trachea at hatch for detection of strain F Mycoplasma
gallisepticum (FMG) tested with PCR: n=76 chicks per treatment (38 in each of 2 trials).
3
Birds swabbed in the choanal cleft at 6 weeks of age for the detection of FMG; n=3 units
per treatment in each of two trials containing surviving birds at 6wk of age. Each unit
originally started with 30 birds each.
4
Birds bled at 6 weeks of age for serum plate agglutination (SPA) testing for detection of
IgM antibodies against MG; n=3 units per treatment in each of two trials containing
surviving birds at 6wk of age. Each unit originally started with 30 birds each.
5
Birds bled at 6 weeks of age for ELISA testing for detection of IgG antibodies against
MG; n=3 units per treatment in each of two trials containing surviving birds at 6wk of
age. Each unit originally started with 30 birds each. One Control bird tested ELISA
positive in trial 1, although it did not test PCR or SPA positive.
Means with differing superscripts within a column are significantly different detected by
least squared means.
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Table 6.3

Percentage post-patch mortality by 6 weeks of age in Hy-Line W-36
chickens that were in ovo vaccinated with a live attenuated strain F
Mycoplasma gallisepticum vaccine (FMG) at 18 days of incubation with or
without a disinfection step between each injection

Treatment1, 2
Trial 1 Trial 2
Control
0
0
Diluent without Disinfectant
1.1
2.2
Diluent with Disinfectant
0
0
FMG without Disinfectant
8.9
1.1
FMG with Disinfectant
1.1
2.2
1
Percentages are based upon number of birds that died out of the total 90 birds reared per
treatment in each trial.
2
In ovo treatments administered at 18 days of incubation included control non-injected
eggs, eggs injected with Marek’s diluent either using a chlorine based disinfectant step
between injections or not, and eggs administered a live attenuated strain F Mycoplasma
gallisepticum (FMG) vaccine at a 10-6 dilution using a chlorine based disinfectant step
between egg injections or not.
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SUMMARY
The results of these studies indicate that layer embryos can be vaccinated against
Mycoplasma gallisepticum (MG) at 18 days of incubation using a live attenuated strain F
MG vaccine (FMG) at a high dilution or low bacteria dose. A 10-6 dilution of Poulvac
Myco F (1000 dose vial) was successfully employed to administer 1-5 colony forming
units of FMG per embryonated egg. Embryos that were administered this dose had
similar hatch results to control eggs, however, post-hatch mortality was variable. These
birds experienced 3.5% and 11.7% mortalities during the first two weeks following hatch
in the two trials presented in Chapter 4. Furthermore, bird mortalities of 1.1%, 2.2%, and
8.9% were observed in the trials of Chapter 6, in which this dose was administered with
and without a disinfection step. At least 50% of the birds given this dose as an embryo
tested positive by the serum plate agglutination test, indicating that there was initial IgM
antibody production in all trials. In addition, 30.3-42.0% of the birds in these trials also
tested positive for IgG antibody production against MG, indicating sequential change in
the class of antibody produced by these birds in response to the FMG vaccine. The birds
in Chapter 4 also exhibited a reduction in body weight at 6 weeks of age that was not
later detected in Chapter 6.
Higher dosages of the FMG vaccine tested (10-4, 10-2, and 1X) have proven to
deliver too large of an FMG bacterial load for an embryonic or young chick. In
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comparison to controls, fewer of these embryos in the higher dosages hatched
successfully in Chapter 3, whereas only the 1X dose caused a reduction in hatch in
Chapter 4. The birds given these higher dosages experienced over a 50% mortality
during the first two weeks post-hatch and later exhibited a significant reduction in weight
gain.
In this research, it was also found that birds that have been in ovo-vaccinated with
live FMG are able to transmit the bacteria to other FMG clean chicks with which they are
in direct contact. A greater transmission rate was observed if the vaccinated bird had a
humoral immune response against the FMG. Transmission, though, did not unanimously
occur, even when the vaccinated birds produced antibodies against FMG and when their
pen mates were exposed to the vaccinated bird for 6 weeks. Transmission was possible
for all dosages of the FMG vaccine tested, with transmission occurring when higher
dosages were administered, even when the vaccinated chick was in contact with its pen
mates for a short duration.
In the final experiment of this dissertation research, it was found that the most
practical FMG dose, which was the lowest dose, showed efficacy when it was
administered using an in ovo injection machine employing a disinfection step that
sanitized needle with a chlorine solution between each in ovo injection. Mycoplasma
galliseticum was still detected in the choanal cleft of these FMG-vaccinated birds at 6
weeks of age. A comparable immune response was also displayed whether or not the
disinfection step was employed. The birds that were vaccinated by the machine
incorporating a disinfection step actually exhibited higher percentage of positive serum
plate agglutination test results at 6 weeks of age than did those belonging to the FMG
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vaccination without a disinfection step treatment. These results indicated that FMG in
ovo vaccination could be directly applied in the commercial layer industry using existing
industry in ovo injection practices with no necessary modifications.
Further work is needed to determine how the performance and
immunocompetence of FMG in ovo-vaccinated birds compare with birds vaccinated
during pullet rearing. The in ovo-vaccinated birds are achieving a humoral immune
response approximately 3 weeks before the normal age that they would be vaccinated
post-hatch (at 9-18 weeks of age). This positions antibody production much earlier in
relation to the initiation of egg production. This may subsequently reduce physiological
stress on the bird. Moreover, the effect of in ovo FMG vaccination on egg production
during the lay cycle and when hens are faced with an MG challenge also needs to be
examined. Future in ovo MG research could also explore the administration of other live
attenuated MG strains other than FMG. This may include investigations of inactivated or
killed MG.
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PRELIMINARY STUDY OF CHICKEN EMBRYO SURVIVABILITY WHEN
ADMINISTERED AN IN OVO VACCINATION OF STRAIN F
MYCOPLASMA GALLISEPTICUM
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Materials and Methods
Eggs were obtained from a 63 week old commercial Mycoplasma gallisepticum
negative/clean Hy-Line W-36 breeder flock and a 61 week old commercial Ross 708
broiler breeder flock. One hundred eighty eggs of each strain were set in a calibrated
NOM 45 NatureForm incubator (Natureform Incubator Company, Jacksonville, Florida)
set at 37.5°C and 53% relative humidity. The eggs from both strains were each weighed
individually prior to incubation and were alternatively placed and equally represented in
four 90 egg capacity trays in the incubator so that both strains were equally represented in
all areas of the incubator during the first 18 days of incubation. All eggs were stored for
two days prior to incubation.
The initial starting time of incubation was monitored by three wireless ZW Series
HOBO temperature and relative humidity data loggers (Onset Computer Corporation,
Bourne, MA) located in the top of the incubator with the incubator’s temperature probe
and on the two levels where the eggs were placed. The starting incubation time was
determined when the three probes reached the stable temperature and relative humidity of
the incubator’s set conditions.
Fifty eggs of each strain were broken out to determine initial egg components
prior to incubation. Each egg was individually weighed and its yolk and albumin
weighed. The yolk and albumin were dried in a 65°C oven for 5 days and reweighed.
All incubated eggs were weighed and candled on days 12 and 18 of incubation.
Clear eggs and dead embryonated eggs were broken open to determine infertility or stage
of embryonic death. After weighing the eggs on day 18 of incubation, the eggs
containing live embryos were assigned to hatching baskets and injection treatments.
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Eggs were injected with a live attenuated strain F Mycoplasma gallisepticum vaccine,
Poulvac Myco F vaccine, (Zoetis, New York, New York) resuspended in Poulvac
Marek’s diluent (Zoetis, Exton, Pennsylvania) in a total 50 μL volume injection solution
using an Avitech single egg injector (Avitech LLC, Salisbury, Maryland). Viability of
the vaccine in the diluent was confirmed prior to the experiment. Five randomly selected
eggs from each strain per each of the four trays were placed into each hatching basket for
a total of 20 eggs per hatching basket. Each metal hatching basket measured 64 cm long,
13.5 cm wide, and 9 cm deep. Each basket was randomly assigned a treatment of either a
control of no injection, a control diluent only injection, a control dry punch injection
(injecting only air), a high dose, a medium dose, or a low dose injection of the vaccine.
The high dose injection was a dilution of 10-2 of the original vaccine vial. The medium
and low doses were dilutions of 10-4 and 10-6, respectively. Each dilution was plated to
determine the colony forming units per dose of each dilution treatment. An injection
sample from the Avitech single egg injector was taken in a 1.5 mL tube prior to, during,
and after the injection of each vaccine and strain treatment for plating to confirm vaccine
viability during injection. The two strains served as replicates for each treatment. Broiler
and layer baskets were alternatively placed on each of the first two levels of the incubator
with the same treatment located directly above one other. Due to space, the broiler and
layer dry punch treatment hatch baskets were placed on the bottom third level of the
incubator. Once the eggs were injected and placed in their hatching baskets, the set
incubation temperature was reduced to 36.7°C and 53% relative humidity. Twenty-three
randomly selected live embryonated eggs from each of the four trays were injected with 1
mL sterile blue dye (Northeast Laboratory, Waterville, Maine) diluted in 3 mL of
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Marek’s diluent. These embryos were euthanized using a 20 minute exposure to carbon
dioxide and then cooled at 4°C overnight. These eggs were placed in a -12.8°C freezer
two hours before opening the eggs to determine the location of the dye injection using an
embryo staging system developed by Embrex, Inc. (Avakian, 2006).
A hatch pattern was recorded for each hatching basket. The eggs were monitored
for the start of external pipping, after which the number of chicks that hatched and were
fully dried were recorded every 6 hours until the hatch was completed. The hatch was
considered complete two hatch counts after the largest number of chicks was recorded.
Each strain’s time of completion of hatch was monitored separately. After the
completion of hatch per each strain, hatched chicks from each of the hatching baskets
were euthanized by carbon dioxide. Each chick was individually weighed and its yolk
sac removed and weighed. The yolk sac was dried at 65°C for 5 days and reweighed.
Twelve chicks from both the control non-injected treatment and the high dose treatment
from both chicken strains were swabbed for the presence of Mycoplasma gallisepticum.
The chicks were swabbed at four locations: inside the mouth and down the esophagus,
down the trachea through the larynx, on the surface of the yolk sac membrane, and inside
the duodenal loop of the small intestine anterior to the jejunum. The swabs were stored
in 1.5 mL tubes containing 110 µL of PBS. Unhatched eggs were evaluated to determine
age of embryonic death.
Egg weights and moisture loss, initial egg component data, and chick and residual
yolk weight data were all analyzed as a general linear model using SAS Version 9.3 on
an individual egg or chick basis. Significance between chicken strains or treatments was
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based on P ≤ 0.05, and any differences were examined using Fisher’s least significant
difference.
Results and Discussion
The initial start of incubation began one hour after the eggs were placed in the
incubator when the three probes reached a stable temperature and relative humidity near
the set incubation conditions. The layer eggs weighed an average 7.705 g less than the
broiler eggs and had a 2.1% and 3.1% greater percentage moisture loss at 12 and 18 days
of incubation, respectively (Table A.1). There was no difference in initial egg weights
among the four trays (P = 0.9587), and there was no difference in percentage moisture
loss among the four trays at 12 days (P = 0.7678) and at 18 days (P = 0.6633) of
incubation.
The initial egg components for both strains are summarized in Table A.2. The
sampled egg weights were similar to the total incubated egg weights. The percentage of
the egg devoted to solid matter versus water was not different between the layer eggs and
the broiler eggs. In the solid matter of the egg, the albumin and the calculated shell were
not different between the two strains, but the percentage of yolk was an average 2.1%
greater in the broiler eggs than the layer eggs prior to incubation.
The layer and broiler eggs had similar and reasonable percentages of early and
middle age embryonic mortality (Table A.3). The greatest difference between the strains
was the 11.2% higher infertile egg percentage in the broilers as compared to the layer
eggs. This indicates reduced reproductive success of broilers compared with layer
breeders at the older flock ages of this trial (61 and 63 week old breeders).
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The in ovo injection on day 18 of incubation had several troubles. During the in
ovo injection of the vaccine, the Avitech single egg injector had a large amount of air
pockets in the tubing that could not be cleared. The collection of injection samples from
the injector had varying amounts of liquid- not a steady 50 µL injection. Many of the
samples also had a clear appearance as compared with the orange coloring of the diluent.
Plating of the 10-4 dilution of the vaccine determined that the 10-2 dilution had
1.61 x 104 cfu per dose, the 10-4 dilution had 1.61 x 102 cfu per dose, and the 10-6 dilution
had 1.61 cfu per dose. The plating results of the vaccine taken from the single egg
injector, however, had no growth even after the plates were incubated for 8 days at 37°C.
We presumed that the extra clear liquid observed in the injection samples was the 10%
bleach solution that bathes the injection needle between each injected egg. We tested an
artificial egg consisting of a small container covered in Parafilm laboratory film
(American National Can, Chicago, Illinois) to mimic an eggshell. With only air in the
injection tubing, approximately 25 µL of disinfectant liquid was injected inside the
artificial egg. Some disinfectant sat on top of the parafilm, as is observed on an eggshell
of an injected egg, yet the drop sitting over the injection hole did not appear to leak or
drip into the artificial egg. We conclude that the disinfectant is being injected into the
egg with the Mycoplasma gallisepticum vaccine which kills the bacteria when using the
Avitech single egg injector.
Observing the location of dye injection in the embryo was not successful. The
sterile blue dye used was not concentrated enough to be visible in the compartments of
the embryonated eggs. In all but one egg, the needle puncture was observed in the inner
membrane of the air cell, and a pinpoint amount of blue dye was visible directly beneath
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the inner membrane in 7 eggs. The 23 layer embryos were an average stage score of 1.0
and the 23 broiler embryos were an average stage score of 1.4. Based on a Pfizer Animal
Health Study Report (No. 01-00-1101) using broiler eggs comparing the site of injection
with the stage of the embryo, stage 1.0 embryos had 90% of injections located in the
amnion. Our injection trial cannot confirm majority amnion injections. Embrex reports
that lower embryo scores have greater percentage of injections administered into the
amnion with lesser extent delivered to the allantois, air cell, and yolk sac with higher
embryo scores exhibiting a greater percentage of injections into the embryo itself with
decreasing percentage injections being delivered into the amnion (Avakian, 2006).
Overall the broiler chicks hatched 6 hours faster than the layer chicks (Figure
A.1). The broilers reached a peak in hatching at 498 hours of incubation and were
removed from the hatcher at 510 hours of incubation. The layers reached their peak
hatch at 504 hours of incubation, and were removed from the incubator at 528 hours of
incubation. The dry punch and diluent injected control treatments hatched 6 hours earlier
than the non-injected control eggs in both the layer and broiler strains (Figures A.2 and
A.3). The low and medium dose vaccine treatments reached a peak hatch 6 hours earlier
than the high dose vaccine treatment in the layer strain, but the medium and high dose
vaccine treatments in the broiler eggs reached a peak hatch 12 hours earlier than the low
dose vaccine treatment (Figures A.4 and A.5).
The layers had an overall 93.3% hatch of the live embryonated eggs placed in the
hatching baskets. The broilers had 95.0% hatch of live embryonated eggs. The hatch of
each treatment is summarized in Table A.4. The control treatments had 100% hatch with
the exception of the non-injected and the diluent injected layers. The vaccine
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administration, although the bacteria was killed, did depress hatch at most by 15% in both
layers and broilers, although not in a dose dependent manner. Out of the 6 broiler eggs
that failed to hatch, 4 contained late embryonic mortality and 2 contained embryos that
had externally pipped and then died before hatching-one from the low dose treatment and
the other from the high dose treatment. The 8 layer eggs that did not hatch contained late
dead embryos with the exception of one chick from the low dose treatment that had
externally pipped and was still alive at the time the hatch was removed from the
incubator.
The delayed removal from the hatcher of the layer chicks from the incubator
could potentially have had a drying effect on the chick and yolk weights in comparison to
the broiler chicks which were pulled at exactly two hatch counts after the largest amount
of chicks hatched. In comparison of hatch progression, the layer chicks remained in the
hatcher 12 hours longer than the broiler chicks.
Broiler yolk-free chick weights were an average 5.736 g heavier than layer chicks
(Table A.5). The average layer yolk-free chick weight was 59.7% of the average initial
layer egg weight, and the average broiler yolk-free chick weight was 61.3% of the
average broiler initial egg weight. There was no difference in yolk-free chick weights
between injection treatments (P = 0.5726), and there was no interaction between strain
and injection treatments (P = 0.8763).
Broiler chicks had heavier dry yolk weights than layer chicks (Table A.5) and had
an average 2.6% greater dry yolk weight as a percentage of total chick weight. There was
no difference in dry yolk weights (P = 0.4344) or percentage dry yolk weight of chick
weight (P = 0.4550) among injection treatments. Based on the initial and final
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percentages of yolk (Table A.6), the layer embryos utilized 67.6% of their yolk matter
and the broiler embryos utilized 55.8% of their yolk during their incubation period.
The swab samples taken originally to check for the presence of Mycoplasma
gallisepticum in the twelve non-injected and the twelve high dose treatment broiler and
layer hatched chicks have mainly served as preliminary testing for the identification of
easily repeatable sites to be swabbed in future trials.
Thus, this preliminary trial mainly demonstrated the differences between broilers
and layers. The next step to determine the survivability of embryos administered the
three dosages of the live attenuated vaccine is via hand injection of the eggs (See Chapter
3). This will eliminate any machine error (bubbles in the tubes) and will prevent the
mixing of the disinfectant with the bacteria. Based on the apparent similarity in embryo
stage and with only a six hour longer hatching time observed in the present trial, we feel
confident to proceed incubating only layer embryos and injecting them at 18 days of
incubation. A stronger dye will be used in future trials and may further evaluate the
proper incubation time for injection at a later date depending on the incubator chosen for
the full scale project and the survivability results obtained from a hand injection trial.
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Table A.1

Egg weight and moisture loss of Hy-Line W-36 layer and Ross 708 broiler
hatching eggs at 12 and 18 days of incubation

Initial
12 d
18 d
12 d
18 d
Egg Wt
Egg Weight
Egg Weight
Moisture Loss
Moisture
(g)
(g)
(g)
(%)
Loss (%)
1
Layer
62.921
57.914
55.258
8.2
12.4
2
Broiler
70.626
66.367
64.240
6.1
9.3
P value
<.0001
<.0001
<.0001
<.0001
<.0001
1
Layer-Hy-Line W-36; Initial egg weight n = 180; 12 day egg weight n = 166; 18 day egg
weight n = 166.
2
Broiler-Ross 708; Initial egg weight n = 180; 12 day egg weight n = 145; 18 day egg
weight n = 143.
Strain

Table A.2

Egg components of fertile Hy-Line W-36 layer and Ross 708 broiler
hatching eggs

Strain

Weight
Water
Solids
Albumen
Yolk
Shell
(g)
---------------%------------- ----------------% of total solids------------Layer
63.584
64.3
35.7
6.9
14.2
14.6
Broiler 71.987
64.7
35.3
6.7
16.3
12.3
P value <.0001
0.1300
0.1300
0.2537
<.0001
0.6611
n = 50 Hy-Line W-36 layer eggs and 50 Ross 708 broiler eggs.

Table A.3

Percentages of infertile eggs and early and middle embryonic mortality in
Hy-Line W-36 Layers and Ross 708 Broilers
Infertility2 (%)

Early Dead3
Middle Dead4
Strain1
Embryos (%)
Embryos (%)
Layer
4.4
2.8
0.6
Broiler
15.6
3.9
1.1
1
Percentages taken out of a total 180 eggs per each strain.
2
Infertility and early embryonic mortality was determined at 12 days of incubation.
3
Early embryonic mortality encompasses days 0-6 of incubation
4
Middle point of incubation embryonic mortality was determined at both 12 and 18 days
of incubation. Middle embryonic mortality was considered as days 7-13 of incubation.
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Table A.4

Strain
Layer
Broiler
Layer

Survival to hatching of live embryonated Hy-Line W-36 layer and Ross
708 broiler eggs when in ovo injected with a live attenuated strain F
Mycoplasma gallisepticum vaccine at 18 days of incubation using an
Avitech single-egg-injector
Treatment1

# of
Embryos in
Basket
20
20
20

# of
Hatched
Chicks
19
20
19

% Hatch
(of live embryonated
eggs)
95.0
100.0
95.0

No injection
No injection
Diluent
Injection
Broiler Diluent
20
20
100.0
Injection
Layer
Dry Punch
20
20
100.0
Broiler Dry Punch
20
20
100.0
Layer
Low Dose
20
17
85.0
Broiler Low Dose
20
19
95.0
Layer
Medium Dose
20
19
95.0
Broiler Medium Dose
20
17
85.0
Layer
High Dose
20
18
90.0
Broiler High Dose
20
18
90.0
1
Treatments were administered to live embryonated layer (Hy-Line W-36) and broiler
(Ross 708) chicken eggs at 18 days of incubation using an Avitech single egg injector.
Treatments included no injection, diluent injection using Marek’s disease diluent, a
control dry punch injection (injecting only air), and a high, medium, and low dose of a
live attenuated strain F Mycoplasma gallisepticum (FMG) vaccine. The high dose
injection was a dilution of 10-2 of the original vaccine vial, the medium dose was a 10-4
dilution and the low dose was a 10-6 dilution. Dilutions were done with Marek’s diluent.
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Table A.5

Chick and residual yolk sac weights of Hy-Line W-36 layer and Ross 708
broiler chicks

Yolk-Free
Chick Weight
(g)
1
Layer
37.565
2
Broiler
43.301
P value
<.0001
1
Layer-Hy-Line W-36; n = 112.
2
Broiler-Ross 708; n = 114.
Strain

Table A.6

Dry Yolk
Weight (g)

% Dry Yolk Weight of
Total Chick Weight

1.941
3.645
<.0001

4.6
7.2
<.0001

Comparison of yolk consumption of Hy-Line W-36 layer and Ross 708
broiler embryos during incubation

Initial % dry
Finial % dry
Strain
yolk of egg
yolk of chick
weight
weight
1
Layer
14.2
4.6
2
Broiler
16.3
7.2
P value
<.0001
<.0001
1
Layer-Hy-Line W-36; Initial dry yolk percentage n = 50; Final dry yolk percentage n =
112.
2
Broiler-Ross 708; Initial dry yolk percentage n = 50; Final dry yolk percentage n = 114.
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Broiler and Layer Hatch Every 6 Hours
60

Percent Hatch

50
40
30

Layer

20

Broiler

10
0

474

480

486

492

498

504

510

516

522

528

Hours of Incubation
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Figure A.1

Broiler and Layer Hatch Times

Overall broiler and layer hatch times recorded every 6 hours starting at 474 hours of
incubation represented as the percentages that hatched each hatch count and the total
percentages that hatched. The broilers were removed from the incubator at 510 hours of
incubation and the layers were removed from the incubator at 528 hours of incubation.
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Layer Control Treatments
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Broiler Control Treatments
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Figure A.2

Control Broiler and Layer Hatch Each 6 Hours

The percentages of control treatment broiler and layer chicks that hatched every 6 hours
starting at 474 hours of incubation represented as the percentages that hatched each hatch
count. The no injection treatment did not receive an injection, the diluent injection
received a 50 µL injection of Poulvac Marek’s diluent, and the dry punch treatment was
injected with only air. The broilers were removed from the incubator at 510 hours of
incubation and the layers were removed from the incubator at 528 hours of incubation.
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Cumulative Layer Control Treatments
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Cumulative Broiler Control Treatments
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Figure A.3

Control Broiler and Layer Cumulative Hatch

The percentages of control treatment broiler and layer chicks that hatched every 6 hours
starting at 474 hours of incubation represented as the total percentages that hatched. The
no injection treatment did not receive an injection, the diluent injection received a 50 µL
injection of Poulvac Marek’s diluent, and the dry punch treatment was injected with only
air. The broilers were removed from the incubator at 510 hours of incubation and the
layers were removed from the incubator at 528 hours of incubation.
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Layer Vaccine Treatments
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Broiler Vaccine Treatments
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Figure A.4

Broiler and Layer MG Treatments Hatch Each 6 Hours

The percentages of broiler and layer chicks that hatched every 6 hours starting at 474
hours of incubation represented as the percentages that hatched each hatch count that
were in ovo injected with a live attenuated Mycoplasma gallisepticum vaccine. The
Poulvac Myco F vaccine was resuspended and diluted with Poulvac Marek’s diluent.
The low dose was a dilution of 10-6, the medium dose was a dilution of 10-4, and the
high dose was a dilution of 10-2 of the original vaccine vial. The broilers were removed
from the incubator at 510 hours of incubation and the layers were removed from the
incubator at 528 hours of incubation.
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Cumulative Layer Vaccine Treatments
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Cumulative Broiler Vaccine Treatments
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Figure A.5

Broiler and Layer MG Treatments Cumulative Hatch

The percentages of broiler and layer chicks that hatched every 6 hours starting at 474
hours of incubation represented as the total percentages that hatched that were in ovo
injected with a live attenuated Mycoplasma gallisepticum vaccine. The Poulvac Myco F
vaccine was resuspended and diluted with Poulvac Marek’s diluent. The low dose was a
dilution of 10-6, the medium dose was a dilution of 10-4, and the high dose was a
dilution of 10-2 of the original vaccine vial. The broilers were removed from the
incubator at 510 hours of incubation and the layers were removed from the incubator at
528 hours of incubation.
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